

# NCI Fund

## Legislative Report

December 1, 2020 – May 31, 2021

Winthrop P. Rockefeller Cancer Institute

## NCI Designation Overview

National Cancer Institute Designation is recognition by the National Cancer Institute (NCI) for exceptional cancer research.

In 1971, President Richard Nixon signed the landmark National Cancer Act authorizing a national cancer program with funding to establish 15 new cancer centers. These new cancer centers were charged with conducting clinical research, training and demonstration of advanced diagnostic and treatment methods for cancer. The ultimate goal was for these centers to be distributed geographically such that 75% of the U.S. population would have access to care at one of these centers without requiring an overnight stay.

Today, the NCI cancer centers program has grown to include 71 cancer centers distributed throughout 36 states (**Figure 1**). These 71 centers represent the top 2% of cancer centers in the U.S.

Arkansas, Louisiana and Mississippi are the only cancer centers in the south that do not currently have an NCI Designated cancer center. The nearest NCI designated centers providing adult cancer care reside in Dallas, Oklahoma City, Kansas City, St. Louis and Nashville. These centers are all ~300+ miles (5+ hours drive) away from central Arkansas and not a feasible cancer care solution for most Arkansans.

Sylvester Cancer Center in Miami, FL was the most recent cancer center to become designated in 2019. Prior to that, the most recently designated cancer centers were Stephenson Cancer Center in Oklahoma City, OK in 2018, Markey Cancer Center in Lexington, KY in 2013 and the University of Kansas Cancer Center in Kansas City, KS in 2012.

The NCI cancer centers program continues to value the geographic distribution of its cancer centers and patient access to research driven cutting-edge care. The NCI recognizes that there is a great need and opportunity for Arkansas to have an NCI Designated cancer center, and it stands ready to support the Winthrop P. Rockefeller Cancer Institute on its journey toward NCI Designation.

## Value of NCI Designation

NCI Designation is an enormous asset for any state that houses an NCI designated cancer center. Benefits include the following:

1. Direct monetary support from NCI will support cancer research that benefits Arkansans. While many cancer centers conduct research, the Winthrop P. Rockefeller Cancer Institute is the only academic institution in the U.S. focused on improving cancer outcomes in Arkansas. In fact, NCI requires its designated cancer centers to define their research portfolio based on what will make a difference in cancer prevention, awareness, treatment, survival and quality of life in the population they serve.
2. Indirect monetary gains include a projected \$70 million economic impact on the state of Arkansas annually. Further growth following NCI Designation is expected to increase that impact value. (Source: *Arkansas Center for Health Improvement, 2018*)

3. Becoming a member of the NCI Cancer Centers program will give Arkansas a seat at the table to drive national strategic planning for cancer research toward opportunities that will benefit Arkansas.
4. Arkansans will have access to clinical trials and new cancer treatments that are only available to cancer centers that are NCI designated.
  - Access to grant funding opportunities that are only available to NCI Designated cancer centers
  - Access to cutting edge clinical trials and investigative drugs that are only available to NCI Designated cancer centers
5. Cancer researchers at the Winthrop P. Rockefeller Cancer Institute will have access to cancer research grants that are only available to NCI designated cancer centers. This provides the opportunity to increase the amount of cancer research designed to benefit Arkansans by ~60%.
6. The opportunity to partner with an NCI Designated cancer center will attract biotechnology and pharmaceutical companies to Arkansas.

### **Process to Attain NCI Designation (Figure 2)**

NCI Designation is attained through strategic recruitment of cancer researchers and establishment of a sophisticated cancer research infrastructure prescribed by the NCI in its p30 Cancer Center Support Grant (CCSG) (<https://grants.nih.gov/grants/guide/pa-files/PAR-20-043.html>).

Our estimated cost to attain NCI designation by 2025 is \$200 million. This cost is in line with recent successful NCI Designation efforts. Oklahoma's Stephenson Cancer Center became the 70<sup>th</sup> NCI Designated cancer center on May 2, 2018, stating it took 12 years and \$400 million to become designated. Twenty-nine percent of the \$400 million came from the state, predominantly through a statewide tobacco tax, according to Stephenson Cancer Center Director, Robert Mannel, MD<sup>1</sup>. The Sylvester Comprehensive Cancer Center in Miami, Florida reported that it spent \$250 million over five years to become the country's 71<sup>st</sup> NCI Designated cancer center on July 29, 2019. Sylvester's director, Stephen Nimer, MD, said that the state of Florida contributed a little over \$16 million per year during that time to support their efforts to become NCI Designated<sup>2</sup>.

Cancer centers seeking NCI Designation undergo annual review by an External Advisory Board (EAB) to ensure that NCI's standards for a designated center are being met. These EAB meetings are critical to keep a cancer center on track for Designation and result in a formal report about the cancer center being filed with NCI. Once an EAB has determined that a cancer center is ready to apply for NCI Designation, the cancer center must meet with NCI and get their approval to apply for NCI Designation.

Once NCI approves a center to apply for NCI Designation, the center submits its CCSG to NCI according to the timeline set by NCI. Preparation of a CCSG generally takes two years and is often begun well before NCI approves a center to apply for Designation. Following submission of the grant, the cancer center will host a site visit from NCI and leaders from other cancer centers to review the cancer center.

<sup>1</sup>"Oklahoma's Stephenson Cancer Center earns coveted NCI Cancer Center Designation." The Cancer Letter, 2 May 2018, Volume 44 No. 18, [https://cancerletter.com/conversation-with-the-cancer-letter/20180504\\_3/](https://cancerletter.com/conversation-with-the-cancer-letter/20180504_3/)

<sup>2</sup>"Sylvester becomes 71<sup>st</sup> NCI-designated cancer center." The Cancer Letter, 29 July 2019, [https://cancerletter.com/conversation-with-the-cancer-letter/20180504\\_3/](https://cancerletter.com/conversation-with-the-cancer-letter/20180504_3/)

Both the written grant and site visit comprise the scores that determine if an NCI cancer center becomes designated.

After NCI Designation is attained, it must be renewed every five years with the submission of another CCSG and hosting of a site visit. This ensures that the standards set forth by NCI for a designated cancer center continue to be upheld.

### **Expected Timeline**


The Winthrop P. Rockefeller Cancer Institute is targeting submission of its CCSG in ~4 years. Two critical factors may extend or decrease this timeline: 1) how quickly strategic cancer research recruitments can be made and 2) the timeline set by NCI for submitting a CCSG application.

### **Impact of COVID-19:**


Over the last 6 months COVID-19 has continued to impact our state and the delivery of healthcare to our citizens. Although the pandemic appears to be winding down, UAMS has continued to alter many processes and services to provide the safest environment possible for all of our patients. UAMS is still screening patients and employees but with a modified process. In addition, we still limit the number of visitors allowed for patient safety. Our surgery activity has recovered somewhat, but remains down considerably compared to a similar period in 2019. However, our medical oncology clinics have continued to see an increase in volumes and for the period of January through May of 2021 and have achieved levels comparable to the same period in 2019. From January through May of 2021, our infusion room visits were 81% compared to volumes from the same period in 2019. For Medical Oncology/Myeloma, the clinic volumes equated to 99.5% of the volume from the same period in 2019. Overall, the volumes for all clinics were 88.9% compared to the same period in 2019. In October of 2020, we opened our brand-new infusion area on the 6<sup>th</sup> floor, including a 10-bed Phase I unit. This unit gives us the ability to conduct Phase I drug trials, which previously was not available in the state, and patients had to be referred out-of-state for these trials. Our second infusion room was moved to the 4<sup>th</sup> floor in January 2021. Also, we completed and opened a brand new, state of the art breast imaging center on the third floor in March 2021. Our Stem Cell Transplantation Program continues to be a Center of Excellence. We are the only facility in the state of Arkansas to provide CAR-T therapy, which is a specialized state of the art therapy for patients with lymphomas and leukemias.

Laboratory research has continued unaffected throughout the COVID-19 pandemic at UAMS. The majority of clinical research has continued with only a few trials halting enrollment for a few weeks. Our new investigator recruitment has also been robust despite the limitations due to COVID. While our initial screening and interview process shifted to the virtual environment, the majority of final candidates who appeared likely for recruitment have been able to come on campus for visits. To date we have offered letters and signed 6 new research faculty since the last 6-month report (**Table 1**). At the time of this report, we are now shifting to a more targeted recruitment to fill specific gaps in our scientific portfolio. As all institutions are dealing with these challenges, we have not lost any candidates as a result of COVID-19, and we have been very pleased with our success in recruitments.

**Figure 1. NCI Designated Cancer Centers.** There are currently 71 NCI Designated cancer centers across 36 states and the District of Columbia. The 36 states with one or more NCI Designated cancer centers are depicted in shading below:



# Roadmap to NCI Designation



**Winthrop P. Rockefeller Cancer Institute  
Senate Bill 151  
Trust Fund - Pursuit of a National Cancer Institute Designation  
FY2021 Semiannual Report Due July 1, 2021**

**Trust Fund Reporting Period (12/1/2020 - 5/31/2021)**

Beginning Balance (12/1/2020)	\$18,476,951.14
Total Transfers In	\$0.00
Special Revenue: Cigarette Paper Tax	\$843,715.85
**Processing Charges by DF&A on Special Revenue	( <b>\$26,155.19</b> )
Net Revenue Received	<u>\$19,294,511.80</u>
 Expense:	
**Workers Comp Charged direct by DF&A	( <b>\$4,191.25</b> )
Expense Draws Posted For Period (12/01/2020 - 5/31//2021)	<u>(<b>\$2,216,679.80</b>)</u>
Ending Balance (5/31/2021)	<u>\$17,073,640.75</u>
Expense Draws For May Not Yet Posted to AASIS	( <b>\$385,265.77</b> )
Adjusted Ending Balance	<u>\$16,688,374.98</u>

\*\*Department of Finance and Administration adjustments

**Expense Breakdown - Senate Bill 151 - Trust Fund For NCI Designation**

Program Account Description	Semiannual Report July 1, 2021				Notes
	Salary	Fringe	M&O	Total Expense	
Atiq, Omar, MD (COM Internal Medicine-Medical Oncology)	0.00	0.00	969.28	969.28	Support of head & neck clinical trial
Cancer Service Line Support	7,725.00	1,465.58	0.00	9,190.58	Clinical research effort for Jibrán Ahmed, MD
Hauer-Jensen, Martin, MD, PhD (COP - Radiation Health)	26,824.17	7,780.15	0.00	34,604.32	Bridge funding for resubmission of COBRE grant
Cancer Institute Administration	55,238.59	13,242.56	49,871.95	118,353.10	Staff salaries, equipment, supplies, etc.
Cancer Clinical Trials Research Administration (CCTRA)	10,071.37	2,304.10	0.00	12,375.47	Cancer Clinical Trials
Lewis, Gary, MD (COM - Radiation Oncology)	33,560.00	5,664.70	0.00	39,224.70	Recruitment package support
Leung, Ricky, PhD (COM Pharmacology Toxicology)	56,047.00	13,154.27	25,746.40	94,947.67	Recruitment package support
Birrer, Michael, MD, (Cancer Institute)	34,584.72	10,962.99	94,479.62	140,027.33	Recruitment package support
Manzano, Mark, PhD (COM Microbiology & Immunology)	2,425.02	597.78	914.73	3,937.53	Recruitment package support
Zhan, Frank MD, PhD (COM Internal Medicine - Medical Oncology)	88,909.14	19,201.92	3,008.79	111,119.85	Recruitment package support
Cancer Institute Bioinformatics Core Support	0.00	0.00	131,630.00	131,630.00	Supplement to Core for expense in excess of operating revenue
Belido, Teresita, PhD (COM Physiology and Biophysics)	643.54	1.36	25,785.68	26,430.58	Recruitment package support
Stephens, Kimberly, MD (COM Peds Care)	28,094.04	7,725.46	18,594.29	54,413.79	Recruitment package support
Su, Joseph, MD (CPH Epidemiology)	23,977.16	9,169.64	21,909.92	55,056.72	Recruitment package support
Cancer Institute Genomics Core Support	0.00	0.00	237,257.62	237,257.62	Supplement to Core for expense in excess of operating revenue
Cancer Institute Health Disparities - Ronda Henry-Tillman, MD	18,507.72	3,447.44	0.00	21,955.16	Retention package support
Core Voucher Program	0.00	0.00	35,061.42	35,061.42	Cancer core use vouchers for CI members
Cancer Pilot Program	0.00	0.00	400,000.00	400,000.00	Support for 4 cancer pilot projects at \$100K each
Amick, Benjamin III, PhD (CPH Epidemiology)	32,004.00	5,782.77	7,388.10	45,174.87	Recruitment package support
Cornett, Larry (AR INBRE grant support)	3,889.00	1,136.74	1,693.03	6,718.77	Program support
Ryan, Katie, PhD (COM Biochemistry)	44,002.22	10,761.49	25,070.74	79,834.45	Recruitment package support



<b>Program Account Description</b>	<b>Salary</b>	<b>Fringe</b>	<b>M&amp;O</b>	<b>Total Expense</b>	<b>Notes</b>
Cancer Institute Community Outreach	21,599.93	5,065.74	0.00	26,665.67	Support for Associate Director for Community Outreach and Engagement
Delgado-Calle, Jesus, MD, (COM Physiology & Biophysics)	0.00	0.00	42,993.87	42,993.87	Recruitment package support
DFA Charges - Workers Comp	0.00	4,191.25	0.00	4,191.25	Charges administered by DFA
Radiation Core	0.00	0.00	182,490.00	182,490.00	Purchase of x-ray cabinet
Tricot, Guido, MD (COM Myeloma Center)	9,585.23	733.52	0.00	10,318.75	Recruitment package support
Shaughnessy Jr., John (COM Myeloma Center)	25,000.02	6,283.04	0.00	31,283.06	Recruitment package support
Dr. Karbassi Breast Vaccine Support	0.00	0.00	8,459.38	8,459.38	Support of clinical trial for a breast cancer vaccine
Roy Choudhury, Samrat, PhD (COM Pediatrics)	53,793.35	19,558.82	43,551.92	116,904.09	Recruitment package support
Yeh, Ed (COM Internal Medicine)	0.00	0.00	4,612.81	4,612.81	Recruitment package support
Miah, Syem (COM Biochemistry)	40,416.65	10,763.42	22,595.44	73,775.51	Recruitment package support
Seeds of Science Pilot Program	0.00	0.00	200,000.00	200,000.00	Support 4 Pilot Projects at \$50K each
Park, Mark (COPH Epidemiology)	37,166.70	8,935.88	23,102.28	69,204.86	Recruitment package support
Enemark, Eric (COM-Biochemistry)	9,064.17	2,407.94	58,722.03	70,194.14	Recruitment package support
Chang, Ming (COM Pharmacology and Toxicology)	0.00	0.00	116.31	116.31	Recruitment package support
Brochausen, Mathias (DBMI)	6,909.09	1,599.15	0.00	8,508.24	Recruitment package support
Lu, Williams (COM Pathology)	18,070.59	5,681.69	66,897.92	90,650.20	Recruitment package support
WPRCI Diversity	3,499.23	564.03	0.00	4,063.26	Support for Associate Director for Diversity, Equity, and Inclusion
Chambers, Tim (COM Biochemistry)	0.00	0.00	1,422.21	1,422.21	Project Collaboration Support
Racine-Miousse, Isabella (COM Biochemistry)	0.00	0.00	2,000.00	2,000.00	Recruitment package support
<b>Total Expense</b>	<b>691,607.65</b>	<b>178,183.43</b>	<b>1,736,345.74</b>	<b>2,606,136.82</b>	

## Expense Detail Justification

All expenses posted to the Trust Fund for NCI Designation support the advancement of cancer research directly or through support of clinical initiatives that enable the conduct of clinical research.

- **Atiq Omar, MD** - Research support was provided to Dr. Omar Atiq to conduct a head and neck cancer clinical trial entitled, "A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients in Remission to Reduce Recurrence Regardless of HPV Status". This trial is expanding on a peer-reviewed cancer clinical trial funded by NCI for another Cancer Institute researcher, Mayumi Nakagawa, MD, PhD.
- **Cancer Service Line Support**- Dr. Jonathon Laryea provided leadership of the Cancer Service Line between transitioning Cancer Institute directors.
- **Martin Hauer-Jensen, MD, PhD** - Bridge funding of research is a valuable and essential resource for researchers, and it is common practice for a cancer center to provide it to support research through small gaps in funding due to grant award timelines. Peer-reviewed grant funds are often awarded 7-12 months following submission of a grant. Support of research during this waiting period for new funding is strategic and critical. Dr. Martin-Hauer Jensen's multi-million dollar COBRE grant has been resubmitted, but bridge funding was required to keep projects going until the grant could be reviewed. This grant was successfully renewed.
- **Cancer Institute Administration** – Funds were used to support CI Administration salaries, fringe, equipment, supplies and travel.
- **Cancer Clinical Trials Research Administration (CCTRA)** – Funds were used to support clinical trials office infrastructure needs.
- Multiple cancer researcher recruitment packages were supported through this mechanism (**Lewis, Leung, Birrer, Manzano, Zhan, Belido, Stephens, Su, Amick, Ryan, Delgado-Calle, Tricot, Shaughnessy, Roy Choudhury, Yeh, Miah, Park, Enemark, Chang, Brochhausen, Lu, Racine-Miousse**). Cancer research faculty recruited during the current reporting period are shown in **Table 1**.
- **Cancer Institute Bioinformatics Core Support** – Funds were used to support scientific shared resource for expenses exceeding operating revenue.
- **Cancer Institute Genomics Core Support** - Funds were used to support scientific shared resource for expenses exceeding operating revenue.
- **Cancer Institute Health Disparities** – Funds were used to support the retention of Ronda Henry-Tillman, MD.
- **Core Voucher Program** - Core vouchers are available to Cancer Institute researchers through competitive application. These funds directly support cancer research projects.
- **Cancer Pilot Program** – Pilot cancer research grants are available to Cancer Institute researchers through competitive application. These funds directly support cancer research projects. Four \$100,000 grants were awarded.
- **AR INBRE** – Funds were used to provide supplemental support to the INBRE grant held by Larry Cornett, PhD
- **Cancer Institute Community Outreach** – Funds were used to support the new Associate Director for Community Outreach and Engagement role filled by Pearl McElfish, PhD, MBA, March 1, 2021.

- **DFA Charges Workers Comp** – These charges are imposed by the Arkansas Department of Finance and Administration and are identified on the AASIS ledgers as “Workers Comp”.
- **Radiation Core** – Funds were used to purchase an X-ray cabinet for research use.
- **Dr. Karbassi Breast Vaccine Support** – This is long-term support for the continued study of a breast cancer vaccine clinical trial initiated by Tom Kieber-Emmons, PhD under a U.S. Army Department of Defense grant.
- **Seeds of Science Pilot Program** – Pilot cancer research grants are available to Cancer Institute researchers through competitive application. These funds directly support cancer research projects. Four \$50,000 grants were awarded.
- **WPRCI Diversity** – Funds were used to support the new Associate Director for Diversity, Equity and Inclusion role filled by Gwendolyn Bryant-Smith, MD, May 1, 2021.
- **Tim Chambers (COM Biochemistry) WPRCI Diversity** – Funds were used to support a collaborative cancer research project led by Biochemistry faculty member Tim Chambers, PhD.

State Funds - NCI Designation

	Projected Expense									Total
	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7	Year 8	Year 9	
	FY20 (Actual Expense)	FY21	FY22	FY23	FY24	FY25	FY26	FY27	FY28	
<b>Funds Committed by Year</b>	1,556,705	7,385,550	22,133,865	18,368,302	18,778,915	17,585,694	14,778,591	6,908,591	2,600,000	<b>110,096,214</b>

## Progress Toward Achieving NCI Designation December 1, 2020 – May 31, 2021

### Detailed Progress:

- 1. Large scale recruitment of cancer researchers continues:** In January and February, 2020, an omnibus ad seeking multiple cancer researchers was placed in four top scientific journals and their accompanying online sites (see previous reports). From this effort, thirty-six top candidates have been interviewed via Zoom, and twenty-six candidates have had on-campus interviews. **Table 1** shows the six successful recruitments from this reporting period. Their CVs are provided in **Appendix A**. The sum total of these efforts to date is fourteen diverse candidates across academic rank and home departments; we have two offer letters still pending. We are extremely excited about all of these recruits and believe they will contribute significantly to our research portfolio.
- 2. Strategic recruitment of cancer researchers across UAMS:** The Cancer Institute works with departments across the UAMS campus to recruit faculty of interest to the departments. When departments discover a candidate they would like to pursue who is engaged in cancer research, the Cancer Institute becomes engaged in that process. This allows Cancer Institute research priorities to be considered in all relevant recruitments across campus.
- 3. Targeted recruitment of cancer researchers:** In October 2020, Cancer Institute Director, Michael Birrer, MD, PhD personally reached out to recent NCI K99 award recipients. We are still in the process of finishing in-person interviews for these candidates, and we are hopeful to have at least two offers drafted from this particular effort. In March 2021, the Cancer Institute drafted and placed targeted advertisements for myeloma researchers in high impact journals; we are also working on approvals for targeted recruitment efforts related to Community-Engaged Cancer Researchers and Cancer Epidemiologists. We hope to have these advertisements active on high impact scientific job boards in the next couple of months, and we expect a robust applicant response.
- 4. Increased Research Funding:** Our recruitment of active researchers has brought in additional cancer research funding. Our fourteen signed recruits are bringing an impressive \$3.5 million of active external peer-reviewed funding; this number does not include all of the recruits' planned grant submissions once arriving on campus. In addition, our current researchers continue to submit multiple grants to cancer-related funding sources such as NCI, ACS, and DoD. Our researchers were awarded \$6.7 million in new peer-reviewed cancer related funding (total) during the current reporting period of December 1, 2020 – May 31, 2021. As of May 31, 2021 our cancer researchers held \$17.8 million in peer-reviewed cancer related annual project direct cost grant funding.
- 5. Philanthropic Fundraising:** We continue to actively pursue philanthropic support for the Cancer Institute over this legislative cycle. We have secured 1,149 gifts and pledges, totaling \$5.04 million between December 1, 2020 and May 31, 2021. These donations address the pledged matching funds from the Cancer Institute according to the agreed upon legislative monies.

6. **Strategic Recruitment of Oncology Clinical Faculty and Staff:** We have hired three new medical oncologists to join our impressive clinical team who will be starting on July 1, 2021: Neelakanta Dadi, MD specializes in benign hematology (see previous report); Samer Ahmad Al-Hadidi, MD specializes in multiple myeloma; and Sindhu Malapati, MD specializes in breast medical oncology. We continue to utilize medical search firms and our own advertisements to recruit top medical oncologists from around the country.
  
7. **New Cancer Institute Senior Leadership:** We are excited to have recently announced four new Cancer Institute leaders that will help develop the infrastructure for the programs required for our NCI Designation application.
  - a. Alan Tackett, PhD, Professor of Biochemistry at UAMS, Director of the Cancer Institute Proteomics Shared Resource, and Cancer Institute Associate Director for Basic Research was appointed as Deputy Director of the Cancer Institute. He will have a large role in writing our application for NCI Designation.
  - b. Pearl McElfish, PhD, MBA, Vice Chancellor of UAMS Northwest campus, was appointed as Cancer Institute Associate Director of Community Outreach and Engagement. She has initiated implementation of our statewide cancer navigator program and other infrastructure projects around the state.
  - c. Tom Kelly, PhD, Associate Professor of Pathology at UAMS was appointed as Associate Director of Research Training and Education. Dr. Kelly currently leads an NCI R25 grant providing cancer research training to medical students over the summer. In April 2021, he introduced the inaugural Winthrop P. Rockefeller Cancer Institute Special Award for Outstanding Cancer Research at the Arkansas State Science and Engineering Fair.
  - d. Amy Jo Jenkins, Former Chief of Staff to Chancellor Cam Patterson, was appointed as Cancer Institute Director of Clinical Trials. Jenkins brings over 20 years of clinical trials experience and served as president of the national SOCRA organization (Society of Clinical Research Associates). Jenkins will lead expansion of our clinical trial portfolio and phase I unit.
  
8. **Cancer Research Grant Activity: Table 3** summarizes grant activity occurring December 1, 2020 – May 31, 2021.

**Table 1. Cancer Research Recruitments December 1, 2020 - May 31, 2021**

Candidate	Current/Previous Institution	Recruited Rank	Recruitment Status	Recruitment Home Department	Research Interest	Peer-Reviewed Cancer Research Funding at Time of Legislative Reporting	CI investment*
Mei Bai, PhD	University of Missouri, St. Louis	Assistant Professor	Started June 1, 2021	College of Nursing	Methodologies to assist coping in newly diagnosed cancer patients	None	\$75,000 total CI investment for start up resources over 3 years (\$25,000 per year FY21 - FY23)
Mathias Brochhausen, PhD	University of Florida	Professor	Started March 8, 2021	Bioinformatics	Cancer Informatics	None	\$350,000 total investment start up funds over three years (\$25,000 in FY21, \$175,000 in FY22, \$150,000 in FY23)
Dina Jones, PhD	UAMS	Assistant Professor	Started June 1, 2021	Health Behavior and Health Education, College of Public Health	Tobacco prevention and control	None	\$459,865 total CI investment for start up resources over three years (\$153,288.33 start up funds per year, FY21 - FY23)
Yong-Chen (William) Lu, PhD	National Cancer Institute, National Institutes of Health	Assistant Professor	Started March 1, 2021	Pathology	Immunotherapy for metastatic cancer	None	\$1,100,000 total CI investment for start up resources over 5 years (\$250,000 FY21, \$300,000 FY22, \$200,000 FY23, \$150,000 FY24, \$100,000 FY25, \$100,000 FY26)
Hung Luu, MD, PhD	University of Pittsburgh Medical Center	Associate Professor	Begins January 1, 2022	Epidemiology	Environment and lifestyle factors affecting gastrointestinal cancers	None	\$1,500,000 total CI investment for start up resources over 5 years (\$300,000 per year for five years, FY22 - FY26)
Mohammad Rahman, PhD	Cold Spring Harbor Laboratory	Assistant Professor	Begins August 2, 2021	Biochemistry	Genetic splicing in cancer	None	\$1,800,000 total CI investment for start up resources over 5 years(\$400,000 FY22, \$350,000 FY23, \$350,000 FY24, \$350,000 FY25, \$350,000 FY26)

\*Cancer Institute investment represents the total commitment made by the Winthrop P. Rockefeller Cancer Institute to support the cancer research candidate and generally represents a three to five year period. This support is to pay for operating expenses including lab equipment, personnel salary and fringe, supplies, services, and other relative cancer research costs.

**Table 2. Clinical Oncology Recruitments December 1, 2020 - May 31, 2021**

<b>Incoming</b>	<b>Anticipated Start Date</b>	<b>Clinic</b>	<b>Subspecialty</b>	<b>Previous Organization</b>
Samer Ahmad Al Hadidi, MD, MS	7/1/2021	Myeloma Center	Myeloma	Fellow, Hematology and Oncology at Baylor College of Medicine, Houston, TX
Erin Eyberg, MD	8/1/2021	Ladies Oncology	Breast Surgery Fellow	General and trauma surgeon at Weatherby Healthcare
Munawwar Hussain, MD	7/1/2021	Inpatient	Hospitalist (Myeloma)	IM Attending Physician at Conemaugh Health System, Johnstown, PA
Fatima Khan, MD	7/1/2021	Inpatient	Hospitalist (Hem/Onc)	IM Hospitalist at Christus Trinity Mother Frances Hospital, Tyler, TX
John "Charlie" Kincaid, MD	7/1/2021	Palliative Care	Palliative Medicine	Fellow, Hospice and Palliative Care at UAMS, Little Rock, AR
Timothy Langford, MD	10/1/2021	Urology Oncology	Urology	Arkansas Urology, Little Rock, AR
Jacob Leffert, MD	7/1/2021	Inpatient	Hospitalist (Hem/Onc)	IM Resident at UAMS, Little Rock, AR
Sindhu Malapati, MD	7/1/2021	Medical Oncology	Breast Oncology	Chief Fellow, Hematology and Oncology at Ascension St. John Hospital and Medical Center, Grosse Pointe, MI
Hasan Rana, MBBS	7/1/2021	Inpatient	Hospitalist (Myeloma)	Hospitalist at Ascension St. Vincent Hospital, Indianapolis, IN
Mishanth Thalambedu, MD	7/1/2021	Inpatient	Hospitalist (Myeloma)	IM Resident at Abington Jefferson Health, Abington, PA
Min C Yoo, MD	8/1/2021	Ladies Oncology	Breast Surgery Fellow	Assistant Professor, Department of Surgery, Division of Transplant Surgery at the University of Tennessee Medical Center, Knoxville, TN



**Samer Ahmad Al Hadidi, M.D., M.S.**

**Specialty: Myeloma**

Dr. Al Hadidi received his medical degree, conferred with highest honors, from the University of Jordan School of Medicine in Amman, Jordan. He completed a residency in Internal Medicine at Michigan State University in Flint, MI before going on to earn his Masters in Clinical Research and Statistical Analysis from the University of Michigan in Ann Arbor, MI. Most recently, Dr. Al Hadidi completed a fellowship in Hematology and Oncology at the Baylor College of Medicine in Houston, TX with NIH T32 and grant funding.

**Erin Eyberg, M.D.**

**Specialty: Breast Surgery**

Dr. Eyberg received her medical degree from the University of Minnesota Medical School in Minneapolis, MN. She completed a surgical and research residency at Hennepin County Medical Center in Minneapolis before going on to complete an additional surgical residency at the University of Minnesota in Minneapolis. Dr. Eyberg is certified by the American Board of Surgery and is a member of the American College of Surgeons and American Medical Women's Association.

**Munawwar Hussain, M.D.**

**Specialty: Hospitalist**

Dr. Hussain graduated with a Bachelors of Medicine and Bachelors of Surgery from Punjab Medical College in Pakistan before completing an Internal Medicine residency at the Temple University Conemaugh Health System. Most recently, Dr. Hussain has served as an attending physician on the Internal Medicine faculty at Conemaugh Health System. Dr. Hussain is certified by the American Board of Internal Medicine.

**Fatima Khan, M.D.**

**Specialty: Hospitalist**

Dr. Khan received her Bachelor of Medicine and Bachelor of Surgery from King Edward Medical University in Pakistan. She went on to complete an Internal Medicine residency at Mount Sinai Medical Center in Miami, FL and a Geriatric Medicine fellowship at George Washington University Hospital in Washington, D.C. Most recently, Dr. Khan has served as an Internal Medicine hospitalist at Christus Trinity Mother Frances Hospital in Tyler, TX.

**John "Charlie" Kincaid, M.D.**

**Specialty: Hospice and Palliative Medicine**

Dr. Kincaid received his medical degree from the University of Arkansas for Medical Sciences in Little Rock, AR. He went on to complete a residency in Internal Medicine and, most recently, a fellowship in Hospice and Palliative Care Medicine, also at UAMS. Dr. Kincaid is certified by the American Board of Internal Medicine.

**Timothy Langford, M.D.**

**Specialty: Urology**

Dr. Langford received his medical degree from the University of Arkansas for Medical Sciences in Little Rock, AR. He went on to complete an internship in general surgery and residencies in general surgery and urology also at UAMS. In his final years of training he served as Chief Urology Resident. In 1993 he joined Arkansas Urology PA. Dr. Langford is certified by the American Board of Urology.

**Jacob Leffert, M.D.****Specialty: Hospitalist**

Dr. Leffert received his medical degree from the University of Arkansas for Medical Sciences in Little Rock, AR. He is currently working towards completing a residency in Internal Medicine, also at UAMS, in 2021. Dr. Leffert is a member of the American College of Physicians and the American Medical Society.

**Sindhu Malapati, M.D.****Specialty: Breast Oncology**

Dr. Malapati is a graduate of the Goa Medical College in Goa, India. She completed a residency in Internal Medicine at John H. Stroger Jr. Hospital of Cook County in Chicago, IL before completing a fellowship in Hematology and Oncology at Ascension St. John Hospital and Medical Center in Grosse Pointe, MI where she served as Chief Fellow. Dr. Malapati was the recipient of the Conquer Cancer / ASCO Foundation Merit Award from the American Society of Clinical Oncology in 2019 and 2020. Her research on solid tumor cancers has been published in numerous articles, publications, and abstracts. Dr. Malapati is certified by the American Board of Internal Medicine.

**Hasan Rana, M.B.B.S.****Specialty: Hospitalist**

Dr. Rana graduated with a Bachelors of Medicine and Bachelors of Surgery from the Lahore Medical & Dental College in Lahore, Pakistan. Most recently, Dr. Rana served as a hospitalist at Ascension St. Vincent Hospital in Indianapolis, IN with an adjunct academic appointment at Indiana University.

**Mishanth Thalambedu, M.D.****Specialty: Hospitalist**

Dr. Thalambedu received his Bachelor of Medicine and Bachelor of Surgery from the Kurnool Medical College in India. Most recently, he received his medical degree from Abington Jefferson Health in Abington, PA where he also completed a residency in Internal Medicine.

**Min C Yoo, M.D.****Specialty: Breast Surgery**

Dr. Yoo received her medical degree from the University of Texas Southwestern Medical School in Dallas, TX. She went on to complete a General surgery residency at UTSW before completing fellowships in renal transplant/access at UTSW and abdominal transplant surgery at the University of Tennessee Health Science Center, Methodist Transplant Institute in Memphis, TN. Most recently, Dr. Yoo served as an Assistant Professor in the Department of Surgery, Division of Transplant Surgery at the University of Tennessee Medical Center in Knoxville, TN.

**Table 3. Cancer Research Grant Activity**

	External Peer-Reviewed New Grants Awarded (#)	Awarded External Peer-Reviewed New Grant Funding (Annual Project Period Direct Costs)	External Peer-Reviewed New Grants Submitted (#)	Proposed Peer-Reviewed Grant Funding Submitted (Total Costs for All Years)
December 1, 2020 – May 31, 2021	<b>9</b>	<b>\$2,336,110</b>	<b>102</b>	<b>\$128,892,658</b>

# APPENDIX A

*Curricula vitae of  
cancer research recruits*

## CURRICULUM VITAE

---

**Name:** Mei Bai

**Email:** [mei.bai@aya.yale.edu](mailto:mei.bai@aya.yale.edu) (primary); [baimei@umsl.edu](mailto:baimei@umsl.edu) (secondary)

**Education:**

2016 - 2017 Postdoctoral associate at Yale University, New Haven, Connecticut  
2014 - 2015 Postdoctoral fellow at Emory University, Atlanta, Georgia  
2009 - 2014 Doctor of Philosophy in Nursing, Yale University, New Haven, Connecticut  
2001 - 2004 Master of Medicine in Nursing, Peking Union Medical College, Beijing, China  
1997 - 2001 Bachelor of Science in Nursing, Peking Union Medical College, Beijing, China

**Licenses:**

Registered Nurse at the State of Missouri (License No. 2018001860; compact status: multistate)  
Registered Nurse at the State of Connecticut (License No.137570)  
Registered Nurse at the State of Georgia (License No. RN248878)  
Registered Nurse in China (License No. 310000302280)  
Registered Higher Education Faculty Member in China (License No. 20053120171000256)

**Career:**

2018 - **Principal Investigator:** Self-affirmation intervention for people newly diagnosed with advanced cancer: a feasibility and preliminary efficacy trial. [University of Missouri-St. Louis IRB 2028763] St. Louis, Missouri

2018 - **Assistant Professor** University of Missouri-St. Louis, College of Nursing.

2016 - 2017 **Principal Investigator:** Expressive writing intervention for people newly diagnosed with cancer: a pilot study. Protocol submitted to the Yale University Human Investigation Committee (HIC), the Yale Cancer Center (YCC) and the Yale Center for Clinical Investigation (YCCI) Committees of Yale-New Haven Hospital, New Haven, Connecticut

2016 - 2017 **Palliative Care Research Scholar:** The evolution, trends and patterns of inpatient palliative care consultation service at Yale-New Haven Hospital over years 2007-2012 (supported by the palliative care postdoctoral fellowship from the Yale Cancer Center) New Haven, Connecticut

2014 - 2015 **Principal Investigator:** A study examining the effect of expressive writing for people newly diagnosed with advanced cancer (funded postdoctoral fellow feasibility study) Emory University School of Nursing, Atlanta, Georgia

2012 - 2013 **Teaching Fellow** for graduate courses of *Statistics for Clinical Nursing Research* and *Chronic Disease: Prevention and Management* at Yale University School of Nursing, New Haven, Connecticut

2011 - 2014 **Dissertation Research** Spiritual well-being in people with cancer (parent study funded by NIH, NINR, 5R01NR011872-02, PI McCorkle) New Haven, Connecticut

2010 - 2013 **Graduate Research Assistant:** An Intervention to Improve outcomes in patients with advanced cancer (funded by NIH, NINR 5R01NR011872-02, PI McCorkle) New Haven, Connecticut

2009 - 2010 **Graduate Research Assistant:** Internet cognitive-behavioral coping skills training program (CST) for adolescents with diabetes (funded by NIH, NINR 5R01NR004009-15, PI Grey), New Haven, Connecticut

2004 - 2009 **Faculty**, School of Nursing, Fudan University, Shanghai, China

2004 - 2008 **Nurse Tutor** at Zhongshan Hospital (cardiac, respiratory, surgical wards & intensive care

- units); Huashan Hospital (neurology, hematology & nephrology wards) Shanghai, China
- 2004 - 2007 **Principal Investigator:** Perceptions of nursing roles in the perspectives of clients, nurses and doctors –an ethnographic study. (funded by the Fudan University School of Nursing, China) Shanghai, China
- 2002 - 2004 **Principal Investigator:** Knowledge, competencies and attitudes required of differentiated academic levels of nurses in China - a revised Delphi study. (thesis research) Beijing, China
- 2002 - 2003 **Graduate Research Assistant:** Duty analyses and human resource forecasting in nursing profession (funded by the Ministry of Health in China, PI Shen), Beijing, China
- 2001 - 2004 **Nurse Tutor** at Fuwai Hospital, Cardiovascular Institute of China, Beijing, China

### Professional Honors or Recognition:

- May 2014 The 2014 Connecticut Holistic Health Association Prize for Academic Excellence.
- Feb. 2012 APOS 9th Annual Conference Poster Award for Excellence in the Presentation: Relationship among spiritual well-being, symptom distress and social dependency in patients newly diagnosed with advanced cancer (Bai, M., Ercolano, E., Ma, T., Lazenby, M., & McCorkle, R.)
- May 2010 Sigma Theta Tau International Delta Mu Chapter Yale University Honor Nursing Society Member
- Jan. 2008 The Translation Committee Member of the Chinese Consortium for the Higher Nursing Education

### Bibliography:

#### Original Articles

1. **Bai, M.** Psychological response to the diagnosis of advanced cancer: a systematic review. *Annals of Behavioral Medicine* (under review)
2. **Bai, M.** (2018). A critique of expressive writing experiment in the cancer population: focus on construct validity. *Current Psychology*, <https://doi.org/10.1007/s12144-018-0042-1>
3. Saracino, R. M., **Bai, M.**, Blatt, L., Solomon, L., & McCorkle, R. (2018). Geriatric palliative care: meeting the needs of a growing population. *Geriatric Nursing*, *39*, 225-229.
4. Henderson, R. G., McCloskey, B., Walter, E., Rimar, J., **Bai, M.**, & Moritz, E. D. (2017). Using the Rothman Index and length of stay as a trigger for palliative care in the medical intensive care unit and step-down units. *Journal of Hospice and Palliative Nursing*, *19*, 232-237.
5. Boxleitner, G., Jolie, S., Shaffer, D., Pasacreta, N., **Bai, M.**, & McCorkle, R. (2017). Comparison of two types of meditation on patient's psychosocial responses during radiation therapy for head and neck cancer. *Journal of Alternative and Complementary Medicine*, *23*, 355-361.
6. **Bai, M.**, Dixon, J., Williams, A. L., Jeon, S., Lazenby, M., & McCorkle, R. (2016). Exploring the individual patterns of spiritual well-being in people newly diagnosed with advanced cancer: a cluster analysis. *Quality of Life Research*, *25*, 2765-2773.
7. **Bai, M.**, Lazenby, M., Jeon, S., Dixon, J., & McCorkle, R. (2015). Exploring the relationship between spiritual well-being and quality of life among patients newly diagnosed with advanced cancer. *Palliative & Supportive Care*, *13*, 927-935.
8. **Bai, M.**, & Lazenby, M. (2015). A systematic review of associations between spiritual well-being and quality of life at the scale and factor levels in studies among patients with cancer. *Journal of Palliative Medicine*, *18*, 286-298.
9. **Bai, M.**, & Dixon, J. K. (2014). Exploratory factor analysis of the 12-item Functional Assessment of Chronic Illness Therapy--Spiritual Well-being Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer. *Journal of Nursing Measurement*, *22*, 404-420.
10. Lazenby, M., Dixon, J., **Bai, M.**, & McCorkle, R. (2014). Comparing the distress thermometer (DT) with the patient health questionnaire (PHQ)-2 for screening for possible cases of depression among patients newly diagnosed with advanced cancer. *Palliative & Supportive Care*, *12*, 63-8.

11. Crooks, M., Seropian, S., **Bai, M.**, & McCorkle, R. (2014). Monitoring patient distress and related problems before and after hematopoietic stem cell transplantation. *Palliative & Supportive Care, 12*, 53-61.
12. **Bai, M.**, Reynolds, N., & McCorkle, R. (2013). The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. *Palliative & Supportive Care, 11*, 503-522.
13. Ercolano, E., **Bai, M.**, Lazenby, M., Ma, T., & McCorkle, R. (2013). Emotional distress in patients newly diagnosed with late stage cancers. *Palliative Care & Medicine, S3*: 002 doi:10.4172/2165-7386.S3-002.
14. Fodeh, S. J., Lazenby, M., **Bai, M.**, Ercolano, E., Murphy, T., & McCorkle, R. (2013). Functional Impairments as symptoms in the symptom cluster analysis of patients newly diagnosed with advanced cancer. *Journal of Pain and Symptom Management, 46*, 500-510.
15. **Bai, M.** (2006). The gap between nursing theory and practice. *Journal of Nurses Training (in Chinese), 21*, 1082-4.
16. Shen, N., Liu H. P., & Zuo, Y. R., **Bai, M.**, & Li, J. Y. (2005). A study on the forecast of demands for nursing human resource in China. *Journal of Nursing Administration (in Chinese), 5*, 6-9.
17. Li, J. Y., **Bai, M.**, Liu, H. P., Shen, N., & Zuo, Y. R. (2004). Application of the Delphi method in the analysis of nursing duties and the requirement forecast for the human resources. *Journal of Nursing Management (in Chinese), 4*, 35-7.
18. Shen, N., Li, J. Y., **Bai, M.**, Liu H. P., & Zuo, Y. R. (2004). A predictive study forecasting nursing education needs in China. *Chinese Journal of Nursing Education (in Chinese), 1*, 17-20.
19. **Bai, M.**, & Shen, N. (2003). Review: Qualification recommendations for the nursing practitioners. *Chinese Journal of Nursing (in Chinese), 38*, 828-30.
20. Huang, H. Y., **Bai, M.**, & Shi, X. Y. (2003). A survey of working status of the first batch of college graduated nursing students after the nursing education reform. *Nursing Research (in Chinese), 17*, 418-21.
21. **Bai, M.** (2003). On self-directed learning in medical education. *Fudan Education Forum (in Chinese), 1*, 88-90.

#### Book Chapters:

1. Lazenby, M., McCorkle, R., & **Bai, M.** (2019). Chronic illness and end-of-life care. In: L. Honan (Ed.) *Focus on adult health medical-surgical nursing* (2<sup>nd</sup> ed.). (pp. 27-51). Lippincott Williams & Wilkins.
2. Lazenby, M., **Bai, M.**, & McCorkle, R. (2018) Chronic illness. In: J. J. Fitzpatrick (Ed.) *The encyclopedia of nursing research* (4<sup>th</sup> ed.). (pp. 82-85). New York, NY. Springer Publishing Company, LLC.

#### Presentations:

1. **Bai, M.**, Dixon, J., Williams, A., Jeon, S., Lazenby, M., & McCorkle, R. Exploring the individual patterns of spiritual well-being in relation to quality of life outcomes in people newly diagnosed with advanced cancer: a cluster analysis. Podium presentation. The American Psycho-Oncology Society. Washington, D.C., July 2015.
  2. **Bai, M.**, Lazenby, M., Ercolano, E., Dixon, J., & McCorkle, R. Exploring the relationship between spiritual well-being and quality of life in people newly diagnosed with advanced cancer during existential plight. Poster presentation. Eastern Nursing Research Society, Philadelphia, PA, April 2014.
  3. **Bai, M.**, Ercolano, E., Ma, T., & McCorkle, R. Spiritual well-being and symptom distress in patients newly diagnosed with advanced cancer. Poster presentation. Eastern Nursing Research Society, New Haven, CT, March 2012.
  4. **Bai, M.**, Ercolano, E., Ma, T., Lazenby, M., & McCorkle, R. Relationship among spiritual well-being, symptom distress, and social dependency in patients newly diagnosed with advanced cancer. Poster presentation. The American Psycho-Oncology Society. Miami, FL, February 2012.
  5. Weissman, G., & **Bai, M.** East meets West. End of life issues. (lecture presented to the Nurse Practitioner Council of the Palm Beach County) West Palm Beach, FL, April 2007.
-

## **Curriculum Vitae**

Mathias Brochhausen

### **Business address:**

Department of Health Outcomes and Biomedical Informatics  
University of Florida  
Clinical and Translational Research Building  
2004 Mowry Road, Suite 3228  
PO Box 100147  
Gainesville, FL 32610-0147  
Email: [mbrochhausen@ufl.edu](mailto:mbrochhausen@ufl.edu)

### **Home address**

2822 NW 67<sup>th</sup> Place  
Gainesville FL, 32653  
Tel: 501 831 3119

### **Education**

Johannes Gutenberg-Universität, Mainz, Germany	PhD (Dr. phil.)	2000- 2004	Philosophy
Johannes Gutenberg-Universität Mainz, Germany	M.A.	1995- 2000	Philosophy

### **Professional Experience**

2019-present	Associate Director of Education Programs and Associate Professor, Department of Health Outcomes and Biomedical Informatics, University of Florida
2017-2019	Associate Professor, Department of Medical Humanities and Bioethics (Secondary Appointment), University of Arkansas for Medical Sciences
2017-2019	Vice-Chair for Faculty Development, Department of Biomedical Informatics, University of Arkansas for Medical Sciences
2016-2019	Associate Professor (with tenure), Department of Biomedical Informatics, University of Arkansas for Medical Sciences
2014-2019	Affiliate Graduate Faculty, University of Arkansas, Little



Rock

2014-2015	Interim Associate Director, Comprehensive Informatics Resource Center, Translational Research Institute, University of Arkansas of Medical Sciences
2011-2016	Assistant Professor, Department of Biomedical Informatics, University of Arkansas for Medical Sciences
2010-2011	Visiting Adjunct Instructor, Department of Philosophy, State University of New York, University at Buffalo, Buffalo, NY
2007-2010	Institute Manager, Institute for Formal Ontology and Medical Information Science, Universität des Saarlandes, Saarbrücken, Germany
2006-2011	Executive Director, European Centre for Ontological Research, Universität des Saarlandes, Saarbrücken, Germany
2005-2011	Researcher, Institute for Formal Ontology and Medical Information Science, Universität des Saarlandes, Saarbrücken, Germany
2005-2010	Lecturer, Universität des Saarlandes, Saarbrücken, Germany
2005	Lecturer, Department of Philosophy, Johannes Gutenberg-Universität, Mainz, Germany

**Current Research Funding**

1. U24CA215109      Prior (PI)      09/22/2017 – 07/31/2022  
National Cancer Institute      \$3,700,000  
TCIA Sustainment and Scalability – Platforms for Quantitative Imaging Informatics in Precision Medicine  
Role: Co-I (10%)
2. R01GM111324      Brochhausen (PI)      03/05/2015 - 02/29/2021  
National Institute for General Medical Sciences      \$1,289,512  
*Comparative Assessment Framework for Environments of Trauma Care (CAFÉ)*  
Role: PI (10%)

**Past Research Funding**

1. 1 CDC-RFA-TP18-1802      Adams (PI)      09/01/2018 – 08/30/2019  
CDC      \$2,000,000  
*Cooperative Agreement for Emergency Response: Public Health Crisis Response*  
Co-Investigator (10%)
  
2. 3UL1TR00255301S1      Boulware (PI)      07/01/2018 – 04/30/2019  
NCATS      \$1,180,257  
*CTSA Admin Supplement – Hammond/Nordo sIRB Standards,*  
Co-Investigator (20%)
  
3. 3U24CA215109-02S1      Prior (PI)      08/01/2018 – 07/31/2019  
NIH/NCI      \$375,000  
*Informatics Platform for Cancer-Related Cognitive Impairment and Dementia*  
*Research*  
Role: Co-Investigator (5%)
  
4. U24CA215109      Prior (PI)      9-22-2017-07-31-2022  
National Cancer Institute      \$8,318,449  
*TCIA Sustainment and Scalability – Platforms for Quantitative Imaging*  
*Informatics*  
Role: Co-Investigator (10%)
  
5. U24 HD090912      Lee (PI)      9/21/2016 – 8/30/2020  
Eunice Kennedy Shriver National Institute for Child Health and Human  
Development  
*Data Coordinating and Operations Center (DCOC) for the IDeA States Pediatric*  
*Clinical Trials Network*  
Role: Co-Investigator (10%)
  
6. R01LM011838-01      Boyce (PI)      7/1/2014 - 1/30/2018  
DHHS/BARDA. Passthrough Univ. of Pittsburgh  
UAMS Total Direct Costs: \$169,487  
*Addressing Gaps in Clinically Useful Evidence on Drug-Drug Interactions*  
Role: Co-Investigator (20%)
  
7. UL1TR000039      James (PI)      7/1/2009 – 6/30/2014  
National Center for Advancing Translational Science  
Overall Total Direct Costs: \$15,004,455  
*Arkansas Translational Research Institute*  
Role: Co-Investigator (10%)
  
8. HHSN275201300009C      Topaloglu (PI)      09/26/2013-09/25/2014  
Health and Human Services  
Overall Total Direct Costs: \$2,538,074

*The Arkansas Comprehensive Research Informatics Suite Hub in the National Children's Study*

Role: Co-Investigator (50%)

+ Dr. Brochhausen's involvement with the project was discontinued after 01/31/2015 after the National Children's Study has been closed by the NIH.

9. R01GM101151 Hogan (PI)/Wagner (PI) 04/18/2012-03/31/2017  
National Institute for General Medical Sciences  
UAMS Total Direct Costs: \$374,286  
*Apollo: Increasing access and use of epidemic models through the development and adoption of standards*  
Role: Co-Investigator (20%)+  
+ Dr. Brochhausen's involvement with the project was discontinued due to the relocation of the subcontract from UAMS to UF
10. Contract #HHSN275200800026C Hobbs (PI) 09/26/2008-09/25/2013  
Health and Human Services  
UAMS Total Direct Costs: \$1,413,899  
*The National Children's Study, Information Management System Hosting*  
Role: Co-Investigator (50%)
11. FP7-ICT- 270089 Graf (PI) 02/01/2011 to 01/31/2015  
The European Commission (FP7-ICT)  
Total amount: EUR 13 329 898  
*From data sharing and integration via VPH models to personalised medicine (P-MEDICINE)*  
Role: Co-Investigator (50%)+  
+ Due to his relocation to the US Dr. Brochhausen had to step down as Co-Investigator. Based on his contribution to the proposal and his expertise he was appointed external advisor to the project.
12. FP7-ICT- 216461 Rosso (PI) 02/01/2008 to 05/31/2012  
The European Commission (FP7-ICT)  
Total amount: EUR 7 249 995  
*An open, ubiquitous and adaptive chronic disease management platform for COPD and renal insufficiency (CHRONIOUS)*  
Role: Subcontractor (until 2011)
13. FP7-ICT- 224991 Linden (PI) 07/01/2008 to 12/31/2013  
The European Commission (ICT-PCP)  
Total amount: EUR 17 999 000  
*European Patients Smart Open Services (epSOS)*  
Role: Subcontractor (fulfilled 2011)
14. FP6-IST-026996 Tsiknakis (PI) 02/01/2006 to 07/31/2010  
The European Commission

Total amount: EUR 11 887 000  
*Advancing Clinico-Genomic Trials on Cancer (ACGT)*  
Role: Co-Investigator

### Professional Memberships

1. Association for Symbolic Logic 2017-present
2. International Society for Biocuration 2014-present
3. American Medical Informatics Association 2012-present
4. The International Association for Ontology and its Application 2010-present
5. Institute of Electrical and Electronics Engineers 2008-2009, 2017-present

### Honors and Awards

- 2017 Best Poster Award, International Conference for Biomedical Ontologies (ICBO) 2017, Newcastle, UK for: Bona J, Grohol J, Zozus M, Zozus R, **Brochhausen M**: Toward using ontologies to improve results in searches for mental health information.
- 2014 Distinguished Paper Award of FOIS 2014 (Formal Ontologies in Information Systems) for: Schulz S, Martinez Costa C, Cornet R, **Brochhausen M**, Rector A: *An Ontological Analysis of Reference in Health Record Statements*
- 2001-2003 Rhineland-Palatine PhD Fellowship Program (Total amount awarded: \$ 24,100)
- 2000 Graduated with Highest Distinction, Johannes Gutenberg-Universität, Mainz

### Study Sections/Review Panels

1. Reviewer for the Vienna Science and Technology Fund, Austria; Information and Communication Technology Call 2012
2. Reviewer for Program "CORE 2011", "Core 2012", "Core 2013", and "Core 2014"; Fonds National de la Recherche Luxembourg (National Research Grant Program of Luxembourg), 2011-2014.
3. Reviewer for the Institute National du Cancer, Paris, France, 2017, 2019.
4. NIH Small Business Health Informatics (ZRG1-HDME11) review panel, 2019.
5. NIH Clinical Informatics on Substance Abuse (ZRG1-HDM-E90) review panel, June 2019.
6. NLM Special Emphasis Panel (SEP) to review applications in response to the NLM's funding opportunity "Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed) (PAR-18-796)", May 2020

## External Advisory Boards

1. The European Commission (FP7-ICT) *From data sharing and integration via VPH models to personalised medicine (P-MEDICINE)*, FP7-ICT- 270089, 2012-2015.
2. The European Commission (FP7-ICT) *Semantic Interoperability for Health Network (SemanticHealthNet)*, FP7-ICT- 288408, 2012-2015.
3. Member of the Advisory Board, Tissue Bank of the Comprehensive Cancer Center Ostbayern, Regensburg, Germany.

## Publications

### Peer-reviewed publications

1. Kerstjens DP, **Brochhausen M**. Krankheiten als natürliche Arten. In: Schultz M et al.: Schnittstelle Mensch – Umwelt in Vergangenheit, Gegenwart und Zukunft. Göttingen. 2000: 448-449.
2. **Brochhausen M**. Understanding Recent Apes As Parallel Models in Paleoanthropology. *Anthropologie XL/2*, 2002: 115-118.
3. **Brochhausen M**. The derives from relation in biomedical ontologies. *Stud Health Technol Inform*. 124:769-74, 2006. PMID: 17108607.
4. Tsiknakis M, Rueping S, Martin L, Sfakianakis C, Bucur A, Sengstag T, **Brochhausen M**, Pucaski J, Graf N. Developing a European grid infrastructure for cancer research: vision, architecture and services. *Ecancermedicinescience* 2007; 1:56. PMID: 22275955.
5. Weiler G, **Brochhausen M**, Graf N, Schera F, Hoppe A, Kiefer S. Ontology based data management systems for post-genomic clinical trials within a European Grid Infrastructure for Cancer Research. *Conf Proc IEEE Eng Med Biol Soc*. 2007; 6435-8. PMID: 18003495.
6. Tsiknakis M, **Brochhausen M**, Nabrzyski J, Pucacki J, Sfakianakis SG, Potamias G, Desmedt C, Kafetzopoulos D. A semantic grid infrastructure enabling integrated access and analysis of multilevel biomedical data in support of postgenomic clinical trials on cancer. *IEEE Trans Inf Technol Biomed*. 2008 Mar;12(2):205-17. PMID: 18348950.
7. Smith B, **Brochhausen M**. Establishing and harmonizing ontologies in an interdisciplinary health care clinical research environment. *Stud Health Technol Inform*. 2008;134:219-33. PMID: 18376049.
8. Wagner M, Breiner T, Betz T, Bernhardt I, Pütz N, Weichert F, Shamaa A, **Brochhausen M**, Awad S, Richards T, Groh A, Linder R, Landes CA. Virtual tissue. Quaoaring. *Pathologe*. 2008 Nov;29 Suppl 2:123-8. PMID: 19039616.
9. **Brochhausen M**, Weiler G, Cocos C, Stenzhorn H, Graf N, Doerr M, Tsiknakis M. The ACGT Master Ontology on Cancer - a New Terminology Source for Oncological Practice, In: Puuronen S, Pechenizkiy M, Tsymbal A, Lee DJ (eds.): Proceedings of the 21st IEEE International Symposium on Computer-Based Medical Systems, IEEE Computer Society, Los Alamitos. 2008: 324-329.

10. **Brochhausen M**, Weiler G, Martín L, Cocos C, Stenzhorn H, Graf N, Dörr M, Tsiknakis M, Smith B (2008) Applications of the ACGT Master Ontology on Cancer, R. Meersman, Z. Tari, and P. Herrero (eds.): Proceedings of 4th International IFIP Workshop On Semantic Web & Web Semantics (OTM 2008: Workshops), Springer, Heidelberg, Berlin. LNCS 5333, 2008: 1046–1055.
11. Martín L, Anguita L, Maojo V, Bonsma E, Bucur AID, Vrijnsen J, **Brochhausen M**, Cocos C, Stenzhorn H, Tsiknakis M, Doerr M, Kondylakis H. Ontology Based Integration of Distributed and Heterogeneous Data Sources in ACGT; In: Azevedo L, Londral AR, (eds). Proceedings of the First International Conference on Health Informatics, HEALTHINF 2008, Funchal, Madeira, Portugal, January 28-31, 2008, Volume 1. INSTICC. 2008: 301-306.
12. **Brochhausen M**, Slaughter L. Patient Empowerment by Ontology-Based Multilingual Systems. *IFMBE Proceedings 25/XII*, Springer, Heidelberg, Berlin. 2009: 439-42.
13. Smith B, **Brochhausen M**. Putting Biomedical Ontologies to Work. *Methods Inf Med*. 2010 Mar 16;49(2):135-40. PMID: 20135080.
14. **Brochhausen M**, Spear AD, Cocos C, Weiler G, Martín L, Anguita A, Stenzhorn H, Daskalaki E, Schera F, Schwarz U, Sfakianakis S, Kiefer S, Dörr M, Graf N, Tsiknakis M. The ACGT Master Ontology and its applications - towards an ontology-driven cancer research and management system. *J Biomed Inform*. 2011 Feb;44(1):8-25. PMID: 20438862.
15. **Brochhausen M**, Slaughter L, Stenzhorn H, Graf N. User-specific perspectives on ontologies. *Stud Health Technol Inform*. 2010;156:114-21. 2010. PMID: 20543346.
16. Stenzhorn H, Weiler G, **Brochhausen M**, Schera F, Kritsotakis V, Tsiknakis M, Kiefer S, Graf N. The ObTiMA system - ontology-based managing of clinical trials. *Stud Health Technol Inform*. 2010;160(Pt 2):1090-4. 2010. PMID: 20841852.
17. Grigonyte G, **Brochhausen M**, Martín L, Tsiknakis M, Haller J (2010) Evaluating Ontologies with NLP-Based Terminologies – A Case Study on ACGT and Its Master Ontology, In: Galton A, Mizoguchi R (eds.): Formal Ontology in Information Systems - Proceedings of the Sixth International Conference (FOIS 2010), IOS, Amsterdam, 2010: 131-142.
18. Martín L, Anguita A, Graf N, Tsiknakis M, **Brochhausen M**, Rüping S, Bucur A, Sfakianakis S, Sengstag T, Buffa F, Stenzhorn H. ACGT: advancing clinico-genomic trials on cancer - four years of experience. *Stud Health Technol Inform*. 2011;169:734-8. 2011. PMID: 21893844.
19. Schneider L, **Brochhausen M**, Koepsell D. On Some Best Practices in Large-Scale Ontology Development: The Chronious Ontology Suite as a Case Study. In: Formal Ontology Meets Industry 5th International Workshop Proceedings, IOS Press, Amsterdam, 2011: 28-38.
20. Schneider L, **Brochhausen M**. The CHRONIUS Ontology Suite: Methodology and Design Principles. International Conference on Biomedical Ontologies (ICBO) 2011, University at Buffalo, Buffalo NY, 2011: 167-173.
21. Schulz S, **Brochhausen M**, Hoehndorf R. Higgs Bosons, Mars Missions, and Unicorn Delusions: How to Deal with Terms of Dubious Reference in Scientific Ontologies. International Conference on Biomedical Ontologies (ICBO) 2011, University at Buffalo, Buffalo NY, 2011: 183-189.

22. epSOS contributors (including **M. Brochhausen**). epSOS learnings: semantics a matter of patient safety and the ultimate health care delivery system. *Swiss Medical Informatics*. 2011;73:23-26.
23. **Brochhausen M**, Blobel B. Architectural approach for providing relations in biomedical terminologies and ontologies. *Stud Health Technol Inform*. 2011;169:739-43. PMID: 21893845.
24. Blobel B, **Brochhausen M**, González C, Lopez DM, Oemig F. A system-theoretical, architecture-based approach to ontology management. *Stud Health Technol Inform*. 2012;180:1087-9. PMID: 22874362.
25. Almeida MB, Slaughter L, **Brochhausen M**. Towards an ontology of document acts: Introducing a document act template for healthcare. OTM 2012 Workshops, LNCS 7567, Berlin, New York, Heidelberg, 2012: 420–5.
26. **Brochhausen M**, Fransson MN, Eriksson M, Merino-Martinez R, Norlin L, Kjellqvist S, Anderberg M, Hogan WR, Litton J-E. Developing an ontology for sharing biobank data based on the BBMRI minimum data set MIABIS. Ontologies in Biomedicine and Life Sciences (OBML) 2012, Universität Leipzig, Medizinische Fakultät, Leipzig, 2012: 1-6.
27. Slaughter L, **Brochhausen M**, Hogan W, Nytrø Ø. The core clinical protocol ontology (C2PO): A realist ontology for representing the recommendations within clinical guidelines. *Stud Health Technol Inform*. 2013;192:997. PMID: 23920771.
28. Hogan WR, Hanna J, Joseph E, **Brochhausen M**. Towards a Consistent and Scientifically Accurate Drug Ontology. Proceedings International Conference on Biomedical Ontology 2013. Main Conference. Montreal, 2013: 68-73.
29. Hanna J, Joseph E, **Brochhausen M**, Hogan WR. Building a Drug Ontology based on RxNorm and Other Sources. Proceedings International Conference on Biomedical Ontology 2013. Workshops. Montreal 2013: 63-68.
30. Sahay R, Ntalaperas D, Kamateri E, Hasapis P, Beyan OD, Strippoli M, Demetriou C, **Brochhausen M**, Bouras T, Tian T, Antoniadis A, Georgousopoulos C, Hauswirth M, Decker S. An Ontology for Clinical Trial Data Integration. In: IEEE SMC 2013 - IEEE International Conference on Systems, Man, and Cybernetics, Manchester, UK, United Kingdom, 2013, 3244-50.
31. **Brochhausen M**, Fransson M, Kanaskar N, Eriksson M, Merino-Martinez R, Hall RA, Norlin L, Kjellqvist S, Hortlund M, Topaloglu U, Hogan WR, Litton JE. Providing a semantically rich ontology for sharing biobank data based on Minimum Information About Biobank data Sharing. *J Biomed Semantics*. 2013 Oct 8;4(1):23. PMID: 24103726.
32. Hanna J, Joseph E, **Brochhausen M**, Hogan WR. Building a drug ontology based on RxNorm and other sources. *J Biomed Semantics*. 2013 Dec 18;4(1):44. PMID: 24345026.
33. Blobel B, Goossen W, **Brochhausen M**. Clinical modeling - a critical analysis. *Int J Med Inform*. 2014 Jan;83(1):57-69. PMID: 24161541.
34. Bian J, Xie M, Hudson TJ, Eswaran H, **Brochhausen M**, Hanna J, Hogan WR. CollaborationViz: Interactive visual exploration of biomedical research collaboration networks. *PLoS One*. 2014 Nov 18;9(11):e111928. PMID: 25405477.

35. Schulz S, Martínez Costa C, Karlsson D, Cornet R, **Brochhausen M**, Rector A. An Ontological Analysis of Reference in Health Record Statements. In: Garbacz P, Kutz O (eds.), *Formal Ontologies in Information Systems. Proceedings of the 8th International Conference on Formal Ontologies in Information Systems 2014*, Sep 22-25, Rio de Janeiro, Brazil, 289-302.
36. **Brochhausen M**, Schneider J, Malone D, Empey PE, Hogan WR, Boyce RD. Towards a foundational representation of potential drug-drug interaction knowledge. *Joint Proceedings of The First International Workshop on Drug Interaction Knowledge Management (DIKR 2014), The Second International Workshop on Definitions in Ontologies (IWOOD 2014), and The Starting an OBI-based Biobank Ontology Workshop (OBIB 2014)*, co-located with the International Conference on Biomedical Ontologies 2014 (ICBO 2014), Houston, TX, USA, October 6-9, 2014. CEUR-WS.org, online
37. **Brochhausen M**, Hogan WR, Levander JD, Brown ST, Millet NE, Hanna J, Wagner MM: A novel representation of terms related to infectious disease epidemiology for epidemic modeling. *Proc. Of the 5<sup>th</sup> International Conference for Biomedical Ontologies* Houston, TX, USA, Oct. 6-9, 2014, CEUR-WS.org, online.
38. Fransson MN, Rial-Sebbag E, **Brochhausen M**, Litton JE. Toward a common language for biobanking. *Eur J Hum Genet.* 2015 Jan;23(1):22-8. PMID: 24713663.
39. Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti N, Vilar S, **Brochhausen M**, Samwald M, Rastegar-Mojarad M, Dumontier M, Boyce RD. Toward a complete dataset of drug-drug interaction information from publicly available sources. *J Biomed Inform.* 2015 Jun;55:206-17. PMID: 25917055.
40. Smith B, Arabandi S, **Brochhausen M**, Calhoun M, Ciccicarese P, Doyle S, Gibaud B, Goldberg I, Kahn CE Jr, Overton J, Tomaszewski J, Gurcan M. Biomedical imaging ontologies: A survey and proposal for future work. *J Pathol Inform.* 2015 Jun 23;6:37. PMID: 26167381.
41. Utecht J, **Brochhausen M**. Measuring the usability of triple stores for knowledge management on trauma care organizations. *CEUR workshop proceedings.* 2015; 1546:241-242.
42. **Brochhausen M**, Zheng J, Birtwell D, Williams H, Masci AM, Ellis HJ, Stoeckert CJ Jr. OBIB – a novel ontology for biobanking. *J Biomed Semantics.* 2016 May 2;7:23. PMID: PMC4855778.
43. Hogan WR, Wagner MM, **Brochhausen M**, Levander J, Brown ST, Millet NE, DePasse J, Hanna J,: The Apollo Structured Vocabulary: an OWL2 ontology of phenomena in infectious disease epidemiology and population biology for use in epidemic simulation. *J Biomed Semantics.* 2016 7:50. PMID: PMC4989460
44. Bandrowski A, Brinkman R, **Brochhausen M**, Brish MH, Bug B, Chibucos MC, Clancy K, Courtot M, Derom D, Dumontier M, Fan L, Fostel J, Fragoso G, Gibson F, Gonzalez-Beltran A, Haendel MA, He Y, McGee M, Morrison N, Overton JA, Parkinson H, Peters B, Rocca-Serra P, Ruttenberg A, Sansone SA, Scheuermann RH, Schober D, Smith B, Soldatova LN, Stoeckert CJ Jr, Taylor CF, Torniai C, Turner JA, Vita R, Whetzel PL, Zheng J. The Ontology for Biomedical Investigations. *PLoS One.* 2016 11(4):e0154556. PMID: PMC4851331



45. Hicks A, Hanna J, Welch D, **Brochhausen M**, Hogan WR. The ontology of medically related social entities: recent development. *J Biomed Semantics*. 2016 Jul 12;7:47.
46. Utecht J, Judkins J, Colvin T Jr., Otte JN, Rogers N, Rose R, Alvi M, Hicks A, Ball J, Bowman SM, Maxson RT, Nabaweesei R, Pradhan R, Sanddal ND, Tudoreanu ME, Winchell R, **Brochhausen M**. OOSTT: a Resource for Analyzing the Organizational Structures of Trauma Centers and Trauma Systems. CEUR Workshop Proc. 2016 Aug;1747. [http://ceur-ws.org/Vol-1747/IT504\\_ICBO2016.pdf](http://ceur-ws.org/Vol-1747/IT504_ICBO2016.pdf)
47. **Brochhausen M**, Utecht J, Judkins j, Schneider J, Boyce RD. Formalizing Evidence Type Definitions for Drug-drug Interaction Studies to Improve Evidence Base Curation. *Stud Health Technol Inform* 2017; 245:960-964.
48. Judkins J, Tay-Sontheimer J, Boyce RD, **Brochhausen M**. Extending the DIDEO Ontology to Include Entities from the Natural Product Drug Interaction Domain of Discourse. *J Biomed Semantics* 2018 May 9; 9(1): 15.
49. Bona JP, Prior FW, Zosus MN, **Brochhausen M**. Enhancing Clinical Data and Clinical Research Data with Biomedical Ontologies – Insights from the Knowledge Representation Perspective. *IMIA Yearbook of Medical Informatics* 2019; 28: 140-151.
50. Utecht J, Ball J, Bowman SM, Dodd J, Judkins J, Maxson RT, Nabaweesei R, Pradhan R, Sanddal ND, Winchell RJ, **Brochhausen M**. Development and validation of a controlled vocabulary: an OWL representation of organizational structures of trauma centers and trauma systems. *Stud Health Technol Inform* 2019; 264:403-407.
51. Bona JP, **Brochhausen M**, Hogan WR. Enhancing the drug ontology with semantically-rich representations of National Drug Codes and RxNorm unique concept identifiers. *BMC Bioinformatics*. 2019 Dec 23;20(Suppl 21):708.
52. Forthcoming: Bona JP, Utecht J, Bost S, Hayes C, **Brochhausen M**. Building a Shared Ontology Use Patterns Repository. *International Conference on Biomedical Ontology (ICBO) 2019*, Buffalo, NY, July 30 - August 2, 2019.
53. Blobel B, Ruotsalainen P, **Brochhausen M**, Oemig F, Uribe GA. Autonomous Systems and Artificial Intelligence in Healthcare Transformation to 5P Medicine - Ethical Challenges. *Stud Health Technol Inform*. 2020 Jun 16;270:1089-1093. doi: 10.3233/SHTI200330. PMID: 32570549.
54. (accepted) Brochhausen M, Ball J, Sanddal ND, Dodd J, Braun N, Bost S, Utecht J, Winchell RJ, Sexton KW. Collecting Data on Organizational Structures of Trauma Centers: The CAFE Web Service. *Journal of Trauma Surgery and Acute Care Open*.

#### Published Abstracts and Posters

1. Hanna J, Chen C, Crow WA, Hall R, Liu J, Pendurthi T, Schmidt T, Jennings SF, **Brochhausen M**, Hogan W. Simplifying MIREOT: A MIREOT Protégé Plugin. Presented at the International Semantic Web Conference, Boston, Massachusetts, November 13, 2012. NIHMSID: 446691.
2. Hogan WR, **Brochhausen M**, Smith B. A Call to Urgent Action On Standard Ontologies for Translational Science. *Clinical and Translation Science* 2013, 6(2): 157.

3. Chen C, Hanna J, Talburt JR, **Brochhausen M**, Hogan WR. A Demonstration of Entity Identity Information Management Applied to Demographic Data in a Referent Tracking System. Proceedings International Conference on Biomedical Ontology 2013. Main Conference. Montreal, 2013: 135-136.
4. Nzinga A, Mehdi K, Topaloglu U, **Brochhausen M**. Extending an ontology for biobank administration to cover data related to studies, study participants and specimens. SE Regional IDeA Meeting 2013 Proceedings, 58.
5. Ayvaz S, Zhu Q, Hochheiser H, **Brochhausen M**, Horn, J, Dumontier, M, Samwald M, Boyce, RD. "Drug-Drug Interaction Data Source Survey and Linking." AMIA Jt Summits Transl Sci Proc. 2014: 16. PMC4333686.
6. Judkins J, Utecht J, **Brochhausen M**. Easy Extraction of Terms and Definitions with OWL2TL. CEUR Workshop Proc. 2016 Aug;1747. pii: D205. [http://ceur-ws.org/Vol-1747/D205\\_ICBO2016.pdf](http://ceur-ws.org/Vol-1747/D205_ICBO2016.pdf).
7. **Brochhausen M**, Empey PE, Schneider J, Hogan Wr, Boyce RD. Adding Evidence Type Representation to DIDEO. CEUR Workshop Proc. 2016 Aug;1747. [http://ceur-ws.org/Vol-1747/IP02\\_ICBO2016.pdf](http://ceur-ws.org/Vol-1747/IP02_ICBO2016.pdf)
8. Bona J, Grohol J, Zozus M, Zozus R, **Brochhausen M**: Toward using ontologies to improve results in searches for mental health information. ICBO 2017, Sep 13-15, Newcastle UK, CEUR Workshop Proc. 2018 Jul;2137, [http://ceur-ws.org/Vol-2137/paper\\_37.pdf](http://ceur-ws.org/Vol-2137/paper_37.pdf).
9. Judkins J, Tay-Sontheimer J, Boyce RD, Brochhausen M: Extending the DIDEO ontology to include entities from the natural product drug interaction domain of discourse. Vaccine and Drug Ontology Studies 2017, Sep 13, Newcastle UK (in press).
10. Utecht J, Bona J, Brochhausen M: Creating RDF Data on Trauma Care Organizations from Questionnaires. AMIA 2017 Annual Symposium, Washington DC, November 4-8 2017.
11. Boyce RD, Ragueneau-Majlessi I, Yu J, Sontheimer J, Kinsella C, Brochhausen M, Judkins M, Pinkleton B, Cooney R, Paine M, McCune J: Toward a Reliable and Interoperable Public Repository for Natural Product Drug Interaction Study Data. AMIA 2017 Annual Symposium, Washington DC, November 4-8 2017.
12. Forthcoming: Bona JP, Kemp AS, Nolan T, Larson-Prior L, Das A, Virmani T, Pillai L, **Brochhausen M**, Prior FW. Semantic Integration of Neuroinformatics Data in the Arkansas Image Enterprise System with Open Biomedical Ontologies. *International Conference on Biomedical Ontology (ICBO) 2019*, Poster session, Buffalo, NY, July 30 - August 2, 2019.
13. Forthcoming: Bost S, Eklund N, Silander K, Zheng J, Stoeckert CJ, **Brochhausen M**. Mapping Data Annotated with the Minimum Information About Biobank data Sharing (MIABIS) 2.0 to the Ontology for Biobanking (OBIB). *International Conference on Biomedical Ontology (ICBO) 2019*, Poster session, Buffalo, NY, July 30-August 2, 2019.
14. Forthcoming: Bona JP, Utecht J, **Brochhausen M**. Providing a User-oriented Interface to Enable Semantic Queries in PRISM. *American Medical Informatics Association 2019 (AMIA) Annual Symposium*, Poster session, Washington, DC, November 16 - 20, 2019.

15. Forthcoming: Kemp AS, Bona JP, Nolan TS, Larson-Prior L, Virmani T, Pillai L, **Brochhausen M**, Tarbox L, Prior FW. Semantic Representations of Multi-Modal Data, NeuroInformatic Processing Pipelines, and Derived Neuroimaging Results in the Arkansas Image Enterprise System (ARIES). *American Medical Informatics Association 2019 (AMIA) Annual Symposium*, Poster session, Washington, DC, November 16 - 20, 2019.
16. Forthcoming: Hayes CJ, Bona JP, **Brochhausen M**. Using Semantic Representations for Urine Drug Tests in the Veterans Health Administration. *American Medical Informatics Association 2019 (AMIA) Annual Symposium*, Poster session, Washington, DC, November 16 - 20, 2019.

### **Edited Conference Proceedings, Monographs, Book Chapters, and Book Reviews**

1. **Brochhausen M**. Krankheit als subjektives Ereignis. In: Kemkes-Grottenthaler A & Henke W (Hg.). Pein und Plagen. Aspekte einer Historischen Epidemiologie. Edition Archaea: Gelsenkirchen, 2001: 13-20.
2. Brochhausen C, **Brochhausen M**. Relativistische Wissenschaftskritik als epistemologischer Ansatz in der Historischen Epidemiologie. In: Kemkes-Grottenthaler A & Henke W (Hg.): Pein und Plagen. Aspekte einer Historischen Epidemiologie. Edition Archaea: Gelsenkirchen, 2001: 59-72.
3. Brochhausen C, **Brochhausen M**, Seyberth HW. Pädiatrie zwischen Patientenschutz und Therapiesicherheit – eine interdisziplinäre Herausforderung. In: Alt KW & Kemkes-Grottenthaler A (Hg.): Kinderwelten. Anthropologie – Geschichte - Kulturvergleich. Böhlau: Köln, Weimar, Wien, 2002, 458-471.
4. Brochhausen C, **Brochhausen M**, Seyberth HW. In wessen bestem Interesse? Mögliche finanzielle Interessenkonflikte in der klinischen Forschung und ihre Relevanz für die Pädiatrie. In: Wiesemann C, Dörries A, Wolfslast G, Simon A (Hg.): Das Kind als Patient. Ethische Konflikte zwischen Kindeswohl und Kindeswille. Campus. Frankfurt am Main. 2003: 251-263.
5. **Brochhausen M**. Wissenschaftsphilosophische Aspekte der Evolutionären Anthropologie. Studie zum Ursprung des anatomisch modernen Menschen. Remagen, Mainz, 2005.
6. **Brochhausen M**. Review of: Hagner M. Geniale Gehirne. Zur Geschichte der Elitegehirnforschung. *Homo: Journal of Comparative Human Biology*, 2005: 250.
7. **Brochhausen M**. Review of: Grupe G, Christiansen K, Schröder I, Wittwer-Backofen U. Anthropologie. Ein einführendes Lehrbuch. *Anthropos: International Review of Anthropology and Linguistics* 100/02, 2005: 605-606.
8. **Brochhausen M**. Evolution und Gesellschaft von einem naturalistischen Standpunkt aus. *Erwägen Wissen Ethik* 16(3), 2005: 378-380.
9. **Brochhausen M**. Don't Panic! It's the Tractatus. *Philosophy Now* 58, 2006: 13-14.
10. **Brochhausen M**. Review of: Millikan R. Language: A Biological Model. *Homo: Journal of Comparative Human Biology*, 2006: 177-8.

11. Hainaut, JL, Rundensteiner EA, Kirchberg M, Bertolotto M, **Brochhausen M**, Chen P, Sisaid Cherfi S, Doerr M, Han H, Hartmann S, Parsons J, Poels G, Rolland C, Trujillo J, Yu E, Zimlanyi E (eds.). Advances in Conceptual Modeling - Foundations and Applications · ER 2007 Workshops CMLSA, FP-UML, ONISW, QoIS, RIGiM, SeCoGIS, Auckland, New Zealand, November 5-9, 2007, Proceedings. Springer, Heidelberg, Berlin, New York. 2007.
12. **Brochhausen M**. Review of: Friedman Ross L. Children in Medical Research. Access versus Protection. *Homo: Journal of Comparative Human Biology*, 2007: 193-4.
13. Elmasri R, Doerr M, **Brochhausen M**, Han H (eds.). Proceedings of the 2nd International Workshop on Ontologies and Information Systems for the Semantic Web, ONISW 2008, Napa Valley, California, USA, October 30, 2008. ACM, New York. 2008.
14. **Brochhausen M**. How Upper Level Ontologies Deal With Functions and Other Realizable Entities. *Biomedical Computation Review*, Fall 2008: 25.
15. **Brochhausen M**, Burgun A, Ceusters W, Hasman A, Leong TY, Musen M, Oliveira JL, Peleg M, Rector A, Schulz S. Discussion of "Biomedical Ontologies: Toward Scientific Debate". *Methods Inf Med*. 2011 50 3: 217-236. PMID: 21566855.
16. **Brochhausen M**, Almeida MA, Slaughter L. Towards a formal representation of document acts and the resulting legal entities. In: Ingthorsson, R.D., Svennerlind, C., and Almäng J (eds.) *Johanssonian Investigations*. Ontos, Frankfurt, 2013, 120-139.
17. Boyce RD, **Brochhausen M**, Empey PE, Haendel M, Hogan WR, Malone DC, Ray P, Rutenberg A, Seppälä S, Stoeckert CJ, Zhen J (eds.). Joint Proceedings of The First International Workshop on Drug Interaction Knowledge Management (DIKR 2014), The Second International Workshop on Definitions in Ontologies (IWOOD 2014), and The Starting an OBI-based Biobank Ontology Workshop (OBIB 2014) <sup>[1]</sup>co-located with the International Conference on Biomedical Ontologies 2014 (ICBO 2014). CEUR-WS.org, online urn:nbn:de:0074-1309-5.
18. Hogan WR, Arabandi S, **Brochhausen M** (eds.). Proceedings of the 5th International Conference on Biomedical Ontology (ICBO 2014), Houston, Texas, USA, October 8-9, 2014. CEUR-WS.org, online.
19. **Brochhausen M**. Classificatory challenges in physical disease. In: Solomon M, Simon JR, Kincaid H: *The Routledge Companion to Philosophy of Medicine*. New York, 2016.
20. **Brochhausen M**, Bona J, Blobel B. The Role of Axiomatically-rich Ontologies in Transforming Medical Data to Knowledge. *Stud Health Technol Inform*. 2018; 249:38-49.
21. Blobel B, **Brochhausen M**, Ruotsalainen P. Modeling the Personal Health Ecosystem. *Stud Health Technol Inform*. 2018; 249:3-16.
22. Bost SJ, Ball JW, Sanddal ND, Dodd J, Utecht J, Winchell RJ, **Brochhausen M**. ACS COT Participates in Study to Develop Comparative Data on Trauma Care Organization. *Bull Am Coll Surg* 2020 Apr;105(4):43-48.

## Abstracts and Presentations

### **National/International**

1. "Why We Need an Ontology of Paleontology: A Case Study of the Mladec Remains." Paleoanthropology Meeting. San Juan, Puerto Rico, 2006.
2. "Towards a Cancer Ontology: Present Status and Challenges." ICT Technologies for Cancer Research and Management in the Post-Genomic Era: Status and Challenges, ITAB 2006. Ioannina, Greece, 2006
3. "The European Centre for Ontological Research. Future Perspectives in Biomedical Ontology." MedNet 2007. Leipzig, Germany, 2007.
4. "Biomedical Ontologies: Principles and Perspectives of Exploitation – A critical review. Special Session on Personalized Medicine: Current Trends and Scientific Challenges." TEMU 2008, International Conference on Telecommunications and Multimedia. Ierapetra, Greece, 2008.
5. "How Can We Utilize Ontologies to Maximize Our Data/Knowledge Base?" 3rd Annual DKI (Discovery Knowledge & Informatics). Brussels, Belgium, 2008.
6. "The ACGT Master Ontology on Cancer: a necessary tool to cover semantics on clinical trials on cancer." ACGT (Advancing Clinico-Genomic Trials) Workshop, European Breast Cancer Conference 6 (EBCC 6). Berlin, Germany, 2008.
7. "Semantic Services im epSOS-Projekt: Statusbericht." Jahrestagung 2009 der HL7-Benutzergruppe in Deutschland e. V. Göttingen, Germany, 2009.
8. "The Ontology of Paleobiology." (Half-day tutorial), International Conference on Biomedical Ontologies (ICBO). Buffalo New York, July 20, 2009.
9. "Ontologies and Medical Records." Monumentum.doc, 11th Annual Labont Workshop. Torino, Italy, 2010.
10. "Ontology-based Semantic Modeling." 3rd CALlepSO Workshop: Open Semantic Services. Brussels, Belgium, 2010.
11. "Ist Speziation ein Prozessmuster?" Bioprozesse – Logik und Ontologie lebender Systeme. Rostock, Germany, 2010.
12. "An Introduction to the Protege Ontology Editor & A Practical Exercise in Ontology Building." (Half-day tutorial, with A. Hicks), International Conference on Biomedical Ontologies. Buffalo, New York, July, 26, 2010.
13. "Applied Ontology and the Management and Use of Guidelines." Guidelines and Decision Support in the EHR. HelsIT-conference. Trondheim, Norway, September 20, 2012.
14. "OMRSE: Current Status and Our Strategy for Future Development" (with William R. Hogan). Social Ontology 2012 Buffalo NY, USA, November 26, 2012.
15. "Enabling Semantic Integration of Biobank Administrative Data Using OMIABIS". CTSA Ontology Workshop, Orlando FL, USA, February 11-12, 2013.
16. "Ontological Representations for the Biobanking Domain". AMIA 2013 Summit on Translational Bioinformatics, San Francisco CA, USA, March 18-20, 2013.
17. "Predictions, Simulations, Assessments: How to Deal with Data Items that are Not About Something". Information Artifact Ontologies. Formal Ontologies in Information Systems (FOIS) 2014, Rio de Janeiro, Brazil, September 22, 2014.
18. "Ontologies and the semantic integration of biobank data". International Symposium "Life at the Interface", Mainz, Germany, May 22, 2015.

19. "Semantic Web - Technologien und translationale Medizin am Beispiel Arzneimittelwechselwirkungen und Biobanken". Ehealth Summit Austria, Wien, Austria, June 18, 2015
20. "The OBIB Ontology for Biobanking" (with C. Stoeckert and J. Zheng). Ontology in Practice - The Fourth Clinical and Translational Science Ontology Workshop, Charleston, SC, September 23-25, 2015.
21. "Documents and Document Acts". Ontology in Practice - The Fourth Clinical and Translational Science Ontology Workshop, Charleston, SC, September 23-25, 2015.
22. "Relations between Institutional roles and deontic roles in biomedical organizations." (with Neil Otte). ICBO Workshop: Representing Social and Legal Entities in the Biomedical Domain, Corvallis OR, August 1, 2016
23. "Using OBIB for managing biobank data". 1. Biobanking Summer School, Regensburg, Germany, September 24-25, 2018.
24. "The Use of Axiomatically-Rich Ontologies in Biomedical Research". **Keynote:** Ontobras 2019, Porto Alegre, Brazil, September 2, 2019.
25. "Transforming Clinical and Clinical Research Data to Ontology-Driven Linked Data. Ontobras 2019, Porto Alegre, Brazil, September 4, 2019.
26. "The document act ontology (d-acts) and how it is related to VIVO entities". **Keynote:** 11<sup>th</sup> Annual VIVO Conference 2020, Online, June 16-18, 2020.

### Local

1. "Der Ursprung des anatomisch modernen Menschen." Museumsverein Hildesheim, Germany, March 3, 2004.
2. "Mythen in Quines Wissenschaftsphilosophie." Philosophisches Institut der Universität des Saarlandes, Saarbrücken, Germany, November 15, 2005.
3. "Evolutionäre Zeit im molekularen Zeitalter." Ringvorlesung „Zeit“ der Fachschaft Philosophie der Johannes Gutenberg-Universität. Mainz, Germany, January 04, 2006.
4. "Prospects of biomedical ontologies." (Postgraduate Medical Education, Half-day) Hospital of Pediatrics, Saarland University Hospital. Homburg Germany, August 1, 2007.
5. "Building a Cancer Ontology - Bringing Together Clinical Practice and Ontological Theory." Center for Cognitive Science Colloquia, University at Buffalo. Buffalo, New York, September 26, 2007.
6. "Bones, Stones, and Artifacts: Representing Bioarchaeological Reality." Department of Anthropology Colloquium, University at Buffalo. Buffalo, New York, September 28, 2007.
7. "Speciation and Biological Change." Philosophy of Biology Conference. Department of Philosophy, University at Buffalo. Buffalo, New York, September 29, 2007.
8. "Biological Perspectives in Philosophical Anthropology." (Postgraduate Education, Full day). Landesinstitut Pädagogik und Medien. Dudweiler, Germany, February 22, 2008.
9. "Exploiting Ontologies in Clinical Research and Practice." Nation Center for Electronic Patient Records (NSEP). Trondheim, Norway, October 15, 2008.
10. "Ontologie-basierte IT-Systeme für die klinische Forschung." Institut für Pathologie, Johannes Gutenberg-Universität. Mainz, Germany, October 28, 2008.

11. "Myths, Truth, and Science." (Postgraduate Education, Full day). Landesinstitut Pädagogik und Medien. Dudweiler, Germany, December 08, 2009.
12. "Clinical Reality Representation - Creation, Formalization, Maintenance." Department of Medical and Health Sciences, Linköping University. Linköping, Sweden, December 15, 2009.
13. "Ethical Benefit from Semantic Interoperability in eHealth," Department of Philosophy, Faculty of Technology, Policy and Management, Delft University of Technology. Delft, Netherlands, January 18, 2010.
14. "The Relevance of Philosophy to Applied Ontology." Grand Valley State University Philosophy Colloquium. Grand Rapids, Michigan, November 12, 2010.
15. "Using Semantic Web Technologies for Biomedical Data." Center for Biomedical Informatics. University of Tennessee Health Science Center. Memphis TN, November 12, 2014.
16. "Dynamic Data Management for Biobanks Using Semantic Web Technologies." Inaugural Regensburg Biobank Lecture. Department of Pathology, University of Regensburg. Regensburg, Germany, October 26, 2016.
17. "Biobank Data for Research – Breaking Open Silos." Cancer Grand Rounds. UAMS Winthrop P. Rockefeller Cancer Institute. Little Rock, AR, November 2, 2016.
18. "Words, Words, Words – How Semantic Web Technologies and Ontologies Help with Biomedical Data". Biomedical Informatics Research and Application Seminar Series. College of Medicine, UAMS. Little Rock, AR, January 19, 2017.
19. "Advancing Medical Research Using Semantic Web Technologies". Hutton Lecture Series, Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati OH, May 5, 2017.
20. "Improving Data Quality in Biomedical Data Using Semantic Web Technologies". EIT Colloquium Series, University of Arkansas, Little Rock, September 8, 2017.
21. "Advanced Knowledge Management for Biomedicine Using Semantic Web Technologies". IBI Seminar, Perelman School of Medicine, University of Pennsylvania, Philadelphia, September 27, 2017.
22. "Using Semantic Web Technologies to Improve Data Quality in Biomedical Research". DBMI Research Application Seminar, University of Arkansas for Medical Sciences, October 5, 2017.
23. "The Cancer Imaging Archive as an Example of Semantic Data Integration." UF Cancer Center Oncology Grand Rounds, Gainesville, FL, November 13, 2019.

### **Symposiums**

1. Co-organizer. International Workshop on Ontologies and Information Systems for the Semantic Web - ONISW 2007, November 07-09, 2007, Auckland, New Zealand.
2. Co-organizer. International Workshop on Ontologies and Information Systems for the Semantic Web - ONISW 2008, October 26-30, 2008, Napa Valley, USA.
3. Invited Session Co-chair: Clinical Annotations. At: 7<sup>th</sup> International Biocuration Conference 2014. April 6-9, 2014, Toronto, Canada.
4. Co-organizer: Workshop on Information Artifact Ontologies (FOIS 2014 Workshop). September 22, Rio de Janeiro, Brazil

5. Co-organizer: Drug-Drug Interaction Knowledge Representation Workshop 2014 (ICBO2014 Workshop). Oct 6-7, 2014, Houston TX, USA.
6. Co-organizer: Starting an OBI-based Biobank Ontology 2014 (ICBO2014 Workshop). Oct 6-7, 2014, Houston TX, USA.
7. Co-organizer: Representing social and legal entities in the biomedical domain (ICBO2016 Workshop). August 1, 2016, Corvallis OR, USA.
8. Co-organizer: 2<sup>nd</sup> Workshop on representing social and legal entities in the biomedical domain (ICBO2017 Workshop). September 13, 2017, Newcastle UK.
9. Co-chair: AMIA Workshop "Knowledge Representation and Semantics Working Group Pre-Symposium: Doctoral Consortium, Highlights, and Late-Breaking Research". November 3, 2018, Washington DC.
10. Organizer: Workshop: Semantic - web technologies for biobanking. 1. Biobanking Summer School, Regensburg, Germany, September 24-25, 2018.
11. Co-organizer: JOWO SOLEE 2019: Joint Ontology Workshops 2019: Ontology of Social, Legal, and Economic Entities, September 23-25, Graz, Austria.
12. Co-chair: AMIA Workshop "Knowledge Representation and Semantics Working Group Pre-Symposium: Doctoral Consortium, Highlights, and Late-Breaking Research". November 17, 2019, Washington DC.

#### **Dissertation and Master committees chaired**

1. Jie Zhang, Interdisciplinary Biomedical Sciences, UAMS, Advisor – Dr. Mathias Brochhausen, Status – expected Feb 2019
2. John Judkins, Bioinformatics, UAMS-UALR Joint Program, Advisor – Dr. Mathias Brochhausen, Status – MA received March 2018
3. Daniel Foltz-Morrison, UALR Interdisciplinary Studies, Advisor – Dr. Mathias Brochhausen, Status – expected February 2019

#### **Additional dissertation committees**

1. Martin Berzell, Department of Medical and Health Sciences, Linköping University, Sweden, Advisor – Dr. Ingemar Nordin, Status – PhD received
2. Gilbert Maiga, Department of Computer Science, Makerere University, Uganda, Advisor - , Status – PhD received
3. Debanjan Mehata, Information Quality, UALR, Advisor – Dr. John Talburt, Status – PhD received
4. Xinsong Du, Department of Health Outcomes and Biomedical Informatics, UF, Advisor – Dr. Dominick Lemas, Status – ongoing.

#### **Graduate student mentoring (Bioinformatics Rotation)**

1. John Judkins (2015-2018)

#### **Additional mentoring & committee work**

Faculty Mentoring (Member of Mentoring Committee):

1. Dr. Kevin Sexton (Surgery)
2. William Bennett (DBMI)



Jun. 23, 21

3. Dr. Yasir Rahmatallah (DBMI)
4. Tracy Nolan (DBMI)
5. Dr. Se Ran Jun (DBMI)
6. Dr. Melody Penning (DBMI)

#### Graduate students

1. Ghirmay Weldemichael (2012) MS candidate
2. Jie Zhang (2012-2019) PhD candidate
3. Josh Hanna (2013-2014) PhD candidate
4. Alice Nzinga (2013-2014) completed MSIQ
5. Kashif Mehdi (2013-2014) completed MSIQ
6. Debanjan Mehata (2013-2015) completed PhD degree
7. Anuj Shah (2014-2018) PhD candidate
8. Mohammadreza Rezaie (2015-2019) MS candidate

#### Undergraduate students (Arkansas INBRE program)

1. Jean Mugiraneza (2013)
2. Daniel Blankson (2017)

#### Medical students (Biomedical Informatics Elective)

1. Eric Joseph (2013)
2. Mareen Ashad (2014)
3. Clelland J. Chatman (2014)
4. Mai Vuong (2014)
5. Nicholas Rogers (2015)
6. Robert Rose (2015)
7. Daniel Liu (2017)
8. Nathaniel B. Alexander (2017)
9. Dillon M. Gibson (2018)

#### **Campus contributions and committees**

1. Division of Biomedical Informatics Leadership Team, University of Florida (2019 – present)
2. Member of Ad Hoc Promotion and Tenure Committee. Department of Medical Humanities and Bioethics (2019).
3. Member of the UAMS Biomedical Informatics Curriculum Committee (2017-2019)
4. Member of the AR-CDR (Data Warehouse) Direction Committee (2017-2019)
5. Member of the UAMS Biomedical Informatics Admission Committee (2017-2018)
6. UAMS Translational Research Institute Leadership Council (2015-2019)
7. Member of the UAMS/UALR Joint Bioinformatics Program Steering Committee (2013-2016)
8. Member of the UAMS/UALR Joint Bioinformatics Program Admissions Committee (2013-2018)

Jun. 23, 21

9. Members of the BINF Curriculum Task Force, UAMS/UALR Joint Bioinformatics Program (2013-2014)
10. UAMS delegate for the Arkansas Bioinformatics Meeting (leading to the Arkansas Bioinformatics Consortium (ArBiC) (2013-2014)

#### **UAMS didactic work**

1. Graduate School curriculum
  - a. BINF 5013 Reasoning Medical Data – Intro to Logic and Its Use in Biomedical Computing (Course creator and course director 2012-2019)
  - b. BINF 5023 Using Semantic Web Technology in Biomedical Research (Course co-creator and course co-director 2014-2019)
  - c. BIMG 5001 Information Modelling – From Data to Knowledge (Course creator and course director 2018-2019)
  - d. BMIG 6050 Research Design (Course co-director 2018-2019)
2. Medical School curriculum
  - a. Practice of Medicine I & II, Instructor/Judge (2015-2019)
  - b. 4<sup>th</sup> year Biomedical Informatics Elective (2015-2019)

#### **UF didactic work**

1. Graduate School curriculum
  - a. GMS 6805: Applied Ontologies; 3 credit hours (Course director 2019)
  - b. GMS 7887: HOBI PhD Research Seminar (Summer A & B); 1 credit hour (Course co-director 2020)
  - c. PHC 7083: Computational Epidemiology in Population Science; 2 credit hours) (Guest lecturer, 2020)

#### **Editorial activities and Academic Citizenship**

Since 2020 Member of Editorial Board of *Applied Ontology*

Since 2017 Associate Editor of *BMC Medical Informatics and Decision Making*.

Since 2017 Member of the AMIA Awards Committee.

#### **Journal Refereeing**

1. BMC Bioinformatics 2011
2. Journal of Biomedical Semantics 2012, 2013, 2015, 2016, 2017, 2018
3. Artificial Intelligence in Medicine 2012
4. International Journal of Medical Engineering and Informatics 2013
5. Journal of Biomedical Informatics 2013, 2015, 2016, 2017, 2018
6. Ecancermedalscience 2013
7. Methods of Information in Medicine 2013, 2015
8. Journal for Cheminformatics 2014
9. Applied Clinical Informatics 2015
10. Applied Ontology 2017, 2018
11. Journal for Healthcare Engineering 2017

12. Knowledge Based Systems 2017, 2018
13. BMC Medical Informatics and Decision Making 2017, 2018, 2019, 2020
14. SLAS Technology 2020

#### Other Refereeing

1. International HL7 Interoperability Conference, 2012
2. Medical Informatics Europe, 2012
3. American Medical Informatics Association Annual Fall Symposium, 2012, 2017.
4. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2011.
5. American Medical Informatics Association Annual Spring Symposium, 2013.

#### Conference Organizing Committees

1. Technical Program Committee. International Conference on Biocomputation, Bioinformatics, and Biomedical Technologies, BIOTECHNO 2008, June 29 - July 5, 2008, Bucharest, Romania.
2. Scientific Committee. Interdisciplinary Ontology Conference, InterOntology 2008, February 26-27, 2008, Tokyo, Japan.
3. Scientific Committee. Interdisciplinary Ontology Conference, InterOntology 2009, February 27 to March 1, 2009 Tokyo, Japan.
4. Scientific Committee. Interdisciplinary Ontology Conference, InterOntology 2010, February 27 to 28, 2010, Tokyo, Japan.
5. Program Committee. Bio-Ontologies 2010: Semantic Applications in Life Sciences. July 9-10, Boston, USA.
6. Program Committee: Formal Ontologies Meet Industry (FOMI) 2011, July 7-8, 2011, Delft, Netherlands.
7. Program Committee: Bio-Ontologies 2011. July 15-16, Vienna, Austria.
8. Program Committee: 7th International Conference on Formal Ontology in Information Systems (FOIS 2012), July 24-27 2012, Graz, Austria.
9. Program Committee: Bio-Ontologies 2012. July 13-14, Long Beach, USA.
10. Scientific Steering Committee. The 9th International Conference on Wearable Micro and Nano Technologies for Personalized Health (pHealth 2012), June 26-28, Porto, Portugal.
11. Program Committee of 8th International Workshop on Ontology Content (OnToContent 2012), Part of the OnTheMove Conferences & Workshops, 10-14 September 2012, Rome, Italy.
12. Program Committee: Bio-Ontologies 2013. July 20, Berlin Germany.
13. Program Committee: Bio-Ontologies 2014. July 12-13, Boston MA, USA.

*Jun. 23, 21*

14. Program Chair: International Conference for Biomedical Ontologies 2014 (ICBO2014). October 6-9, 2014, Houston TX, USA.
15. Program Committee: 8th International Conference on Formal Ontology in Information Systems (FOIS 2014), September 22-25, 2014, Rio de Janeiro, Brazil.
16. Program Committee: International Conference for Biomedical Ontologies 2015 (ICBO2015). July 27-30, Lisbon, Portugal.
17. Program Committee: Bio-Ontologies 2015. July 10-11, Dublin, Ireland.
18. Scientific Committee/Mentor: Early Career Symposium, FOIS2018, September 10-14, Cape Town, South Africa.

## Curriculum Vitae

### **Dina M. Jones, PhD, MPH**

Postdoctoral Research Fellow

Fay W. Boozman College of Public Health  
University of Arkansas for Medical Sciences  
4301 West Markham Street, Suite 3241, #820  
Little Rock, AR 72205  
Office: 501-526-4472  
Email: dmjones2@uams.edu

LinkedIn URL: [linkedin.com/in/dina-jones-22706563](https://www.linkedin.com/in/dina-jones-22706563)  
ORCID ID: [orcid.org/0000-0002-7002-0547](https://orcid.org/0000-0002-7002-0547)

---

#### **EDUCATION**

Georgia State University, School of Public Health, Atlanta, GA	PhD	Public Health, Epidemiology Concentration	2019
University of Minnesota, School of Public Health, Minneapolis, MN	MPH	Epidemiology	2015
Agnes Scott College, Decatur, GA	BA	Public Health, Laboratory Science Track (Cum Laude)	2013

#### **CURRENT POSITION**

Postdoctoral Research Fellow (NIDA T32DA022981) Department of Psychiatry, College of Medicine Center for the Study of Tobacco, Department of Health Behavior and Health Education Fay W. Boozman College of Public Health University of Arkansas for Medical Sciences Primary Mentor: Pebbles Fagan, PhD, MPH			2019-present
---	--	--	--------------

#### **RESEARCH EXPERIENCE**

Second Century Initiative (2CI) Fellow, Tobacco Product Regulatory Science Cluster (NIDA/FDA P50DA036128) Georgia State University, School of Public Health, Atlanta, GA Supervisor: Claire Adams Spears, PhD			2018-2019
Graduate Research Assistant, Cigar Collaborative Research Group Center for Evaluation and Coordination of Training and Research (NCI/FDA 1U54CA189222) Westat, Rockville, MD Supervisor: Howard Fishbein, PhD			2016-2019
Predocctoral Fellow, Tobacco Center of Regulatory Science			2015-2018

(NIDA/FDA P50DA036128)

School of Public Health, Georgia State University, Atlanta, GA

Supervisor: Scott Weaver, PhD

Graduate Research Assistant, Center for Chronic Disease Outcomes 2014-2015  
 Minneapolis Veteran Affairs, Minneapolis, MN  
 Supervisor: Diana J. Burgess, PhD

Statistics Research Intern, Minnesota Center for Health Statistics 2014  
 Minnesota Department of Health, St. Paul, MN  
 Supervisor: Pete Rode, MA

Environmental Health Laboratory Intern, Rollins School of Public Health 2012  
 Emory University, Atlanta, GA  
 Supervisors: P. Barry Ryan, PhD, MS; Dana Boyd Barr, PhD

Undergraduate Researcher, Agnes Scott College, Decatur, GA 2012-2014  
 Supervisors: Harry Wistrand, PhD; Matthew Magee, PhD

### PEER-REVIEWED PUBLICATIONS \*denotes student co-author

#### In Press/Published (n=17)

1. Spears, C A, **Jones, DM**, Weaver, SR, Yang, B, Pechacek, TF, Eriksen, MP (2020). Use of and perceptions about electronic nicotine delivery systems (ENDS) among people with mental health conditions or serious psychological distress, 2018. Drug and Alcohol Dependence, 212:108049. DOI:10.1016/j.drugalcdep.2020.108049. PMID: 32442748
2. Fishbein, H, Bauer, D, Yu, Q, Mermelstein, R, **Jones, DM**, Miller, A, Harrell, M, Loukas, A, Sterling, K, Colip, B, Mittl, B (2019). Harmonizing Cigar Survey Data across TCORS, CTP, and PATH Studies: The Cigar Collaborative Research (CCR) Group. Nicotine and Tobacco Research, ntz201. DOI: 10.1093/ntr/ntz201. PMID: 31665435
3. **Jones, DM**, Ashley, DL, Weaver, SR, Eriksen, MP (2019). Flavored ENDS Use and Perceptions Among Four Smoking and ENDS Use Profiles, 2016-2017. Tobacco Regulatory Science, 5 (6), 518-531. DOI: 10.18001/TRS.5.6.4. PMID: 31696149. PMCID: PMC6834350
4. Spears, CA<sup>^</sup>, **Jones, D M<sup>^</sup>**, Weaver, SR, Huang, J, Yang, B, Pechacek, TF, Eriksen, MP (2019). Sociodemographic correlates of Electronic Nicotine Delivery Systems (ENDS) in the United States, 2016-2017. American Journal of Public Health, 109 (9), 1224-1232. DOI: 10.2105/AJPH.2019.305158. PMID: 31318599. PMCID: PMC6687271. (^ denotes joint first authorship)
5. Sterling, K L, **Jones, DM**, Nyman, AL, Majeed, BA, Weaver, SR (2019). Affect Predicts Small Cigar Use among a National Sample of US Young Adults. Tobacco Regulatory Science, 5 (3), 253-263. DOI: 10.18001/TRS.5.3.4.
6. Spears, CA, **Jones, DM**, Pechacek, TF, Ashley, DL (2019). Use of Other Combustible Tobacco Products among Priority Populations of Smokers: Implications for U.S. Tobacco Regulatory Policy. Addictive Behaviors, 93, 194-197. DOI: 10.1016/j.addbeh.2019.01.031. PMID: 30735829.
7. Spears, C A, **Jones, D M**, Weaver, S R, Yang, B, Pechacek, TF, Eriksen, MP (2018). Electronic Nicotine Delivery System (ENDS) Use in Relation to Mental Health Conditions, Past-Month Serious Psychological Distress, and Cigarette Smoking Status, 2017. Addiction, 114 (2), 315-325. DOI: 10.1111/add.14464. PMID: 30291763.

8. Burgess, DJ, Bokhour, BG, Cunningham, BA, Do, T, Eliacin, J, Gordon, HS, Gravely, A, **Jones, DM**, Partin, MR, Pope, C, Saha, S, Taylor, BC, Gollust, SE (2018). Communicating with providers about racial healthcare disparities: The role of providers' prior beliefs on their receptivity to different narrative frames. Patient Education and Counseling, pii: S0738-3991(18)30624-4. DOI: 10.1016/j.pec.2018.08.030. PMID: 30266266.
9. **Jones, DM**, Popova, L, Weaver, SR, Pechacek, TP, Eriksen, ME (2018). A National Comparison of Dual Users of Smokeless Tobacco and Cigarettes and Exclusive Cigarette Smokers, 2015-2016. Nicotine and Tobacco Research, 20(suppl\_1), S62-S70. DOI:10.1093/ntr/nty010. PMID: 30125015. PMCID: PMC6093383.
10. Spears, CA, **Jones, DM**, Weaver, SR, Pechacek, TF, & Eriksen, MP (2018). Motives and perceptions regarding electronic nicotine delivery systems (ENDS) use, among adults with mental health conditions. Addictive Behaviors, 80, 102-109. DOI: 10.1016/j.addbeh.2018.01.014. PMID: 29407679. PMCID: PMC5857232.
11. Gollust, SE, Cunningham, BA, Bokhour, BG, Gordon, HS, Pope, C, Saha, S, **Jones, DM**, Do, T, Burgess, DJ (2018). What Causes Racial Health Care Disparities? A Mixed-Methods Study Reveals Variability in How Health Care Providers Perceive Causal Attributions. Inquiry, 55:46958018762840. DOI:10.1177/0046958018762840. PMID: 29553296. PMCID: PMC5862368.
12. **Jones, DM**, Majeed, BA, Weaver, SR, Sterling, K, Pechacek, TF, Eriksen, MP (2017). Prevalence and Factors Associated with Smokeless Tobacco Use, 2014-2016. American Journal of Health Behavior, 41(5), 608-617. DOI: 10.5993/AJHB.41.5.10. PMID: 28760183. PMCID: PMC5567985.
13. Burgess, DJ, Bokhour, BG, Cunningham, BA, Do, T, Gordon, HS, **Jones, DM**, Pope, C, Saha, S, Gollust SE (2017). Healthcare Providers' Responses to Narrative Communication about Racial Healthcare Disparities. Health Communication. DOI: 10.1080/10410236.2017.1389049. PMID:29068701.
14. Nyman, AL, Sterling, KL, Majeed, BA, **Jones, DM**, Eriksen, MP (2017). Flavors and Risk: Perceptions of Flavors in Little Cigars and Cigarillos Among U.S. Adults, 2015. Nicotine and Tobacco Research, 20 (9), 1055-1061. DOI: 10.1093/ntr/ntx153. PMID: 28666353. PMCID: PMC6093397.
15. Spears, CA, **Jones, DM**, Weaver, SR, Pechacek, TF, & Eriksen, MP (2017). Use of Electronic Nicotine Delivery Systems among Adults with Mental Health Conditions, 2015. International Journal of Environmental Research and Public Health, 14(1), 10. DOI: 10.3390/ijerph14010010. PMID: 28025560. PMCID: PMC5295261.
16. Sterling, K, Fryer, C, Pagano, I, **Jones, D**, Fagan, P (2016). Association between menthol-flavoured cigarette smoking and flavoured little cigar and cigarillo use among African-American, Hispanic, and white young and middle-aged adult smokers. Tobacco Control, Nov; 25 (Suppl 2): ii21-ii31. DOI: 10.1136/tobaccocontrol-2016-053203. PMID: 27856997.
17. Wilson, KT, Bohnert, AE, Ambrose, A, Davis, DY, **Jones, DM**, & Magee, MJ (2014). Social, behavioral, and sleep characteristics associated with depression symptoms among undergraduate students at a women's college: a cross-sectional depression survey, 2012. BMC Women's Health, 14(1):8, 2014 January. DOI: 10.1186/1472-6874-14-8. PMID: 24410897. PMCID: PMC3893578.

### Manuscripts Under Review (n=7)

1. **Jones, DM**, Guy, MC, Soule, E, Sakuma, K, Pokhrel, P, Orloff, M, Trinidad, D, Smith, D, Browley, S\*, Walker, A\*, Bullock, S\*, Eissenberg, T, Fagan, P Characterization of Electronic Cigarette Warning Statements Portrayed in YouTube Videos. Nicotine and Tobacco Research (revise and resubmit).

2. Fagan, P Eissenberg, T, **Jones, DM**, Cohen, J, Nez Henderson, P, Clanton, M The First Ten Years: Reflecting on Opportunities and Challenges of the Tobacco Products Scientific Advisory Committee of the United States Food and Drug Administration. Journal of Legal Medicine.
3. **Jones, DM**, Guy, MC, Soule, EK, Walker, AP\*, Bullock, S\*, Browley, S\*, Orloff, M, Eissenberg, T, Fagan, P. Do It Yourself (DIY) electronic cigarette liquid mixing behaviors portrayed in YouTube videos. Drug and Alcohol Dependence.
4. **Jones, DM**, Guy, MC, Soule, EK, Sakuma, K, Pokhrel, P, Trinidad, D, Eissenberg, T, Fagan, P. Co-use of electronic cigarettes and marijuana among cigarette smokers. Tobacco Regulatory Science.
5. Cottrell-Daniels, C\*, **Jones, DM**, Bell, SA, Bandlamudi, M\*, & Spears, CA.. Experiences with Mindfulness-Based Text Messaging for Smoking Cessation among Predominantly Low-Income, African American Adults. International Journal of Behavioral Medicine.
6. Guy, MC, **Jones, DM**, Soule, EK, Walker, AP\*, Bullock, S\*, Browley, S\*, Smith, D, Pokhrel, P, Eissenberg, T, Fagan, P. Changes in the prevalence of FDA mandated electronic cigarette and EVALI warning statements portrayed in YouTube videos in 2019. American Journal of Public Health.
7. **Jones, DM**, Masyn, K, Spears, CA. Discrimination, Psychological Functioning, and Substance Use Among U.S. Young Adults Aged 18-28, 2017. American Journal of Public Health.

## DOCKET SUBMISSIONS TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Docket Number: FDA-2017-N-6189

Docket Title: Tobacco Product Standard for Nicotine Level of Combusted Cigarettes\*

Action: Advance notice of proposed rulemaking

Authors: Claire Adams Spears, PhD, **Dina M. Jones, MPH**

\*Confidential Comment

Docket Number: FDA-2017-N-6565

Docket Title: Regulation of Flavors in Tobacco Products\*

Action: Advance notice of proposed rulemaking

Author: **Dina M. Jones, MPH**

\*Confidential Comment

## PEER REVIEWED PRESENTATIONS

\*Denotes student co-author

1. Woods MN, **Jones DM**, McGehee N, Fagan P, Henry-Tillman RS (March 2020). Analysis of Partnerships for Colorectal Cancer Screening. Oral presentation accepted at the 13<sup>th</sup> annual Xavier Health Disparities Conference, New Orleans, LA.
2. **Jones, DM**, Fagan, P, Lovelady, N, Guy, M, Eissenberg, T (March 2020). Past 30 Day Marijuana Co-use With E-cigarettes and Cigars Among Young Adult Smokers Aged 18-35, 2018. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA.
3. Cottrell-Daniels, C\*<sup>^</sup>, **Jones, D<sup>^</sup>**, Elahi, H, Strosnider, C, Luong, J\*, Weaver, S, Pechacek, T, Spears, C (March 2020). Qualitative Study of Experiences With ENDS Use Among Low Income Smokers. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans, LA. (^ denotes joint first authorship)
4. Fagan, P, Guy, MC, Soule, EK, **Jones, D**, Hayes, R, Selig, J, Orloff, M, Prewitt, T, Pokhrel, P, Harrell, P, Trinidad, D, Moore, R, Maloney, S, Thompson, N, Eissenberg, T (October 2019). Developing a Scale to Measure Flavor Outcome Expectancies and the Association with Switching and Quitting



- Behaviors among Young Adult Cigarette Smokers. Oral presentation at the 2019 NIH Tobacco Regulatory Science Meeting, National Institutes of Health, Bethesda, MD.
5. Fagan, P, Guy, M, Soule, E, **Jones, D**, Walker, P\*, Bullock, S\*, Dhuliawala, S\*, Emblom, A\*, Eissenberg, T (October 2019). Warning Statements in YouTube Videos Related to Electronic Cigarettes. Poster presented at the 2019 NIH Tobacco Regulatory Science Meeting, National Institutes of Health, Bethesda, MD.
  6. **Jones, DM** (February 2019). Spatial Associations between State Level Current Cigar Use and Cigar Tax Type. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco, San Francisco, CA.
  7. Cottrell-Daniels, C, Bell, SA, Bandlamudi, M, **Jones, D**, Sigurdardottir, A, Spears, CA (October 2018). Qualitative Smoking Cessation Study of Mindfulness-based Text Messages Low-Income Adult Smokers. Poster presented at the 2018 International Cancer Education Conference, Atlanta, GA. **Received 2<sup>nd</sup> place award in Best Poster Presentation category.**
  8. **Jones, DM**, Ashley, DL, Weaver, SR, Pechacek, TP, Eriksen, ME (February 2018). ENDS Characteristics and Smoking Cessation Profiles, 2017. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MD.
  9. Fishbein, H, Mermelstein, R, Harrell, M, Loukas, A, Sterling, K, **Jones, D**, Miller, A, Colip, B, Yu, Q, Mittl, B (February 2018). Harmonizing Cigar Survey Data across TCORS, CTP, and PATH Studies: The Cigar Collaborative Research (CCR) Group. Oral presentation at the annual meeting of the Society for Research on Nicotine and Tobacco, Baltimore, MD.
  10. **Jones, DM** and Sterling, KL (November 2017). Associations Between High Allostatic Load and Substance Use by Gender and Race. Poster presented at the annual meeting and expo of the American Public Health Association, Atlanta, GA. **Received Outstanding Student Work Award from Alcohol, Tobacco, and Other Drug section.**
  11. **Jones, DM**, Popova, L, Weaver, SR, Pechacek, TP, Eriksen, ME (November 2017). National Comparisons of Dual Users of Smokeless Tobacco and Cigarettes and Exclusive Cigarette Smokers, 2014-2016. Poster presented at the annual meeting and expo of the American Public Health Association, Atlanta, GA.
  12. Gollust, S, Cunningham, B, Bokhour, B, Gordon, H, Pope, C, Saha, S, **Jones, D**, Do, T, Burgess, D (October 2016). What Causes Racial Disparities in Health Care? A Mixed-Methods Study of Providers Negotiating Uncertainty in Attributing Blame and Responsibility. Poster presented at the 38<sup>th</sup> Annual North American Meeting of the Society for Medical Decision Making, Vancouver, BC, Canada.
  13. Burgess, DJ, Bokhour, BA, Cunningham, BG, Do, T, Gordon, HS, **Jones, DM**, Pope, C, Saha, S, Gollust, SE (June 2016). Communicating about healthcare inequality: The role of providers' prior beliefs on their receptivity to different narrative frames. Poster presented at the annual research meeting of AcademyHealth, Boston, MA.
  14. Burgess DJ, Bokhour BG, Cunningham BA, Do TM, Gordon HS, **Jones DM**, Pope C, Saha S, Gollust SE (May 2016). Communicating about healthcare disparities across the ideological spectrum: Findings from the EMPOWER study. Oral presentation presented at the University of Minnesota Promoting Health Equity: Engage. Inform. Act. Regional Conference, Minneapolis, MN.
  15. Burgess, DJ, Gollust, SE, Bokhour, BA, Cunningham, BG, Gordon, HS, **Jones, DM**, Saha, S, Do, T, Pope, C (July 2015). Challenges to engaging providers in disparity-reduction efforts: Findings from the EMPOWER study. Poster presented at the 30th Veteran Affairs Health Services Research and Development Service and Quality Enhancement Research Initiative National Meeting, Philadelphia,

PA.

16. Burgess DJ, Gollust SE, Bokhour BG, Cunningham B, Gordon HS, **Jones D**, Saha S, Do TM, Pope C (July 2015). Misconceptions about racial healthcare disparities may prevent providers from perceiving disparities in VA. Oral presentation presented at the 30th Veteran Affairs Health Services Research and Development Service and Quality Enhancement Research Initiative National Meeting, Philadelphia, PA.
17. **Jones, DM** (April 2012). An Examination of College Students Personal Finances and Stress/Anxiety Levels. Oral presentation presented at Spring Annual Research Conference, Agnes Scott College, Decatur, GA.

## RESEARCH AND SERVICE GRANTS

### Funded Research Support

No grant number, MRC UAPB Jones (PI) 10/01/19-05/15/20  
 A Small Feasibility Intervention to Improve Harm Reduction and Cessation Outcomes Among African American Women Young Adults Who Use Combustible Tobacco  
 Uses a mixed-methods design to assess use and views of tobacco, cessation, and harm reduction products that will be used to develop and test the feasibility of an educational intervention among African American young women who smoke cigarette and/or cigars.  
 Role: PI

### Grants Under Review

U54 MD002329-11, NIMHD Raczynski/Cornell (MPI) Submitted: 03/13/20;  
 Resubmitted: 06/09/20  
 Arkansas Center for Health Disparities  
 A Mixed-Methods Examination of Risk Perceptions, Cessation, and Harm Reduction Among African American Young Adult Smokers  
 As part of the Arkansas Center for Health Disparities, this research project aims to assess the role of nicotine risk perceptions on use of nicotine replacement therapy and e-cigarettes among African American young adult cigarette smokers; it consists of a secondary data analysis of wave 4 of the Population Assessment of Tobacco and Health Study and focus groups.  
 Role: PI

### Previously Submitted Grants (Not Funded)

R36 DA047567-01, NIDA Jones (PI) 02/16/18  
 Project Title: Racial Discrimination, Stress, and Substance Use Among African American Young Adults  
 Funding Agency: National Institute on Drug Abuse (R36)  
 Role: Principal Investigator (PI)  
 Impact Score: 37

## HONORS AND DISTINCTIONS

NIH/NIDA Health Disparities Loan Repayment Program Award, National Institutes of Health	2020-2022
2019 Health Disparities Network Travel Scholarship, Health Disparities Network, Society for Research on Nicotine and Tobacco	2019
2 <sup>nd</sup> Place Best Poster Award, International Cancer Education Conference	2018
Spring 2018 Stats Camp Scholarship, Atlanta, GA	2018

Outstanding Student Work Award, Alcohol, Tobacco, and Other Drug Section, American Public Health Association Annual Meeting	2017
2017 Stats Camp Scholarship, Atlanta, GA	2017
American Association for the Advancement of Science/Science Program for Excellence in Science Award	2017-2019
Community Health Initiative Scholarship, University of Minnesota School of Public Health	2014-2015
Japan Exchange and Teaching Program USA, (Declined)	2013
TriBeta National Biological Honor Society, Agnes Scott College	2013
Bevier Public Health Scholarship, Agnes Scott College	2012
Bahrom Scholarship, Bahrom International Program, Seoul Women's University, Seoul, South Korea	2011
Letitia Pate Evans Scholarship, Agnes Scott College	2010-2013
Zell Miller Scholarship, Georgia Lottery for Education	2010-2013
Hope Scholarship and Grant, Georgia Lottery for Education	2009-2013
Advanced Academy of Georgia Alumni, University of West Georgia	2009-2010
Honors College Student, University of West Georgia	2009

### **INVITED ACADEMIC PRESENTATIONS AND LECTURES**

"To be Titled." Center for the Study of Tobacco Products Scientific Meeting, Virginia Commonwealth University, Richmond Virginia, VA	Fall 2020
"Public Health Research Study Designs: From an Idea to Study." School of Public Health, Georgia State University, Introduction to Research Methods in Public Health: Critical Thinking Through Writing course, Atlanta, GA	Fall 2018
"E-Cigarette Safety, Challenges, and the Changing Tobacco Regulatory Landscape" Honors College, School of Public Health, Georgia State University, Introduction to Controversies in Public Health course, Atlanta, GA	Spring 2018

### **OTHER EDUCATION AND TRAINING EXPERIENCES**

Utah NRMN Grant Writing Coaching Group Study, Cohort 2 (U01 GM132366), Online	08-12/2020
Half Day Workshop on mHealth Interventions for Tobacco Cessation: Engaging Diverse Users and Innovative Technologies led by Michael Businelle, PhD; Jennifer Cantrell, PhD; Ana Paula Cupertino, PhD; Gillian Gould, PhD; Emily Hebert, DrPH; Jaimee Heffner, PhD; Darla Kendzor, PhD; Roger Vilardaga, PhD; and Monica Webb Hooper, PhD, New Orleans, LA	03/2020

Stats Camp, Statistics Training Seminar, Topic: Comprehensive Structural Equation Modeling, led by Todd Little, PhD, and Elizabeth Grandfield, MA, Atlanta, GA	03/2018
Seminar on Tobacco Use Among Vulnerable Populations, led by Claire Adams Spears, PhD, Atlanta, GA	01/2018
Seminar on Communication in Tobacco Regulatory Science, led by Lucy Popova, PhD, Atlanta, GA	11/2017
Seminars on Impactful Tobacco Regulatory Science Research and Cigarette Design, led by David L. Ashley, PhD, Atlanta, GA	10-11/2017
Stats Camp, Statistics Training Seminar, Topic: Applied Latent Class Analysis, led by Katherine E. Masyn, PhD, Atlanta, GA	03/2017
Half Day Workshop, Topic: NIH Funding Opportunities and Grant Writing Tips, Information for Early Career Investigators, led by Samia Noursi, PhD; Dana van Bemmelen, PhD; Danielle Ramo, PhD; Erik Augustson, PhD; and Judith J. Prochaska, PhD, Chicago, IL	03/2016
Manuscript Development Workshops, led by Lisa Casanova, PhD, Atlanta, GA	2015-2016

## PROFESSIONAL AFFILIATIONS AND SERVICE

### Professional Memberships

National Advisory Board, Minority Research Center on Tobacco and Addictions, University of Arkansas at Pine Bluff	2020
Georgia State University Mindful Living Lab, School of Public Health, Georgia State University	2018-2019
American Public Health Association	2017-2018
Health Disparities Network, Society for Research on Nicotine and Tobacco	2015-present
Society for Research on Nicotine and Tobacco	2015-present
Health Disparities Working Group, School of Public Health, University of Minnesota	2014-2015

### Service

Informational Video Interviewee, University of Minnesota School of Public Health	2018
Masters and Doctoral Admissions Recruiter, Georgia State University School of Public Health	2015-2019
Director, Girls Scouts World Workshop Day, Agnes Scott College	2011-2013

## JOURNAL AND CONFERENCE REVIEW ACTIVITIES

### Ad hoc peer reviewer

Qualitative Health Research	2020-present
Tobacco Regulatory Science	2019-present
Addictive Behaviors	2018-present
Tobacco Control	2018-present

### Conference abstract reviewer

26 <sup>th</sup> Annual Meeting, Society for Research on Nicotine and Tobacco	2019
Invited Undergraduate Scientific Poster Reviewer, Georgia State University	2018

### PRESS RELEASES

“Georgia State: People With Mental Health Conditions More Likely to Use ENDS.” *Association of Schools and Programs of Public Health Member Research and Report*, October 18, 2018. References 2018 article published in *Addiction*. Available at: <https://www.aspph.org/georgia-state-people-with-mental-health-conditions-more-likely-to-use-ends/>.

“Public Health Student Wins National Award For Research Presentation.” *Georgia State University News*, November 17, 2017. References 2017 poster presentation at Annual American Public Health Association Meeting. Available at: <https://news.gsu.edu/2017/11/17/public-health-student-wins-national-award/>.

“Georgia State Student Wins Award from APHA for Research Presentation.” *Association of Schools and Programs of Public Health Member Research and Report*, November 15, 2017. References 2017 poster presentation at Annual American Public Health Association Meeting. Available at: <https://www.aspph.org/georgia-state-student-wins-award-from-apha-for-research-presentation/>.

“Georgia State: Smokeless Tobacco May Have Growing Appeal for Women, Minorities.” *Association of Schools and Programs of Public Health Member Research and Report*, October 3, 2017. References 2017 article published in the *American Journal of Health Behavior*. Available at: <https://www.aspph.org/georgia-state-smokeless-tobacco-may-have-growing-appeal-for-women-minorities/>.

“Georgia State Study: Former Smokers with Mental Illness More Likely to Vape.” *Association of Schools and Programs of Public Health Member Research and Report*, January 18, 2017. References 2016 article published in the *International Journal of Environmental Research and Public Health*. Available at: <https://www.aspph.org/georgia-state-study-former-smokers-with-mental-illness-more-likely-to-vape/>.

“Georgia State: Smoking Menthol Cigarettes Linked to Use of Flavored Cigarillos.” *Association of Schools and Programs of Public Health Member Research and Report*, December 8, 2016. References 2016 article published in *Tobacco Control*. Available at: <https://www.aspph.org/georgia-state-smoking-menthol-cigarettes-linked-to-use-of-flavored-cigarillos/>.

### RELEVANT SKILLS

**Statistical software proficiency:** SAS, SPSS, Mplus, R

**Qualitative/mixed-methods software proficiency:** NVivo

**Spatial analysis software proficiency:** GeoDa, QGIS

**Graphic design/video editing software proficiency:** Adobe Creative Suite (i.e., Photoshop, Premiere)

**Licensure/certifications:** HIPAA Certified; Human Subjects Research-Collaborative Institutional Training

Initiative (CITI Program); CPR- AED/First Aid: Adult, Children, and Infants

## REFERENCES

### **Clint Kilts, PhD**

Professor and Director, Brain Imaging Research Center, Associate Director for Research, Psychiatric Research Institute, Department of Psychiatry, College of Medicine, University of Arkansas for Medical Sciences, 430 W. Markham St., Slot # 554, Little Rock, AR, 72205  
Phone: (501) 526-8163, Email: cdkilts@uams.edu

### **Claire Adams Spears, PhD**

Associate Professor, Department of Health Policy & Behavioral Sciences, School of Public Health Georgia State University, Urban Life Building, 140 Decatur St., Suite 612, Atlanta, GA USA 30303, Phone: (404) 413-9335, Email: cspears@gsu.edu

### **Kymberle Landrum Sterling, DrPH**

Associate Professor, Department of Health Promotion & Behavioral Sciences, School of Public Health University of Texas Health Sciences Center, Dallas Campus, 6011 Harry Hines Blvd, Suite V8.112E, Dallas, TX 75390  
Phone: (972) 546-2941, Email: kymberle.l.sterling@uth.tmc.edu

## ***Curriculum Vitae***

### **Yong-Chen “William” Lu, Ph.D.**

TEL: +1 (301) 520-0227

Email: yc.william.lu@gmail.com

Work Address: National Cancer Institute, National Institutes of Health,  
Bldg. 10-CRC, Rm 3W-5930, 10 Center Drive, Bethesda, MD 20892

Home Address: 1620 E Jefferson St., Apt. 111, Rockville, MD, 20852

#### **EDUCATION**

- 06/2009      **Ph.D.**, Department of Medical Biophysics, University of Toronto, Canada.
- 06/2003      **M.S.**, Inst. Microbiology & Immunology, National Yang-Ming University, Taiwan.
- 06/1999      **B.S.**, Major in Chemistry and Minor in Botany, National Taiwan University, Taiwan.

#### **RESEARCH & OTHER EXPERIENCE**

- 07/2016-  
present      **Staff Scientist**, Surgery Branch, National Cancer Institute, National Institutes of Health.
- 07/2014-  
07/2016      **Research Fellow**, Surgery Branch, National Cancer Institute, National Institutes of Health.
- 07/2009-  
07/2014      **Postdoctoral Fellow**, Surgery Branch, National Cancer Institute, National Institutes of Health. Supervisor: Dr. Steven A. Rosenberg. Mentor: Dr. Paul F. Robbins.
- 11/2003-  
03/2009      **Graduate Student**, Department of Medical Biophysics, University of Toronto, Canada. Supervisor: Dr. Pamela S. Ohashi. Co-Supervisor: Dr. Wen-Chen Yeh.
- 09/2001-  
08/2003      M.S. Student, Institute of Microbiology and Immunology, National Yang-Ming University, Taiwan. Supervisor: Dr. Chen-po Hu.
- 10/1999-  
06/2001      Chief Counsellor & Deputy Company Commander, Military Service, Taiwan.
- 07/1997-  
10/1999      Undergraduate Student, Institute of Biological Chemistry, Academia Sinica, Taiwan. Supervisor: Dr. Yasuo Inoue.
- 06/1998-  
09/1998      Summer Student, Department of Biochemistry & Cell Biology, State University of New York at Stony Brook, NY, USA. Supervisor: Dr. William J. Lennarz.

## **INVITED SPEECHES**

1. Block Symposium, The American Association of Immunologists (AAI) Annual Meeting, Pittsburgh, Pennsylvania. *Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions* (May 4, 2014).
2. Press Conference & Clinical Trials Plenary Session, The American Association for Cancer Research (AACR) Annual Meeting, New Orleans, Louisiana. *A phase I study of an HLA-DPB1\*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer* (Apr 17, 2016).
3. Block Symposium, The American Association of Immunologists (AAI) Annual Meeting, Washington DC. *A rapid single-cell RNA-seq approach to identify neoantigen-specific T-cell receptors targeting tumor-specific mutations for use in gene-engineered T-cell immunotherapy* (May 13, 2017).
4. Huntsman Cancer Institute Cancer Immunotherapy Conference, Salt Lake City, Utah. *T-cell therapy targeting MAGE-A3 in solid tumors* (Apr 27, 2018).
5. Plenary Session, Summit for Cancer Immunotherapy, Banff, Alberta, Canada. *TCR-engineered T cells to treat solid tumors: targeting MAGE-A3 and beyond* (Oct 28, 2018).
6. Cancer Center Symposium Series, University of Colorado Anschutz Medical Campus, Aurora, Colorado. *T cell-based immunotherapy targeting shared and unique tumor antigens* (Oct 8, 2019).

## **SESSION CHAIRS**

1. Breakout Session, 5th Annual Single Cell Analysis Investigators Meeting, Bethesda, Maryland. *Immune cell diversity* (June 29, 2017).
2. Symposia Session, National Institutes of Health Research Festival 2017, Bethesda, Maryland. *Diversity of biological insights from single cell analysis across multiple diseases* (Sep 14, 2017).

## **INSTITUTIONAL COMMITTEE ACTIVITIES**

1. NIH Single Cell Genomics Scientific Interest Group Steering Committee (2017 - present).
2. NCI Center for Cancer Research Genetics and Genomics Oversight Committee (2018 - present).
3. NIH Circulating Nucleic Acids/Liquid Biopsies Scientific Interest Group Committee (2019 - present).
4. NCI Technology (Patent Application) Review Group (2020 - present).

## **EDITORIAL AND REVIEW ACTIVITIES**

1. Guest Editor: Molecular Carcinogenesis (2019 - present).
2. Journal Reviewer: Science Translational Medicine, Clinical Cancer Research, Pharmacology & Therapeutics, Frontiers in Immunology, Frontiers in Oncology, *etc.*



## **EMPLOYEE INVENTION REPORT (Patent Application)**

1. A novel T cell therapy against patient-specific cancer mutations (E-229-2014) (PCT/US2014/058805).
2. A novel, personalized T cell therapy: T-cell receptor engineered T cells targeting tumor specific mutations (E-233-2014) (PCT/US2014/058796).
3. T-cell receptor gene therapy against the KRAS G12D hotspot mutation (E-265-2015) (PCT/US2016/050875).
4. HLA-CW8-restricted T-cell receptors against the KRAS G12D mutation (E-175-2016) (PCT/US2017/044615).
5. Anti-MAGE-A3/A6 antibodies, polypeptides, and proteins (E-025-2017) (PCT/US2017/060097).
6. Methods of isolating neoantigen-specific T cell receptor sequences (E-067-2017) (PCT/US2018/024828).
7. T cell receptors targeting p53 hotspot mutations and methods of isolating the same (E-237-2017) (62/565383 & 62/565464).
8. HLA class I-restricted T cell receptors against mutated RAS (E-239-2017) (PCT/US2018/06358).

## **AWARDS & GRANTS**

1. Lee Yuan Tze (Nobel Prize Laureate) Scholarship for Chemistry (1995-1998).
2. Scholarship for Gifted Senior High School Students Studying Mathematics and Natural Sciences (1998-1999).
3. The Ministry of Education Graduate Scholarship for First Student (2001-2003).
4. The Prize of Outstanding Master Thesis (2003).
5. NIH postdoctoral visiting fellowship (2009-2014).
6. NIH Director's Challenge Innovation Award. *Genome-wide RNAi screens: Identifying novel tumor antigens associated with response to T cell therapy* (2012). Role: Co-Investigator (PI: Rosenberg).
7. NCI Director's Innovation Award. *Identification of novel mutated T-cell antigens by minigene libraries based on exome sequencing data* (2013). Role: Investigator & Award Recipient.

## **RESEARCH MENTORSHIP**

1. Lucas A. McDuffie, M.D. (7/2014 – 6/2016). NCI Surgical Oncology Fellowship.
2. Vid Leko, M.D. (1/2017 – 6/2018). Hematology and Oncology Fellowship.
3. Zhili Zheng, M.S. (5/2014 – present). Research Biologist.

## PUBLICATIONS

1. Chen NJ, Mirtsos C, Suh D, **Lu YC**, Lin WJ, McKerlie C, Lee T, Baribault H, Tian H & Yeh WC. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. *Nature* 446, 203-207 (2007).
2. **Lu YC**, Yeh WC & Ohashi PS. Review Article: LPS/TLR4 signal transduction pathway. *Cytokine* 42, 145-151 (2008) (>1000 citations).
3. **Lu YC**, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, Gerondakis S, Akira S, Gaffen SL, Yeh WC & Ohashi PS. Differential role for c-Rel and C/EBP $\beta$ / $\delta$  in TLR-mediated induction of proinflammatory cytokines. *J Immunology* 182, 7212-7221 (2009).
4. Deenick EK, Po L, Chapatte L, Murakami K, **Lu YC**, Elford AR, Saibil SD, Ruland JU, Gerondakis S, Mak TW & Ohashi PS. c-Rel phenocopies PKC $\theta$  but not Bcl-10 in regulating CD8 T cell activation versus tolerance. *European J Immunology* 40, 867-877 (2010).
5. Lin WJ, Su YW, **Lu YC**, Hao Z, Chio I, Chen NJ, Brüstle A, Li WY & Mak TW. Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkappaB2 signaling that contributes to autoimmunity. *Proceedings of the National Academy of Sciences USA* 108, 18354-18359 (2011).
6. Yao X, Ahmadzadeh M, **Lu YC**, Liewehr DJ, Dudley ME, Liu F, Schrumpp DS, Steinberg SM, Rosenberg SA & Robbins PF. Levels of peripheral CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. *Blood* 119, 5688-5696 (2012).
7. **Lu YC\***, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA & Robbins PF\*. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. *J Immunology* 190, 6034-6042 (2013). \*Corresponding authors.
8. Robbins PF, **Lu YC**, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y & Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nature Medicine* 19, 747-752 (2013).
9. Tran E, Turcotte S, Gros A, Robbins PF, **Lu YC**, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC & Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4<sup>+</sup> T cells in a patient with epithelial cancer. *Science* 344, 641-5. (2014).
10. **Lu YC\***, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y,

Rosenberg SA & Robbins PF\*. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. *Clinical Cancer Research* 20, 3401-3410 (2014).

\*Corresponding authors.

11. Tran E, Ahmadzadeh M, **Lu YC**, Gros A, Turcotte S, Robbins PF, Gartner J, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP & Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. *Science* 350, 1387-1390 (2015).
12. **Lu YC\*** & Robbins PF\*. Review Article: Cancer immunotherapy targeting neoantigens. *Seminars in Immunology* 28, 22-27 (2016). \*Corresponding authors.
13. Yao X\*\*, **Lu YC\*\***, Parker LL, Li YF, El-Gamil M, Xu H, van der Bruggen P, Feldman SA, Rosenberg SA & Robbins PF. Isolation and characterization of an HLA-DPB1\*04:01-restricted MAGE-A3 T cell receptor for cancer immunotherapy. *J Immunotherapy* 39, 191-201 (2016) \*\* Co-first authors.
14. **Lu YC** & Robbins PF. Review Article: Targeting neoantigens for cancer immunotherapy. *International Immunology* 28, 365-370 (2016).
15. Tran E, Robbins PF, **Lu YC**, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR & Rosenberg SA. T-Cell transfer therapy targeting mutant KRAS in cancer. *New England J Medicine* 375, 2255-2262 (2016).
16. Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RPT, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, Wunderlich JR, Zheng Z, **Lu YC**, Robbins PF, Rosenberg SA, Goff SL & Feldman SA. Characterization of an immunogenic mutation in a patient with metastatic triple-negative breast cancer. *Clinical Cancer Research* 23, 4347-4353 (2017).
17. **Lu YC**, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC & Rosenberg SA. Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. *J Clinical Oncology* 35, 3322-3329 (2017).
18. **Lu YC\***, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC & Rosenberg SA\*. An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors. *Molecular Therapy* 26, 379-389 (2018). \*Corresponding authors.
19. Zacharakis N, Chinnasamy H, Black M, Xu H, **Lu YC**, Zheng Z, Pasetto A, Langan M, Shelton T,

- Prickett T, Gartner J, Jia L, Trebska-McGowan K, Somerville RP, Robbins PF, Rosenberg SA, Goff SL & Feldman SA. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. *Nature Medicine* 24, 724-730 (2018).
20. Cafri G, Yossef R, Pasetto A, Deniger DC, **Lu YC**, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF & Rosenberg SA. Memory T Cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. *Nature Communications* 10, 449 (2019).
21. Lo W, Parkhurst M, Robbins PF, Tran E, **Lu YC**, Jia L, Gartner JJ, Pasetto A, Deniger DC, Malekzadeh P, Shelton TE, Prickett T, Ray S, Kivitz S, Paria BC, Kriley I, Schrumpp DS & Rosenberg SA. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. *Cancer Immunology Research* 7, 534-543 (2019).
22. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, **Lu YC**, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA & Rosenberg SA. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. *J Immunotherapy* 42, 126-135 (2019).
23. Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett T, Apolo AB, Agarwal PK, Rosenberg SA & **Lu YC\***. Identification of neoantigen-reactive tumor-infiltrating lymphocytes in primary bladder cancer. *J Immunology* 202, 3458-3467 (2019). \*Corresponding author.
24. **Lu YC\***, Jia L, Zheng Z, Tran E, Robbins PF & Rosenberg SA\*. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. *Cancer Immunology Research* 7, 1824-1836 (2019). \*Corresponding authors.

# Complete list of published work in **MyBibliography**

<https://www.ncbi.nlm.nih.gov/myncbi/1vorkObP1Av/bibliography/public/>

## Citation record in **Scopus**

<https://www.scopus.com/authid/detail.uri?authorId=56978320800>

# CURRICULUM VITAE

NAME: Hung Nguyen Luu  
BUSINESS ADDRESS: UPMC Cancer Pavilion  
5150 Centre Avenue  
4<sup>th</sup> Floor –Suite 4C, Room 466  
Pittsburgh, PA 15232  
Phone: 412-623-3386  
Fax: 412-623-3303  
E-mail: [luuh@upmc.edu](mailto:luuh@upmc.edu)  
or [hnl11@pitt.edu](mailto:hnl11@pitt.edu)

I am a molecular epidemiologist ò cancer and have a broad background in medicine and epidemiology, with specific training and expertise in the molecular and genetic epidemiology of cancer as well as large population-based studies. My main research has focused on molecular and genetic epidemiology to investigate the contribution of host susceptibility, environment and lifestyle factors on the etiology and prognosis of gastrointestinal cancers, including colorectal cancer, liver cancer, non-alcoholic fatty liver diseases (NAFLDs), and pancreatic cancer. Recently, my specific focus is the roles the axis microbiota-metabolome-immuno suppression in those gastrointestinal cancers. I have an extensive experience working with three large prospective cohort studies: the Southern Community Cohort Study, the Shanghai Men’s Health Study, and the Shanghai Women’s Health Study (total>230,000 study participants). At the University of Pittsburgh, I have been extensively involved in two other large cohort studies: the Shanghai Cohort Study and Singapore Chinese Health Study as an Investigator. I have been continuously funded by the federal funding agency (NIH/NCI) and foundations. I am the PI for a grant to determine the role of environment and genetic factors in colorectal cancer and adenomas; the PI for a study to evaluate difference in microbiota using difference fecal collection methods and a Co-PI for a grant to evaluate the influence of peanut consumption on cardiovascular risk factors and the gut microbiome. I am also currently the MPI for a newly funded grant to determine the determinants of progression from NAFLD to HCC and a Program Leader for NCI-funded grant to determine the genetic profiles of head and neck squamous cell carcinoma (HNSCC).

## EDUCATION AND TRAINING

### Undergraduate

08/1991-05/1997	Thai Binh Medical University, Thai Binh, Vietnam	MD, 1997	Medicine
-----------------	--	----------	----------

### Graduate

08/2002-12/2003	Tulane University- School of Public Health and Tropical Medicine, New Orleans, LA	MPH, 2003	Public Health
01/2008-08/2011	University of Texas School of Public Health-Houston Health Science Center, School of Public Health, Houston, TX	PhD, 2011	Epidemiology

**Post-Graduate**

09/2011-12/2013	Baylor College of Medicine - Dan L. Duncan Cancer Center, Houston, TX	Post-doctoral, 2013	Molecular Epidemiology of Cancer
01/2014-05/2015	Vanderbilt University Medical Center, School of Medicine, Nashville, TN	Research Fellow, 2015	Molecular and Genetics Epidemiology of Cancer

**APPOINTMENTS AND POSITIONS****Academic**

01/2008-11/2011	Research Assistant	Division of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, University of Texas Health Science Center-Houston, Houston, TX
01/2008-12/2010	Visiting Senior Research Fellow	Institute of Population, Health and Development (PHAD), Hanoi, Vietnam
02/2009-10/2009	Research Fellow	Molecular Tuberculosis Laboratory, Department of Pathology, The Methodist Hospital Research Institute (TMHRI), Houston, TX
09/2011-12/2013	Post-doctoral Associate	Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX
01/2014-05/2015	Research Fellow	Vanderbilt University Medical Center, School of Medicine
06/2015-12/2017	Assistant Professor (Tenured-track)	Department of Epidemiology and Biostatistics, College of Public Health University of South Florida, Tampa, FL
01/2018-present	Assistant Professor (Tenured-track)	Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
01/2018-present	Member	Cancer Epidemiology and Prevention Program, Division of Cancer Control and Population Sciences, Hillman Cancer Center University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA
10/2015-present	Collaborator Member	Department of Cancer Epidemiology Lee H. Moffitt Cancer Center and Research Institute, Tampa, FL
10/2015-present	Assistant Professor of Medicine (Affiliate)	Epidemiology Center-Department of Medicine, Vanderbilt-Ingram Comprehensive Center, Vanderbilt University Medical Center, Nashville, TN

**Non-Academic**

08/1997-08/1998	Project Coordinator/ Research Assistant	UNFPA (United Nations Population Fund), Hanoi, Vietnam
09/1998-03/2000	Program Officer	Save the Children-France ( <i>Enfant et Developpement-EED</i> ), Hanoi, Vietnam

04/2000-07/2002	National Program Officer	International Trachoma Initiative (ITI), Hanoi, Vietnam
01/2004-11/2004	Program Officer	Futures Group International, Hanoi, Vietnam
12/2004-08/2005	Program Officer	HIV/AIDS Surveillance, Research, and Evaluation, Family Health International (FHI), Hanoi, Vietnam
05/2007-12/2007	Epidemiologist/Researcher	AIDS DataHub, United Nations Children's Fund (UNICEF), East Asia and Pacific Regional Office in Bangkok, Thailand

## CERTIFICATION AND LICENSURE

### Specialty Certification

Not Applicable

### Medical or Other Professional Licensure

Not Applicable

## MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

2013-present	American Association for Cancer Research (AACR)-Member #281580
2012- present	International Papillomavirus Society (IPS)
2012- present	American Society of Preventive Oncology (ASPO)
2007- present	Society for Epidemiologic Research, USA
2015- present	Asian Cohort Consortium (ACC)-Active Member
2017- present	Gastric Cancer Consortium (SToP Consortium)-Key Member
2018- present	International Liver Cancer Consortium (ILCAC)-Founding Member

## HONORS

1992	Nguyen Thai Binh Scholarship - Youth Magazine (Bao Thanh Nien), Vietnam
1991-1997	Scholarship for Academic Merit - Thai Binh Medical University
2002-2003	Fulbright Scholarship - US Department of State
2008	Scholarship for Outstanding New Student – University of Texas Health Science Center-Houston, School of Public Health
2008, 2009	Travel grants – Vietnam Education Foundation (VEF)
2008	Award of Excellent Academic Achievement –Vietnam Education Foundation
2008-2009	Vietnam Education Foundation (VEF) Fellowship
2010	Best Presentation Award - Scientific Session, Public Health Track, Annual Conference, Vietnam Education Foundation (VEF), Albany, New York.
2010-2011	Fogarty Pre-doctoral Fellowship-University of Texas Health Science Center-Houston, School of Public Health (R. Palmer Beasley, PI)
2011-2013	Post-doctoral Fellowship - Innovation in Cancer Prevention Research, Institutional training grant, Cancer Prevention Cancer Research Institute of Texas-CPRIT, grant # RP101503 (Roberta B Ness, PI)
2015	R25 Training Post-doctoral Fellowship-National Cancer Institute (NCI), grant #5R25CA160056-03 (Xiao-Ou Shu, PI)

2015, 2016	Faculty International Program Development Award University of South Florida
2016	Travel Grant Award–5 <sup>th</sup> Annual Clinical Cancer Genetics and Genomics Conference, University of Chicago
2016	2015 Top 10 Paper–Vanderbilt University Medical Center, Vanderbilt Epidemiology Center (2 papers awarded as the lead author)
2018-2019	Hillman Fellow for Innovative Early-Career Cancer Research UPMC Hillman Cancer Center

## PROFESSIONAL ACTIVITIES

### 1. Teaching

#### a. Courses Taught

<b>Years Taught</b>	<b>Course Number: Title</b>	<b>Hours of Lecture, credits Average Enrollment</b>	<b>Role in course Primary/Coordinator</b>
2020, Fall	EPI2921: Grant Writing	2 hrs/wk – 2 cr; 9 graduate students	Guest Lecturer
2020, Spring	EPI2171: Cancer Epidemiology	2 hrs/wk – 3 cr.; 11 graduate students	Primary Instructor
2020, Spring	EPI2600: Introduction to Molecular Epidemiology	2 hrs/wk – 3 cr.; 20 graduate students	Guest Lecturer
2019, Fall	EPI2921: Grant Writing	2 hrs/wk – 2 cr; 10 graduate students	Guest Lecturer
2019, Spring	EPI2171: Cancer Epidemiology	2 hrs/wk – 3 cr.; 9 graduate students	Primary Instructor
2019, Spring	EPI2600: Introduction to Molecular Epidemiology	2 hrs/wk – 3 cr.; 25 graduate students	Guest Lecturer
2017, Spring	PHC6007: Cancer Epidemiology	3 hrs/wk – 3 cr.; 7 graduate students	Primary Instructor
2017, Summer	PHC6007: Cancer Epidemiology	3 hrs/wk – 3 cr.; 33 graduate students	Primary Instructor
2016, Fall	PHC6011: Epidemiology Methods II	3 hrs/wk – 3 cr.; 20 graduate students	Co-Instructor
2016, Summer	PHC6007: Cancer Epidemiology	3 hrs/wk – 3 cr.; 17 graduate students	Primary Instructor
2016, Spring	PHC6007: Cancer Epidemiology	3 hrs/wk – 3 cr.; 14 graduate students	Primary Instructor

#### b. Other Teaching (lectures, tutorials and continuing education courses)

<b>Dates(s)</b>	<b>Type of Teaching</b>	<b>Title</b>
2016	Lecture	Long-chain fatty acids and cancer risk
2017	Lecture	Pancreatic Cancer Research with Different Perspectives
2018	Lecture	Molecular epidemiology of cancer
2018	Lecture	Epidemiology of gastrointestinal tract cancers
2019	Lecture	Molecular epidemiology of cancer
2020	Lecture	Molecular epidemiology of cancer



**c. Major Advisor for Graduate Student Essays, Theses, and Dissertations**

<b>Name of Student</b>	<b>Degree Awarded, Year</b>	<b>Type of Document and Title</b>	<b>Notes</b>
Heather Tinsley	MPH, 2015-2017	Rhabdomyosarcoma Incidence and Survival in Whites, Blacks, and Hispanics from 1973-2013: Analysis from the Surveillance, Epidemiology, and End Results Program	Health Service Researcher, Health Services Advisory Group, Inc. (HSAG)
Kiara Diggins-Parker	MPH, 2015-2017	Gastric cancer: biology, epidemiology and prevention	CDC/CSTE Applied Epidemiology Fellow at Douglas County Health Department
Fahad Mukhtar	PhD, 2016-2020	Lifestyle risk factors associated with colorectal cancer mortality	Resident, St. Elizabeth's Hospital, Washington DC

<b>Name of Student</b>	<b>Degree Awarded, Year</b>	<b>Type of Document and Title</b>	<b>Notes</b>
Ovie Utuama	PhD, 2016-2019	Neoadjuvant chemotherapy trends, utility and effects on pancreatic ductal adenoma and intrahepatic cholangiocarcinomas Defended dissertation in December 2019;	USF PhD student Current Position: Post-doctoral Fellow at H. Lee Moffitt Cancer & Research Institute
Linh Duong	PhD, 2020	Identifying Barriers and Facilitators to Improve Hepatitis C Virus Screening Defended dissertation on March 18, 2020;	USF PhD student Currently position: Post-doctoral Fellow - MAGEC Program at Vanderbilt University Medical Center

**d. Service on Masters or Doctoral Committees**

<b>Dates Served</b>	<b>Name of Student</b>	<b>Degree Awarded</b>	<b>Title of Dissertation/Essay</b>
2015-2017	Heather Tinsley	MPH	Rhabdomyosarcoma Incidence and Survival in Whites, Blacks, and Hispanics from 1973-2013: Analysis from the Surveillance, Epidemiology, and End Results Program
2015-2017	Kiara Diggins-Parker	MPH	Gastric cancer: biology, epidemiology and prevention
2016-2020	Fahad Mukhtar	PhD Candidate	Lifestyle risk factors associated with colorectal cancer mortality
2016-2020	Ovie Utuama	PhD Candidate	Neoadjuvant chemotherapy trends, utility and effects on pancreatic ductal adenoma and intrahepatic cholangiocarcinomas

### e. Service on Comprehensive or Qualifying Examination Committees

Dates Served	Student Population	Type of Exam (Qualifying/Comprehensive)
2017	Fahad Mukhtar, PhD Candidate	Comprehensive Exam
2017	Ovie Utuama PhD Candidate	Comprehensive Exam

### f. Supervision of Post-Doctoral Students, Residents, and Fellows

Pedram Paragomi, MD	2020- present	Chronic pancreatitis and pancreatic cancer	Co-mentor
------------------------	------------------	---	-----------

### g. Mentoring of Graduate Students in Field Placements

Dates	Name of Student	Degree/Program Description	Field Site
2018	Linh Duong	Screening practices among Vietnamese in Hanoi, Vietnam and Incidence of Colorectal Cancer in this Population	Vinmec Healthcare System, Hanoi, Vietnam

### h. Other Teaching and Training

Not applicable

## 2. Research and Training

### a. Current Grants and Contracts Received

#### Principal Investigator

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
06/01/2017- 12/31/2020	IOC.17.01 (Luu) Colorectal Cancer and Polyp Research in Vietnam (Role: PI)	Vinmec Healthcare System	\$1,537,500	5.40 calendar months
07/01/2018- 10/30/2020	Influence of Peanut Consumption on Cardiovascular Risk Factors and the Gut Microbiome: A Randomized Clinical Trial (Shu, Luu) (Role: MPI)	Peanut Foundation	\$75,000	1.20 calendar months
09/01/2020- 08/31/2023	VINIF.2020.DA06 (Luu, Tran, Pham) Prediction for the progression of liver fibrosis and the development of hepatocellular carcinoma (HCC) and end-stage liver diseases: a novel approach using Artificial Intelligence technique (Role: MPI)	VinGroup Innovation Foundation (VINIF)	\$166,000	2.40 calendar months
09/01/2020- 08/31/2021	3P30CA047904-32S2 (Ferris) Identifying and potentially mitigating biologic and treatment-related disparities in head and neck squamous cell carcinoma (HNSCC) in India (Role: Program Leader)	NIH/NCI	\$200,000	0.60 calendar months

**Co-Principal Investigator/Sub-contract PI**

<b>Years Inclusive</b>	<b>Grant and/or Contract Number and Title</b>	<b>Source</b>	<b>Annual Direct Costs</b>	<b>% Effort</b>
09/20/2016-08/31/2018	1P20CA210300-01 (Shu, Luu) Regional Center of Research Excellence in Cancer and other Non-communicable Disease Epidemiology and Prevention in Vietnam No-cost extension (08/31/2019) (Role: PI-Subaward)	NIH/NCI	\$223,548	2.16 calendar months
09/01/2019-08/31/2020	1P20CA210300-01 (Shu, Luu)-Supplemental Regional Center of Research Excellence in Cancer and other Non-communicable Disease Epidemiology and Prevention in Vietnam (Role: PI-Subaward)	NIH/NCI	-	
08/05/2014-07/31/2024	Translational Research Training in Cancer Etiology and Prevention (Yuan) (Role: Mentor)	NIH/NCI	\$130,000	0.00 calendar month

**Co-Investigator on Grants**

Not applicable

**Submitted/Pending for Review-Grant Support**

<b>Years Inclusive</b>	<b>Grant and/or Contract Number and Title</b>	<b>Source</b>	<b>Annual Direct Costs</b>	<b>% Effort</b>
03/01/2021-02/28/2026	Translational Research Training in Cancer Etiology and Prevention in Vietnam (Yuan, Luu) (Role: MPI)	NIH/NCI D43CA260647	\$250,000	1.20 calendar months
04/01/2021-03/31/2026	The Synergistic Role of Microbiota, Metabolites and Immunomarkers on the Risk of Colorectal Adenomas and Cancer (Luu) (Role: PI)	NIH/NCI R01CA258699	\$499,969	3.60 calendar months
01/01/2021-12/31/2025	<u>D</u> ietary <u>I</u> ntervention on <u>R</u> educing Risk Determinants of <u>H</u> epatocellular <u>C</u> arcinoma in Patients with Advanced <u>F</u> ibrosis due to <u>N</u> AFLD ( <b>DIRECTION</b> ) (Yuan, Behari) (Role: Co-I)	R01-NIH/NCI	\$250,000	1.20 calendar months
12/01/2020-11/30/2025	Novel determinants for progression of non-alcoholic fatty liver disease to hepatocellular carcinoma and other health outcome (Yuan, Behari) (Role: Co-I) ( <u>Impact score: 28</u> )	R01 – NIH/NCI	\$498,205	1.20 calendar months
07/01/2020 - 06/30/2022	A study of metabolic conditions among HIV-patients in Vietnam (Luu) (Role: PI)	R21 W011710- NIH/NCI	\$135,000	1.80 calendar months
08/01/2020-07/31/2025	Novel and integrative approaches for cancer subtype identification and systems-level characterization (Nguyen, Luu) (Role: MPI)	1U01 CA253514-01 NIH/NCI	\$100,000	2.40 calendar month

08/15/2020-07/14/2022	A Genome-Wide Approach to Decipher the Role of Exosomal micro-RNA in Pancreatic Cancer (Luu) (Role: PI)	R21 CA252362 -NIH/NCI	\$137,500	3.00 calendar month
07/01/2020-06/30/2024	The Role of Microbiome, Metabolome, and Immune Marker in Colorectal Cancer (Luu) (Role: PI)	ACS	\$165,000	3.00 calendar month
08/15/2020-07/30/2025	Novel Approach to Decipher the Roles of Microbiome, Metabolome, and Immune Markers on the Risk of Colorectal Adenomas and Cancer (Luu) (Role: PI)	DP2 OD028970-01	\$300,000	3.60 calendar month
12/01/2019-11/30/2024	An Integrative Approach to Decipher the Role of Microbiome, Metabolome, and Immune Markers on the Risk of Colorectal Adenomas and Cancer (Luu) (Role: PI)	1R01CA247380-01-NIH/NCI	\$499,969	3.00 calendar months
07/01/2019-06/30/2022	Novel Approach of Microbiomes and Metabolomics in Determination of Colorectal Cancer Risk (Luu) (Score=2.1) (Role: PI)	T12714748-Department of Defense	\$120,000	4.80 calendar months
07/01/2019-06/30/2020	Novel Approach of Metabolomics in Determination of Colorectal Cancer Risk (Luu) (Role: PI)	AACR Gertrude B. Elion Cancer Research Award	\$75,000	0.90 calendar months
10/01/2018-09/30/2021	VINM-VR01-K50002 Lung Cancer Among Non-smoking Women in Vietnam (Luu) (Role: PI)	Vinmec Healthcare System	\$250,000	3.00 calendar months
04/01/2019-03/31/2024	Alcohol drinking in the elderly: effects on mortality and disease burden (Boffetta, Luu) (Role: MPI)	NIH/NCI	\$500,000	1.80 calendar months
09/01/2018-08/21/2021	The NNK-metabolizing pathway and markers of lung cancer risk (Yuan, Lazarus) (Role: Co-I)	AACR	-	0.60 calendar months
09/01/2019-08/31/2023	UM1 CA182876 Singapore Chinese Health Study (Yuan) (Role: Co-PI)	NIH/NCI	-	0.60 calendar months

**b. Invited Lectureships and Major Seminars Related to Your Research**

Not applicable

**c. Other Research and Training Activities**

Not applicable

**PUBLICATIONS**

**1. Refereed Articles**

1. Kingah PL, **Luu HN**, Volcik K, Morrison A, Nettleton J, Boerwinkle E. Association of the NOS3 Glu298Asp SNP with hypertension and possible effect modification of dietary fat intake. *Hypertens Res* 2010;33(2):165-169. (PMID: 19960019 - PMCID: PMC2828038).

2. **Luu HN\***, Kingah PL, North K, Boerwinkle E, Volcik K. Interaction of folate intake and the paraoxonase Q192R polymorphism with risk of acute coronary events, strokes and atherosclerosis: the Atherosclerosis Risks in Communities (ARIC) Study. Ann Epidemiol. 2011;21(11):815-823. (PMID: 21982484 - PMCID: PMC3190162) (\*Corresponding author).
3. **Luu HN**, Amirian ES, Beasley RP, Piller L, Chan W, Scheurer ME. CD4+ cell count and HIV viral load as predictors of size of anal warts over time in HIV-infected women. J Infect Dis 2012;205(4):578-585. (PMID: 22246682 - PMCID: PMC3266135).
4. **Luu HN**, Amirian ES, Beasley RP, Piller L, Chan W, Scheurer ME. Association between smoking and size of anal warts in HIV-infected women. Int J STD AIDS 2012;23(11):792-798 (PMID: 23155099 - PMCID: PMC4629988).  
 § Reviewed by Desai M, Clinical Round-up. Sex Transm Infect 2013;89(1):83  
 § Featured at Life Science Weekly, Mar 6, 2012
5. **Luu HN**, Amirian ES, Scheurer ME. The interaction between smoking status and HAART use and the risk of Kaposi's sarcoma in a cohort of HIV-infected men. Br J Cancer 2013;108(5):1173-1177 (PMID: 23422755 – PMCID: PMC3619085).  
 § Featured at AIDS Weekly, May 20, 2013
6. **Luu HN**, Dahlstrom K, Mullen PD, VonVille H, Scheurer ME. Comparison of the accuracy of Hybrid Capture II (HC II) and polymerase chain reaction (PCR) in detecting clinically important cervical dysplasia: A systematic review and meta-analysis. Cancer Med 2013;2(3):367-390 (PMID: 23930214 – PMCID: PMC3699849).
7. **Luu HN**, Adler-Storthz K, Dillon LM, Follen M, Scheurer ME. Comparing the performance of Hybrid Capture II (HC II) and polymerase chain reaction (PCR) for the identification of cervical dysplasia in screening and diagnostic settings. Clin Med Insights Oncol 2013;7:247-255 (PMID: 24137052 – PMCID: PMC3795532).
8. **Luu HN\***, Amirian ES, Beasley RP, Piller L, Chan W, Scheurer ME\*. Clinical implications of the cervical Papanicolaou test results in the management of anal warts in HIV-infected women. PLoS One 2013;8(11):e81751 (PMID: 24312348 - PMCID: PMC3842937) (\*Corresponding authors).
9. Thang VH, Skoog L, **Luu HN**, Van TT, Tani E. Long-term breast cancer survival in Vietnamese women. Breast J 2014;20(3):333-335 (PMID: 24673847 – PMCID: Not available).
10. **Luu HN\***, Amirian ES, Chiao EY, Scheurer ME\*. Age patterns of Kaposi's sarcoma in a cohort of HIV-infected men. Cancer Med 2014;3(6):1635-1643 (PMID: 25139791 - PMCID: PMC4298390) (\*Corresponding authors).
11. **Luu HN**, Qi D, Wen W, Xiang YB, Cai Q, Li H, Yang G, Gao YT, Zheng W, Shu X. Are Dietary Antioxidant Intake Indices Correlated to Oxidative Stress and Inflammatory Marker Levels? Antioxid Redox Signal 2015;22(11):951-959 (PMID: 25602689 – PMCID: PMC4376488).

§ 2015 Top 10 Paper – Vanderbilt University Medical Center, Vanderbilt Epidemiology Center

12. **Luu HN**, Blot WJ, Xiang YB, Cai H, Hargreaves MK, Li H, Yang G, Signorello L, Gao YT, Zheng W, Shu X. Association between nut consumption with total and cause-specific mortality: Evidence from three cohort studies of multi-ethnic populations. JAMA Intern Med 2015;175(5):755-766 (PMID: 25730101 - PMCID: PMC4474488).  
  
 § Editor-Commentary: Katz MH. Live longer ... for peanuts. JAMA Intern Med 2015;175(5):766  
 § Featured at New York Times, Washington Post, New York Post, Reuters, TIME, UPI, CNBC, FOX News, CBS News, etc., Mar 04, 2015  
 § 2015 Top 10 Paper – Vanderbilt University Medical Center, Vanderbilt Epidemiology Center
13. Ren HG, **Luu HN**, Cai H, Xiang YB, Steinwandel M, Gao YT, Hargreaves MK, Zheng W, Blot WJ, Long JR, Shu X. Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysis. Ann Oncol 2016;27(7):1329-1336 (PMID: 27217540 - PMCID: PMC4922320).
14. Beeghly-Fadiel\*, **Luu HN\***, Du L, Parikh AA, McGavic DP, Raskin L. Early onset pancreatic malignancies: Clinical characteristics and survival association. Int J Cancer 2016;2169-2177 (PMID: 27416564-PMCID: not yet available) (\*co-first authors).
15. **Luu HN**, Long JR, Zheng Y, Cai Q, Gao YT, Zheng W, Shu X. Association of genetic risk score for shorter telomere length and risk of breast cancer. Cancer Causes Control 2016;DOI:10.1007/s10552-016-0798-z (PMID: 27581250-PMCID: PMC5061576).
16. Mukhtar F<sup>¶</sup>, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, Tran TV, Zgibor JC, **Luu HN\***. Survival predictors of Burkitt's lymphoma in the United States during 2000-2013 period. Int J Cancer 2017;140(7):1494-1502. (PMID: 28006853-PMCID: Not yet available) (\*Corresponding authors; <sup>¶</sup>Trainee co-author)
17. Berge W, Mundt K, **Luu HN**, Boffetta P. Genital use of talc and risk of ovarian cancer: A meta-analysis. Eur J Cancer Prev 2017; doi: 10.1097/CEJ.0000000000000340 (PMID: 280796030 - PMCID: Not yet available).
18. Chen Y, Wu F, Saito E, Lin Y, Song M, **Luu HN**, Gupta PC, Sawada N, Tamakoshi A, Shu XO, Koh WP, Xiang YB, Tomata Y, Sugiyama Y, Park SK, Matsuo K, Nagata C, Sugawara Y, Qiao YL, You SL, Wang R, Shin MH, Pan WH, Pednekar MS, Tsugane S, Cai H, Yuan JM, Gao YT, Tsuji I, Kanemura S, Ito H, Wada K, Ahn YO, Yoo KY, Ahsan H, Chia KS, Boffetta P, Zheng W, Inoue M, Kang D, Potter JD. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia 2017; 2017;Mar 7. doi: 10.1007/s00125-017-4229-z. (PMID: 28265721 – PMCID: PMC5632944).
19. **Luu HN**, Lin HY, Sørensen K, Ogunwobi OO, Kumar N, Chornokur G, Phelan CM, Jones D, Kidd LC, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Pietro GD. miRNAs associated with Prostate Cancer risk and progression. BMC Urol. 2017;17(18):DOI 10.1186/s12894-017-0206-6 (PMID: 28320379 – PMCID: PMC5359825).
20. Hashim D, Sartori S, Vecchia CL, Maso LD, Serraino D, Matsuo K, Negri E, Winn DM, Moysich KB, Smith E, Levi F, Boccia S, Bosetti C, Cadoni G, Maso LD, **Luu HN**, Lee YCA, Hashibe M,

Boffetta P. Hormone factors play a favorable role in female head and neck cancer risk. Cancer Med 2017;6(8):1998-2007 (PMID: 28707400 – PMCID: PMC5548879).

21. **Luu HN\***, Murff HJ, Li H, Cai Q, Gao YT, Gao J, Lan Q, Yang G, Xiang YB, Zheng W, Shu XO. A prospective study of dietary polyunsaturated fatty acids intake and lung cancer risk Int J Cancer 2018; 143(9):2225-2237 (PMID: 29905376 – PMCID: PMC6195443). (\*Corresponding authors)
22. Mukhtar F<sup>¶</sup>, Boffetta P, Dabo B, Park JY, Tran TV, Tran TTH, Whitney M, Risch HA, Le LC, Chi TDu. Tran, Zheng W, Shu XO, **Luu HN\***. Disparities by race, age, and sex in the improvement of survival for lymphoma: Finding from a population-based study. PLoS One 2018;13(7):e0199745 (PMID: 29995909 – PMCID: PMC6040734). (¶Trainee co-author; \*Corresponding author).
23. Pietro GD, **Luu HN**, Spiess PE, Sexton W, Dickinson S, Parker A, Park JY. Biomarkers and new therapeutic targets in renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2018;22(18):5774-5981. (PMID: 30280768 – PMCID: Not yet available).
24. Nguyen MT, Tran MT, Tran CD, Tran HA, Tuong TVT, Phung LN, Vu HV, Le LC, Boffetta P\*, **Luu HN\***. Birth orders and the risk of childhood brain tumors: A systematic review and meta-analysis. Eur J Cancer Prev 2018 (PMID: 30399044 – PMCID: Not yet available) (\*Corresponding author).
25. Mukhtar F<sup>¶</sup>, Bubu OM, **Luu HN**. Clinical Characteristics and Survival of Patients with Multiple Metachronous Esophageal Tumor. Cancer Treat Res Comm. 2018 (PMID: 30173004 – PMCID: Not yet available) (¶Trainee co-author).
26. Lyons K<sup>¶</sup>, Le LC, Pham YTH, Borron C, Park JY, Tran CTD, Tran TV, Tran HTT, Vu KT, Do CD, Pelucchi C, Vecchia CL, Zgibor J, Boffetta P\*, **Luu HN\***. Gastric cancer: epidemiology, biology and prevention-A mini review. Eur J Cancer Prev 2019;28(5):397-412 (PMID: 31386635) (¶Trainee co-author; \*Corresponding author).
27. **Luu HN\***, Qi M<sup>¶</sup>, Wang R, Adams-Haduch J, Miljkovic I, Opresko PL, Koh WP, Yuan JM. Association between leukocyte telomere length and the risk of colorectal cancer in the Singapore Chinese Health Study during 1993-2015. Clin Transl Gastroenterol. 2019;10(5):1-9 (PMID: 3117113 – PMCID: PMC6602767) (¶Trainee co-author; \*Corresponding author).
28. Boffetta P, Donato F, Pira E, **Luu HN**, Vecchia, CL. Risk of mesothelioma after cessation of asbestos exposure: a systematic review and meta-regression. Int Arch Occup Environ Health. 2019 (Apr 15. doi: 10.1007/s00420-019-01433-4.) (PMID: 30993422 – PMCID: Not yet available)
29. Park JY, **Luu HN**, Park HY, Lin HY, Radlein S, Giuliano DP, Yeo CD, Kim SJ, Kang NH, Antwi S, Sexton W, Speiss P, Dickinson S, Parker A. Telomere length in peripheral blood leukocyte and risk of renal cell carcinoma. Transl Cancer Res. 2019; 8(Suppl 4):S397-S403 | <http://dx.doi.org/10.21037/tcr.2019.06.36>.
30. Huang JY, Larose TL, **Luu HN**, Wang R, Fanidi A, Alcalá K, Stevens VL, Weinstein SJ, Albanes D, Caporaso N, Purdue M, Ziegler R, Freedman ND, Lan Q, Prentice RL, Pettinger M, Thomson CA, Cai Q, Wu J, Blot WJ, Shu XO, Zheng W, Arslan AA, Zeleniuch-Jacquotte A, Marchand LL, Wilkens LR, Haiman CA, Zhang X, Stampfer M, Smith-Warner S, Han J, Giles GG, Hodge AH, Severi G, Johansson M, Grankvist K, Langhammer A, Hveem K, Xiang YB, Li

HL, Gao YT, Visvanathan K, Bolton JH, Ueland PM, Midttun Ø, Ulvik A, Buring JE, Lee IM, Sesso HD, Gaziano JM, Manjer J, Relton C, Koh WP, Brennan P, Johansson M, Yuan JM. Circulating markers of cellular immune activation in pre-diagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium LC3). *Int J Cancer* 2019; Jul 5. doi: 10.1002/ijc.32555. (PMID: 31276202 – PMCID: Not yet available)

31. **Luu HN\***, Huang JY, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. Association between leukocyte telomere length and the risk of pancreatic cancer: Findings from the Singapore Chinese Health Study during 1993-2015. *PLoS One* 2019;14(8):e0221697. doi: 10.1371/journal.pone.0221697. (\*Corresponding author) (PMID: 31465482 – PMCID: PMC6715276)
32. Utuama O<sup>¶</sup>, Mukhtar F, Dabo B, Pham YT-H, Manani P, Moser J, Michael-Asalu A, Tran CTD, Le LC, Boffetta P, Zheng W, Shu XO, **Luu HN\***. Disparities by race, age, and sex in the improvement of survival for leukemia in the US during 1973-2014 period. *PLoS One* 2019;14(8):e0220864. doi: 10.1371/journal.pone.0220864 (¶Trainee co-author; \*Corresponding author) (PMID: 31425527 – PMCID: PMC6699686)
33. Nguyen HD, Phung HT, Le T-N, **Luu HN**. Bone marrow transplantation platform to investigate the role of Dendritic cells in Graft-versus-host disease. *J Vis Exp* 2020;157:e60083 doi.10.3791/600833 (PMID: 32250356).
34. Thuy NT, **Luu HN\***, Nguyen MVT, Tran MT, Tuong TVT, Tran CD, Boffetta P\*. Attributable causes of cancer in Vietnam. *JCO Glob Oncol*. 2020 Feb;6:195-204. doi: 10.1200/JGO.19.00239. (PMID: 32045545) (\*Corresponding author).
35. Pham YT-H, Utuama O<sup>¶</sup>, Thomas CE<sup>¶</sup>, Park JY, Tran CTD, Vecchia CL, Risch HA, Boffetta P, Raskin L\*, **Luu HN\***. High mobility group A protein -2 (HMHA2) as a tumor marker for cancer diagnostic and prognostic: a systematic review and meta-analysis. *Eur J Cancer Prev*. 2020 Sep 3. doi: 10.1097/CEJ.0000000000000602. Online ahead of print. (PMID: 32898013) (¶Trainee co-author; \*Corresponding author).
36. Huang JY, **Luu HN\***, Butler LM, Midttun Ø, Ulvik a, Wang R, Jin A, Gao YT, Tan Y, Ueland PM, Koh WP, Yuan J-M. A prospective evaluation of serum choline metabolites in relation to pancreatic cancer risk in two prospective cohort studies. *Int J Cancer* 2020;March 29: doi.org/10.1002/ijc.32994 (PMID: 32222976) (\*Corresponding author)
37. Phung HT, Pham AG, Nguyen HH, Pham H-T, Pelucchi C, La Vecchia C, Boffetta P, Nguyen HD\*, **Luu HN\***. Emerging roles of circulating tumor cells in gastric cancer. *Cancers* 2020 Mar 15;12(3). pii: E695. doi: 10.3390/cancers12030695. (PMID: 32183503) (\*Corresponding author).
38. Thomas CE<sup>¶</sup>, **Luu HN\***, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. Association between dietary tomato intake and the risk of hepatocellular carcinoma: Findings from a prospective study *Cancer Epidemiol Biomarkers Prev*. 2020; April 13;doi: 10.1158/1055-9965.EPI-20-0051 (PMID: 3225431) (¶Trainee co-author; \*Corresponding author).
39. Tran D, Nguyen H, Le U, Bebis G, **Luu HN**, Nguyen T. A novel method for cancer subtyping and risk prediction using consensus factor analysis. *Front Oncol* 2020; doi: 10.3389/fonc.2020.01052



40. Tran BQ, Hoang MV, Vu LH, Bui LP, Kim GB, Pham NQ, Nguyen LT, Lai TD, Truong BD, Tran PD, Tran HTT, Tran TV, **Luu HN**, Zheng W, Shu XO, Shrubsole M. Risk factors for non-communicable diseases (NCDs) among adults in Vietnam: Findings from the Vietnam STEPS survey 2015. J Glob Health Sci. 2020;Jun;2(1):e7
41. Nguyen S, Li H, Yu D, Cai H, Gao J, Gao YT, **Luu HN**, Tran H, Xiang YB, Zheng W, Shu XO. Dietary fatty acids and colorectal cancer risk: a report from the Shanghai Men's Health Study and a meta-analysis Int J Cancer 2020; Jul 7. doi: 10.1002/ijc.33196. Online ahead of print. (PMID: 32638381)
42. Samavat H<sup>¶</sup>, **Luu HN**, Jin A, Wang R, Koh WP, Yuan JM. Leukocyte telomere length, cancer incidence and all-cause mortality among Chinese adults: Singapore Chinese Health Study. Int J Cancer 2020; 19 July 2020; <https://doi.org/10.1002/ijc.33211> (¶Trainee co-author).
43. Berglund A, Amankwah EK, Kim Y-C, Dickinson S, Spiess PE, Sexton W, Brandon M, Park HY, Yeo CD, **Luu HN**, Di Pietro G, Parker A, Park JY. Influence of gene expression on progression of clear cell renal cell carcinoma. Cancer Med; 2020 Sep 28. doi: 10.1002/cam4.3475 (PMID: 32986937)
44. **Luu HN**<sup>\*</sup>, Neelakantan N, Wang R, Behari J, Adams-Haduch J, Goh GBB, Jin A, van Dam RM, Koh WP, Yuan JM. Association between high-quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study Int J Cancer 2020 (In press) (\*Corresponding author).
45. **Luu HN**<sup>\*</sup>, Wang R, Behari J, Adams-Haduch J, Odegaard AO, Goh GBB, Jin A, Koh WP, Yuan JM. Composite score of healthy lifestyle factors and risk of hepatocellular carcinoma: Findings from a prospective study Cancer Epidemiol Biomarkers Prev 2020 (In press) (\*Corresponding author).
46. Yuan J-M, Wang Y, Wang W, **Luu HN**, Adams-Haduch J, Koh WP, Gao Y-T, Behari J, Lotze MT. Serum interleukin-27 levels predict risk of hepatocellular carcinoma in two prospective cohorts. Cancer Epidemiol Biomarkers Prev 2020 (In press)
47. Tran D, Nguyen H, Tran B, Vecchia CL, **Luu HN**<sup>\*</sup>, Nguyen T<sup>\*</sup>. Fast and precise single-cell data analysis using hierarchical autocoder Nat Commun 2020 (In press) (\*Corresponding authors)

### Preprints

1. Tran D, Nguyen H, Tran B, La Vecchia C, **Luu HN**, Nguyen T. Fast and precise single-cell data analysis using hierarchical autoencoder. bioRxiv 2019; DOI: 10.1101/799817.

### Paper under review

1. **Luu HN**<sup>\*</sup>, Tran CTD, Wang R, Thomas CE<sup>¶</sup>, Adams-Haduch J, Velikokhatnaya L, Nguyen MTV, Tran MT, Tuong TTV, Tran QH, Le LC, Tran HTT, Bui NC, Ngo HTT, Trinh DT, Schoen RE, Jia W, Boffetta P, Clemente JC, Yuan J-M<sup>\*</sup>. The association between ileum juice bile acids and risk of colorectal adenomas and cancer. (¶Trainee co-author; \*Corresponding author)

2. **Luu HN\***, Piras E, Tran CTD, Bui K, Wallach DS, Tamburini S, Kong J, Wang R, Adams-Haduch J, Velikokhatnaya L, Nguyen MTV, Tran MT, Tuong TTV, Tran QH, Le LC, Tran HTT, Bui NC, Ngo HTT, Trinh DT, Schoen RE, Jia W, Yuan J-M, Boffetta P, Clemente JC\*. Integrative network analysis identifies markers of colorectal cancer risk in a treatment-naïve colorectal cancer screening cohort. (\*Corresponding authors)
3. **Luu HN**, Wang R, Thomas CE<sup>¶</sup>, Adams-Haduch J, Furlan A, Xie G, Jia W, Yuan J-M, Behari J. Serum Ursodeoxycholic Acid is Inversely Associated with Liver Fibrosis Score in Patients with Nonalcoholic Steatohepatitis (NASH). (<sup>¶</sup>Trainee co-author).
4. **Luu HN\***, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. The association between dietary vitamin B2 and lung cancer risk: Findings from a prospective cohort study (\*Corresponding author).
5. **Luu HN\***, Paragomi P<sup>¶</sup>, Wang R, Jin A, Brand RE, Koh WP, Yuan JM. Quality diet indexes and risk of pancreatic cancer: Findings from a prospective cohort study (\*Corresponding author). (<sup>¶</sup>Trainee co-author)
6. **Luu HN\***, Wang R, Paragomi P<sup>¶</sup>, Jin A, Brand RE, Koh WP, Yuan JM. Association between composite score of healthy lifestyle factors and the risk of pancreatic cancer: Findings from a prospective cohort study (\*Corresponding author) (<sup>¶</sup>Trainee co-author)
7. **Luu HN\***, Wang R, Paragomi R<sup>¶</sup>, Huang JY, Butler LM, Øivind M, Ulvik A, Jin A, Gao Y-T, Tan Y, Uelan PM, Koh WP, Yuan JM. Association between serum serine and glycine and related-metabolites with pancreatic cancer in two prospective cohort studies (<sup>¶</sup>Trainee co-author; \*Corresponding author)
8. **Luu HN\***, Dabo Bashir<sup>¶</sup>, Mukhtar F<sup>¶</sup>, Saito E, Lin Y, Lee JE, Chen Y, Sawada N, Tamakoshi A, Koh WP, Yuan JM, Wang R, Xiang YB, Tomata Y, Sugiyama K, Sue K, Park SK, Matsuo K, Nagata C, Sugawara Y, Qiao YL, You SL, Shin MH, Pan WH, Tsugane S, Cai H, Gao YT, Tsuji I, Kanemura S, Ito H, Wada K, Ahn YO, Yoo KY, Chia KS, Boffetta P, Inoue M, Kang K, Potter J, Zheng W, Shu XO. Association between body mass index and colorectal cancer incidence and mortality in Asia: A pooled analysis of more than 560,000 individuals. (<sup>¶</sup>Trainee co-author; \*Corresponding author)
9. Paragomi R<sup>¶</sup>, **Luu HN\***, Wang R, , Huang JY, Butler LM, Øivind M, Ulvik A, Jin A, Gao Y-T, Tan Y, Uelan PM, Koh WP, Yuan JM. Association between riboflavin and related-metabolites with pancreatic cancer in two prospective cohort studies (<sup>¶</sup>Trainee co-author; \*Corresponding author)
10. Dabo B<sup>¶</sup>, Pelucchi C, Rota M, Jain H, Bertuccio P, Bonzi R, Palli D, Ferraroni M, Zhang ZF, Sanchez-Anguiano A, Pham YTH, Tran CD, Vu KT, Yu GP, Hu J, Tsugane S, Hidaka A, Hamada GS, Zaridze D, Maximovitch D, Kogevinas M, de Larrea NF, Boccia S, Persiani R, Boccia S, Persiani R, Kurtz RC, Lagiou A, Lagiou P, Vioque J, M. Constanza Camargo MC, Curado MP, Lunet N, Boffetta P, Negri E, La Vecchia C, **Luu HN\***. The association between diabetes and gastric cancer: Findings from STOP Consortium (<sup>¶</sup>Trainee co-author; \*Corresponding author).

- 11.** Behari J, Graham L, Wang R, Schirda C, Borhani A, Methe B, Li K, Morris A, **Luu HN**, Palmieri S, Yuan J-M. Dynamics of Hepatic Steatosis Resolution and Changes in Gut Microbiome with Intensive Weight Loss in Nonalcoholic Fatty Liver Disease
- 12.** Nguyen C-TY, **Luu HN**, Pelucchi C, La Vecchia C, Hashim D, Boffetta. The association between birth order and childhood leukemia: a systematic review and meta-analysis of dose-response effect.
- 13.** Yang Y, Huang J, Wu W, **Luu HN**, Shi J, Moy FM, Tan S, Fu J, Ying T, Withers M, Hoang MV, Mao D, Chen S, Huang Z, Xu W. Performance of initial screening tests for colorectal cancer and subsequent adherence to colonoscopy: An ecological study.
- 14.** Wu W, Huang J, Yang Y, Gu K, **Luu HN**, Tan S, Yang C, Fu J, Bao P, Ying T, Withers M, Mao D, Chen S, Gong Y, Wong MCS, Xu W. Adherence to colonoscopy in cascade screening of colorectal cancer: a systematic review and meta-analysis.
- 15.** Ngo HX, Bach DH, Hoang VH, Luu TT, **Luu HN**, Nguyen HD, Duong HV, Nguyen LH, Ngo TS, Nguyen YTK, Han BW, Nguyen XT, Dinh HTT, Nguyen HN, Tran HTT, Lee SK, Tran PT. *N*-(4-Fluorobenzyl)-1,3-dimethyl-1*H*-indazol-6-amine, a novel IDO1 inhibitor, suppresses cell proliferation through regulating cell cycle arrest in human colorectal cancer cells

## **2. Books and Book Chapters**

Not applicable

## **3. Published Proceedings**

Not applicable

## **4. Invited Articles**

Not applicable

## **5. Review Articles**

Not applicable

## **6. Published Abstracts**

- 1.** Melas ME, **Luu HN**, Rennert G, Lejbkowitz F, Gruber SB, Wiesner GL, Raskin L. Exome sequencing analysis of 41 patients with Familial Colorectal Cancer Type X (FCCTX). *Cancer Res.* 2015;75(15 Suppl): Abstract nr 2745. doi:10.1158/1538-7445.AM2015-2745.
- 2.** Scheurer ME, **Luu HN**, Guillaud M, Montealegre J, Dillon LM, Follen M, Adler-Storthz K. Human papillomavirus (HPV) type distribution in multi-ethnic cohort of women: Implications for vaccination programs. *Cancer Res.* 2015;75(15 Suppl):847-847.
- 3.** **Luu HN\***, Murff HJ, Li H, Cai Q, Gao YT, Gao J, Lan Q, Yang G, Xiang YB, Zheng W, Shu XO. A prospective study of dietary polyunsaturated fatty acid intakes and lung cancer risk. *Cancer Res* 2017;77(13 Suppl):5310-5310.

4. Mukhtar F\*, Boffetta P, Risch HA, Park JY, Bubu OM, Womack L, Tran TV, Zgibor JC, **Luu HN**. Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013. Cancer Res 2017;77(13 Suppl):Abstract nr 3297. doi:10.1158/1538-7445.AM2017-3297 (\*Trainee co-author)
5. Cho SH, Jo A, Chen J, Casale TB, Lockey RF, **Luu HN**, Smith L. Plasminogen Activator Inhibitor-1 Genotype-Specific Effect of Soy Isoflavone on Asthma Control. J Aller Clin Immunol 2017;139(2):AB171.
6. **Luu HN**, Wang R, Shivappa N, Hébert JR, Jin A, Koh WP, Yuan JM. A prospective study of dietary inflammatory index scores and colorectal cancer risk: the Singapore Chinese Health Study. Cancer Res 2018;78(13 Suppl):5264-5264.
7. Tran TV, Tran CD, Tran HTT, Nguyen MT, Tran MT, Tran HA, Tuong TVT, Zheng W, Shu XO, Le LC, Boffetta P, **Luu HN**. Cancer epidemiology research in Vietnam: Current status, challenges and opportunities. Cancer Res 2018;78(13 Suppl):1216-1216.
8. Nguyen MT, Tran MT, Tran CD, Tran QH, Tuong TVT, Le LC, Boffetta P, **Luu HN**. The Association Between Birth Order and Childhood Brain Tumors: A Systematic Review and Meta-analysis. Cancer Res 2018; 78(13 Suppl):1217-1217.
9. Cho SH, Jo A, Casale TB, **Luu HN**, Kumar R, Smith L. Soy isoflavones improv poor asthma control in asthmatics with high PAI-1 producing genotypes. J Aller Clin Immunol 2018;141(2):AB400.
10. **Luu HN**, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. High BMI in relation to low risk of lung cancer among never smokers. Cancer Res 2019;78(13 Suppl):631-631.
11. Samavat H, **Luu HN**, Wang R, Jin A, Koh WP, Yuan JM. Leukocyte temomere length, cancer incidence and all-cause mortality among Chinese adults: Singapore Chinese Health Study. Cancer Res 2019; 78(13 Suppl):3133-3133
12. Tran TV, Tran HTT, Hoang MV, Bui OT, Nguyen SM, Bao P, Cai Q, Shrubsole M, Zheng W, **Luu HN**, Xhu XO. Establishing the Vietnam Center of Research Excellence on Cancer and Other Non-communicable Diseases (V-CORE): Challenges and Opportunities. JCO Glob Oncol. 2020;Suppl 1:19-19.

## 7. Presentations (Out of 40 invited talks)

1. Immunogenetics of HPV Infection: The Role of Toll-like Receptors in Cervical Cancer. Center for International Training and Research (CITAR), School of Public Health, the University of Texas Health Science Center-Houston, Nov 18, 2011, Houston, TX.
2. Comparison the performance of Hybrid Capture II (HC II) and polymerase chain reaction (PCR): A meta-analysis and experience. School of Public Health, the University of Texas Health Science Center-Houston, Nov 29, 2011, Houston, TX.

3. Human Pappillomavirus infection in women: Different perspectives. State University of New York (SUNY)-Albany, School of Public Health, Jul 08, 2012, Albany, NY.
4. Cancers caused by Infectious Agents. Center for International Training and Research (CITAR), School of Public Health, the University of Texas Health Science Center-Houston, Oct 19, 2012, Houston, TX.
5. Human Pappillomavirus infection in women: Different perspectives. University of South Carolina, Arnold School of Public Health, Nov 15, 2012, Columbia, SC.
6. Interpretation of Genome Wide Association Studies (GWAS) and Next-generation Sequencing studies. Center for International Training and Research (CITAR), School of Public Health, the University of Texas Health Science Center-Houston, Dec 07, 2012, Houston, TX.
7. DNA Methylation and Cervical Cancer. Center for International Training and Research (CITAR), School of Public Health, the University of Texas Health Science Center-Houston, Jan 25, 2013, Houston, TX.
8. Human Pappillomavirus infection in women: Different perspectives. Vanderbilt University School of Medicine and Ingram Comprehensive Cancer Center, Jun 11, 2013, Nashville, TN.
9. Long-chain fatty acids and cancer risk. Department of Global Health, University of South Florida, Apr 12, 2016, Tampa, FL
10. Pancreatic Cancer Research with Different Perspectives. University of Pittsburgh Cancer Institute (UPCI), University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, Jan 26 & Apr 12, 2017.
11. The synergistic role of microbiota, metabolites and immunomarkers on the risk of gastrointestinal cancers. Weill Cornell Medical College, Cornell University, New York, NY, Aug 06, 2020.

## **8. Non-Print Media**

Not applicable

## **9. Other Publications – Poster past two years (out of more than 40 posters)**

- 1.** Luu HN, Wang R, Shivappa N, Hébert JR, Jin A, Koh WP, Yuan JM. A prospective study of dietary inflammatory index scores and colorectal cancer risk: the Singapore Chinese Health Study. 2018 Annual Meeting, American Association for Cancer Research (AACR), Chicago, IL, Apr 14-18, 2018.
- 2.** Tran TV, Tran CD, Tran HTT, Nguyen MT, Tran MT, Tran HA, Tuong TVT, Zheng W, Shu XO, Le LC, Boffetta P, Luu HN. Cancer epidemiology research in Vietnam: Current status, challenges and opportunities. 2018 Annual Meeting, American Association for Cancer Research (AACR), Chicago, IL, Apr 14-18, 2018.
- 3.** Nguyen MT, Tran MT, Tran CD, Tran QH, Tuong TVT, Le LC, Boffetta P, Luu HN. The Association Between Birth Order and Childhood Brain Tumors: A Systematic Review and Meta-

analysis. 2018 Annual Meeting, American Association for Cancer Research (AACR), Chicago, IL, Apr 14-18, 2018.

4. **Luu HN**, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. High BMI in relation to low risk of lung cancer among never smokers. 2019 Annual Meeting, American Association for Cancer Research (AACR), Atlanta, GA, Mar 29-Apr 03, 2019.
5. Samavat H, **Luu HN**, Wang R, Jin A, Koh WP, Yuan JM. Leukocyte telomere length, cancer incidence and all-cause mortality among Chinese adults: Singapore Chinese Health Study. 2019 Annual Meeting, American Association for Cancer Research (AACR), Atlanta, GA, Mar 29-Apr 03, 2019.
6. Yuan JM, Samavat H, Wang R, **Luu HN**, Newman A, Jin A, Koh WP. Leukocyte telomere length in relation to risk of mortality and cancer incidence in a prospective cohort of 26,000 middle-aged or older Chinese. 92<sup>nd</sup> Annual Meeting, American Epidemiological Society (AES), Los Angeles, CA, Mar 28-29, 2019.
7. **Luu HN**, Wang R, Behari J, Adams-Haduch J, Odegaard AO, Goh GBB, Jin A, Koh WP, Yuan JM. Composite score of healthy lifestyle factors and risk of hepatocellular carcinoma: Findings from a prospective study. 2020 Annual Meeting, American Association for Cancer Research (AACR), San Diego, CA, Apr 23-29, 2020.
8. **Luu HN**, Neelakantan N, Wang R, Behari J, Adams-Haduch J, Goh GBB, Jin A, van Dam RM, Koh WP, Yuan JM. Association between high-quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. 2020 Annual Meeting, American Association for Cancer Research (AACR), San Diego, CA, Apr 23-29, 2020.
9. Thomas CE, **Luu HN**<sup>\*</sup>, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. Association between dietary tomato intake and the risk of hepatocellular carcinoma: Findings from a prospective study. 2020 Annual Meeting, American Association for Cancer Research (AACR), San Diego, CA, Apr 23-29, 2020.
10. Behari J, Graham L, Wang R, Schirda C, Borhani A, Methe B, Li K, Morris A, **Luu HN**, Palmieri S, Yuan J-M. Dynamics of Hepatic Steatosis Resolution and Changes in Gut Microbiome with Intensive Weight Loss in Nonalcoholic Fatty Liver Disease. 2020 Digital Annual Meeting, American Association for the Study of Liver Disease (AASLD), Nov 13-16, 2020.

## SERVICE

### 1. Service to School and University

Years	Committee	Position
2015-2017	Epidemiology MPH Admission Committee (University of South Florida)	Member
2015-2017	Epidemiology PhD Admission Committee (University of South Florida)	Member
2015-2017	Epidemiology PhD Qualifying Committee (University of South Florida)	Chair

2018-present Epidemiology Graduate (MPH, MSc, PhD) Admission Member  
Committee (University of Pittsburgh)

## 2. Service to Field of Scholarship

### a. Editorial Boards, Editorships

Date	Position	Organization
2016-present	Editorial Board	Cancer Medicine
2018-present	Editorial Board	Primary Care Epidemiology and Global Health

### b. Manuscript and Other Document/Publication Review

Journal Title	Dates
American Journal of Gastroenterology (AJG)	2018-
Annals of Epidemiology	2011-
Annals of Hematology	2017-
Annals of Oncology	2016-
Archives of Medical Research	2014-
Briefing in Bioinformatics	2019-
BMC Medical Genetics	2013-
Breast Cancer Research	2016-
British Medical Journal (BMJ)	2015-
BMJ Case Reports	2016-
Briefing of Bioinformatics	2019-
British Journal of Cancer (BJC)	2011-
Cancer Causes & Cancer (CCC)	2018-
Cancer	2018-
Cancers	2019-
Cancer Control	2018-
Cancer Epidemiology, Biomarkers & Prevention (CEBP)	2013-
Cancer Medicine	2012-
Cancer Prevention Research	2020-
Cancer Research	2020-
Clinical and Translational Gastroenterology	2019-
Disease Markers	2013-
International Journal of Cancer (IJC)	2013-
JAMA Internal Medicine	2015-
International Journal of STD & AIDS	2011-
Journal of Infection	2011-
Molecular Carcinogenesis	2020-
Molecules	2019-
Nutrients	2018-
PLoS One	2014-
Primary Care Epidemiology and Global Health	2018-
Science Reports	2018-

### c. Study Sections, Review Panels, and Advisory Boards

<b>Date</b>	<b>Position</b>	<b>Organization</b>
2017	Ad hoc Member	Special Emphasis Panel (PAR16-052 and PAR-17-097), NIH Fogarty International Center (R21 and D71) Voluntarily withdrawn due to conflict of interest.
2019	Ad hoc Member	Nevada NASA SPSCoR - National NASA EPSCoR Research CAN
2020	Ad hoc Member	European Research Council
2020	Ad hoc Member	Einstein Medical Network

**d. Leadership in Scholarly and Professional Organizations and Honorary Societies**

<b>Date</b>	<b>Position</b>	<b>Organization</b>
2013-	Member	American Association for Cancer Research (AACR)-Member #281580
2015-	Member	Molecular Epidemiology Group-MEG, AACR
2012-	Member	American Society of Preventive Oncology (ASPO)
2012-	Member	International Papillomavirus Society (IPS)
2007-	Member	Society for Epidemiologic Research (SER)
2015-	Member	Asian Cohort Consortium (ACC)
2017-	Member	Gastric Cancer Consortium (SToP Consortium)
2017-	Founding Member/ EAB Member	International Liver Cancer Epidemiology Consortium (ILCEC)

**3, Service for Practice and Policy-Making, including Consultantships**

**a. Governmental Organizations**

Not applicable

**b. Non-Governmental and Community-Based Organizations**

Not applicable

**4. Non-Professional Service**

Not applicable

**5. Clinical and Related Activities (OPTIONAL - if applicable)**

**A. Outpatient: Patient Care**

Not applicable

Supporting descriptive information (if applicable)

Not applicable

**B. Inpatient: Patient Care**

Not applicable



Supporting descriptive information (if applicable)  
Not applicable

### **C. Other Patient Care**

Not applicable

Supporting descriptive information (if applicable)  
Not applicable

### **References**

**1). Xiao-Ou Shu, M.D., Ph.D.**

Ingram Professor of Cancer Research  
Vanderbilt Ingram Cancer Center  
Professor of Medicine  
Vanderbilt University School of Medicine  
Phone: 615-936-0713  
E-mail: [xiao-ou.shu@vumc.org](mailto:xiao-ou.shu@vumc.org)

**2) Wei Zheng, M.D., Ph.D.**

Professor and Chief, Division of Epidemiology  
Anne Potter Wilson Chair in Medicine  
Director, Vanderbilt Epidemiology Center  
Vanderbilt Ingram Cancer Center  
Vanderbilt University School of Medicine  
Phone: 615-936-0692  
E-mail: [wei.zheng@vumc.org](mailto:wei.zheng@vumc.org)

**3) Harvey A. Risch M.D., Ph.D.**

Professor of Epidemiology (Chronic Diseases)  
Department of Epidemiology and Public Health  
Yale School of Public Health  
Yale School of Medicine|Yale Cancer Center  
Yale University  
Phone: 203-785-2848  
E-mail: [harvey.risch@yale.edu](mailto:harvey.risch@yale.edu)

**4) Paolo Boffetta, M.D., M.Sc.**

Professor of Medicine  
Department of Family, Population and  
Preventive Medicine  
Renaissance School of Medicine  
Associate Director-Population Sciences  
Stony Brooke Cancer Center  
Phone: 212-824-7378  
E-mail: [paolo.boffetta@stonybrookmedicine.edu](mailto:paolo.boffetta@stonybrookmedicine.edu)

**5) Jong Park, Ph.D.**

Senior Member and Professor of Oncology  
Division of Population Sciences  
Department of Cancer Epidemiology  
H. Lee Moffitt Cancer Center & Research  
Institute  
Phone: 813-745-1703  
E-mail: [jong.park@moffitt.org](mailto:jong.park@moffitt.org)

**6) Michael E. Scheurer, Ph.D.**

Professor of Pediatrics and Hematology  
Oncology  
Co-Leader, Cancer Prevention and Population  
Sciences  
Dan L. Duncan Comprehensive Cancer Center  
Baylor College of Medicine  
Phone: 713-798-5547  
E-mail: [scheurer@bcm.edu](mailto:scheurer@bcm.edu)

## MOHAMMAD ALINOOR RAHMAN, PhD

### Senior Fellow

Cold Spring Harbor Laboratory  
1 Bungtown Rd, Cold Spring Harbor, NY 11724

**E-mail:** mrahman@cshl.edu

**Cell Phone:** +1-(404)909-0315

**Skype:** rahmanmohammadalinoor

**LinkedIn:** linkedin.com/in/marrahman

## EDUCATION

---

<b>PhD</b> , Molecular Medicine, Nagoya University School of Medicine, Nagoya, Japan	2013
<b>MS</b> , Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh	2005
<b>BSc</b> , Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh	2003

## RESEARCH EXPERIENCE

---

### ACADEMIC RESEARCH:

<b>Senior Fellow</b> , Cold Spring Harbor Laboratory (New York, USA) Therapeutic Targeting of Splicing Alterations in Cancer Mentor: Professor Adrian R. Krainer	2020-
<b>Postdoctoral Research Fellow</b> , Cold Spring Harbor Laboratory (New York, USA) Mechanisms of Splicing Alterations in Cancer Mentor: Professor Adrian R. Krainer	2015-2020
<b>Assistant Professor/ Staff Scientist</b> , Nagoya University (Nagoya, Japan) Department of Neurogenetics, School of Medicine Alternative Splicing Regulation in Neuromuscular Signal Transmission	2014-2015
<b>PhD Candidate</b> , Nagoya University School of Medicine (Nagoya, Japan) RNA Splicing Pathomechanisms in Neuromuscular Junction Disorders Mentor: Professor Kinji Ohno	2009-2013
<b>Research Associate</b> , Center for Neurological Diseases & Cancer (Nagoya, Japan) RNA Splicing Regulation in Physiology and Pathology	2009-2009
<b>Research Associate</b> , Molecular Biology Laboratory, University of Dhaka (Dhaka, Bangladesh) Understanding the Cold Tolerance Trait in Plants	2003-2005

### INDUSTRIAL RESEARCH:

<b>Executive, Research and Development</b> , Square Pharmaceuticals Ltd. (Dhaka, Bangladesh) Drug Development and Drug Bioequivalence Study	2007-2008
<b>Executive, Research and Development</b> , Eskayef Bangladesh Ltd. (Dhaka, Bangladesh) Drug Development and Drug Release Profile Study	2005-2007

## GRANTS/ FELLOWSHIPS

---

The EvansMDS Young Investigator Award (Career Transition Grant), USA	2020-2023
The Global Center of Excellence, Research Support Fund, Japan	2014
The Government of Japan's MEXT Fellowship for PhD Program, Japan	2009-2013
The Global Center of Excellence Fellowship for PhD Program, Japan (Declined)	2009-2013
Center for Neurological Diseases and Cancer, Research Support Scholarship, Japan	2009
The Global Center of Excellence, Research Promotion Fellowship, Japan	2009

## PUBLICATIONS/ BIBLIOGRAPHY

---

\*Equal contribution

1. **Rahman MA**, Lin KT, Bradley RK, Abdel-Wahab O, Krainer AR. (2020) Recurrent SRSF2 mutations in MDS affect both splicing and NMD. *Genes & Development* 34:1-16 [Citations 4, IF 9.5]
2. **Rahman MA**, Krainer AR, Abdel-Wahab O. (2020) SnapShot: Splicing Alterations in Cancer. *Cell* 180:208-208.e [Citations 6, IF 38.6]
3. **Rahman MA\***, Nasrin F\*, Bhattacharjee S, Nandi S. (2020) Hallmarks of splicing defects in cancer: clinical applications in the era of personalized medicine. *Cancers* 12:1381 [Citations 2, IF 6.1]
4. Yoshimi A\*, Lin KT\*, Wiseman DH\*, **Rahman MA**, Pastore A, Intlekofer AM, Wang B, Lee SC, Micol J, Zhang XJ, Botton SD, Penard-Lacronique V, Stein E, Chao H, Miles RE, Inoue D, Albrecht TR, Somerville TCP, Batta K, Amaral F, Simeoni F, Wilks DP, Cargo C, Thompson CB, Levine RL, Dvinge H, Bradley RK, Wagner EJ, Krainer AR, Abdel-Wahab O. (2019) Coordinated alterations in RNA splicing and epigenetic regulation drive leukomogenesis. *Nature* 574:273-277 [Citations 40, IF 42.8]
5. Feng H\*, Bao S\*, **Rahman MA**, Weyn-Vanhentenryck SM, Khan A, Wong J, Shah A, Flynn ED, Krainer AR, Zhang C. (2019) Modeling RNA-binding protein specificity in vivo by precisely registering protein-RNA crosslink sites. *Molecular Cell* 24:1189-1204 [Citations 16, IF 15.6]
6. Aznarez I, Nomakuchi T, Novatt JT, **Rahman MA**, Fregoso O, Rees H, Krainer AR. (2018) Mechanism of nonsense-mediated mRNA decay stimulation by splicing factor SRSF1. *Cell Reports* 23:2186-2198 [Citations 22, IF 8.1]
7. **Rahman MA**. (2018) Oncogenic Landscapes of Splicing-Factor Mutant MDS. *Genomics & Gene Therapy International Journal* 2(1):000105 [Citations 1, IF N/A]
8. Kim YJ, **Rahman MA**. (2018) NMD in diseases and potential therapies. *Journal of Investigative Genomics* 5(2):50-54 [Citations 1, IF N/A]
9. Nazim M, Nasrin F, **Rahman MA**. (2018) Coordinated regulation of alternative splicing and alternative polyadenylation. *Journal of Genetics and Genetic Engineering* 2(3):26-34 [Citations 1, IF N/A]
10. Ahsan KB, Masuda A\*, **Rahman MA\***, Takeda J, Nazim M, Ohkawara B, Ito M, Ohno K. (2017) SRSF1 suppresses selection of intron-distal 5' splice site of *DOK7* intron 4 to generate functional full-length Dok-7 protein. *Scientific Reports* 7:10466 [Citations 2, IF 4.5]

11. Ohno K, **Rahman MA**, Nazim M, Nasrin F, Lin Y, Takeda J, Masuda A. (2017) Splicing regulation and dysregulation of cholinergic genes expressed at the neuromuscular junction. *Journal of Neurochemistry* 142S2:64-72 [Citations **13**, IF **4.8**]
12. Nazim M, Masuda A\*, **Rahman MA\***, Nasrin F, Takeda J, Ohe K, Ohkawara B, Ito M, Ohno K. (2016) Competitive regulation of alternative splicing and alternative polyadenylation by hnRNP H and CstF64 determines acetylcholinesterase isoforms. *Nucleic Acids Research* 45:1455-1468 [Citations **37**, IF **11.5**]
13. Shibata A, Okuno T, **Rahman MA**, Azuma Y, Takeda J, Masuda A, Selcen D, Engel AG, Ohno K. (2016) IntSplice: prediction of the splicing consequences of intronic single-nucleotide variations in the human genome. *Journal of Human Genetics* 61:633-640 [Citations **17**, IF **2.9**]
14. **Rahman MA\***, Nasrin F\*. (2016) Human disease-causing mutations affecting RNA splicing and NMD. *Journal of Investigative Genomics* 3(2):00046 [Citations **1**, IF **N/A**]
15. **Rahman MA**, Azuma Y, Nasrin F, Takeda J, Nazim M, Ahsan KB, Masuda A, Engel AG, Ohno K. (2015) SRSF1 and hnRNP H antagonistically regulate splicing of COLQ exon 16 in a congenital myasthenic syndrome. *Scientific Reports* 5:13208 [Citations **24**, IF **4.5**]
16. **Rahman MA**, Ohno K. (2015) Splicing aberrations in congenital myasthenic syndromes. *Journal of Investigative Genomics* 2(6):00038 [Citations **2**, IF **N/A**]
17. **Rahman MA**, Nasrin F, Masuda A, Ohno K. (2015) Decoding abnormal splicing code in human diseases. *Journal of Investigative Genomics* 2(1):00016 [Citations **8**, IF **N/A**]
18. Nasrin F, **Rahman MA**, Masuda A, Ohe K, Takeda J, Ohno K. (2014) HnRNP C, YB-1 and hnRNP L coordinately enhance skipping of human *MUSK* exon 10 to generate a Wnt-insensitive MuSK isoform. *Scientific Reports* 4:6841 [Citations **24**, IF **4.5**]
19. **Rahman MA**, Masuda A, Ohe K, Ito M, Hutchinson DO, Mayeda A, Engel AG, Ohno K. (2013) HnRNP L and hnRNP LL antagonistically modulate PTB-mediated splicing suppression of *CHRNA1* pre-mRNA. *Scientific Reports* 3:2931 [Citations **35**, IF **4.5**]

## MANUSCRIPT IN PREPARATION/ ONGOING PROJECTS \_\_\_\_\_

1. **Rahman MA**, Abdel-Wahab O, Krainer AR. Antisense-mediated targeted splicing modulation in MDS (Ongoing)
2. **Rahman MA**, Garry N, Lin KT, Krainer AR. SRSF3-regulated alternative splicing in cancer (In preparation)
3. Arun G, Dhingra P, **Rahman MA**, Munch R, Frederic V, Krainer AR, Akerman M. Identification and characterization of novel splice variants in triple-negative breast cancer. (In preparation)
4. Understanding and targeting the mechanisms of oncogenic mutations in U1 snRNA. In collaboration with Dr. Omar Abdel-Wahab, Memorial Sloan Kettering Cancer Center (Ongoing)
5. Decoding splicing regulatory elements (SRE) of *SMN2* using a pentameric SRE library. In collaboration with Professor Yimin Hua, Nanjing Normal University (Ongoing)

## AWARDS & HONORS

---

The EvansMDS Young Investigator Award, The Edward P. Evans Foundation, MA, USA	2020
The Best Poster Award, The 6 <sup>th</sup> Nagoya GCOE Retreat Symposium, Nagoya, Japan	2014
The Best Poster Award, The 5 <sup>th</sup> Nagoya GCOE Retreat Symposium, Nagoya, Japan	2013
The Japanese Government MEXT Scholar, Nagoya University, Japan	2009
The GCOE Scholar, Nagoya University, Japan	2009
Career Development Training Award: USFDA Pharmaceutical GMP Regulation & Validation, Trained by CHRAI Associates USA, Sponsored by Square Pharma., Dhaka, Bangladesh	2008
Career Development Training Award: MHRA Pharmaceutical GMP Regulation & Validation, Sponsored by Eskayef Bangladesh Ltd., Dhaka, Bangladesh	2007
Training and Travel Award on Total Organic Carbon Analyzer, Shimadzu PTE, Singapore	2007
Training and Travel Award on HPLC, Techsquad, Dhaka, Bangladesh	2006
Training Awarded on Recombinant DNA & RNAi, Trained by Winrock International USA, Sponsored by University of Dhaka, Dhaka, Bangladesh	2006

## TRAINING/ WORKSHOP

---

NIH Program Funding and Grants Administration, NIH, MD, USA	2020
Experimental Models of Human Cancers, The Jackson Laboratory, CT, USA	2020
Data Carpentry Genomics, Cold Spring Harbor Lab, NY, USA	2020
Workshop on R, New York University, NY, USA	2020
Science Writing and Communication, Cold Spring Harbor Lab, NY, USA	2020
Biostatistics for Cancer Research, Cold Spring Harbor Lab, NY, USA	2019
Leadership in Bioscience, Cold Spring Harbor Lab, NY, USA	2019
Mass Spectrometry, Cold Spring Harbor Lab, NY, USA	2019
Genome Access Course, Cold Spring Harbor Lab, NY, USA	2018
Grant Writing Workshop, Cold Spring Harbor Lab, NY, USA	2017
Workshop on Splicing Factor Mutations in Cancer, Broad Institute, MA, USA	2016
Workshop on Splicing Factor Mutations in Cancer, Memorial Sloan Kettering, NY, USA	2015
Translational Cancer Research, Nagoya University, Nagoya, Japan	2013
Next Generation Sequencing, Nagoya University, Nagoya, Japan	2012
Protein Expression and Purification, Nagoya University, Nagoya, Japan	2011
CLIP-Seq (HITS-CLIP and PAR-CLIP), Nagoya University, Nagoya, Japan	2010
Operation and Chemstation on Total Organic Carbon Analyzer, Shimadzu PTE, Singapore	2007
Operation and Chemstation on HPLC, Techsquad, Dhaka, Bangladesh	2006
Recombinant DNA & RNAi, Trained by Winrock International, Dhaka University, Dhaka, Bangladesh	2004

## TEACHING EXPERIENCE

---

Assistant Professor, Graduate Program, Nagoya University School of Medicine, Nagoya	2014
Tutor, Neurogenetics, Graduate Program, Nagoya University School of Medicine, Nagoya	2012
Tutor, Neurogenetics, Master Program, Nagoya University School of Medicine, Nagoya	2011
Tutor, Neurogenetics, Graduate Program, Nagoya University School of Medicine, Nagoya	2010

## MENTORING EXPERIENCE

---

Nathaniel Garry, The Undergraduate Research Program (URP), Cornell University, New York	2019
Ansh Jhaveri, Summer Program, The Wheatley School, Old Westbury, New York	2018-2019
Ga-Ram Huang, Graduate Program, Stony Brook University, New York	2017-2018
Danilo Segovia, Graduate Program, Stony Brook University, New York	2017
Adrita Siddque, Graduate Program, Stony Brook University, New York	2016-2017
Khalid Bin Ahsan, Graduate Program, Nagoya University School of Medicine, Nagoya	2013-2014
Mohammad Nazim, Graduate Program, Nagoya University School of Medicine, Nagoya	2012-2014
Li Shin, Master Program, Nagoya University School of Medicine, Nagoya	2011-2012
Chen Guying, Graduate Program, Nagoya University School of Medicine, Nagoya	2011-2012
Farhana Nasrin, Graduate Program, Nagoya University School of Medicine, Nagoya	2010-2014
Shurovi Sayeed, Graduate Program, Nagoya University School of Medicine, Nagoya	2010-2011
Instructor and Coordinator, Pharmaceutical Intern Program for Undergraduate Students, Square Pharmaceuticals Ltd., Dhaka (Trained more than 20 trainees)	2007-2008

## SERVICES/ MEMBERSHIPS

---

Editorial Board Member of Scientific Journal	
Genomics and Gene Therapy International Journal	2018-present
Onjour Healthcare Journal	2019-present
Journal of Cancer Treatment and Research	2020-present
Reviewer of Scientific Journal	2014-present
Executive Member, Meeting & Scientific Symposium, Dhaka University Biochemistry Alumni North America (DUBANA)	2015-present
President, International Graduate Scholar Association, Nagoya University Graduate School of Medicine, Nagoya, Japan	2011-2013
Member, Postdoc Liaison Committee, Cold Spring Harbor Laboratory, New York, USA	2015-present
Professional Associations: RNA Society, American Association for Cancer Research	2016-present

## SELECTED PRESENTATIONS

---

1. **Rahman MA**. Understanding and targeting RNA splicing defects in cancer. University of New Mexico, Albuquerque, NM, USA, 2020 [**Invited Seminar**]
2. **Rahman MA**. NMD as a mediator of oncogenesis in spliceosomal-mutant MDS. Cold Spring Harbor Laboratory, NY, USA, 2019 [**Invited Seminar**]
3. **Rahman MA**, Lin KT, Abdel-Wahab O, Krainer AR. NMD as a potential mechanism of oncogenesis in spliceosomal-mutant MDS. **RNA Society Meeting**, UC Berkeley, CA, USA, 2018 [**Poster Presentation**]
4. **Rahman MA**, Lin KT, Abdel-Wahab O, Krainer AR. NMD as a potential mechanism of oncogenesis in spliceosomal-mutant MDS. **STARR Cancer Consortium Retreat**, Cold Spring Harbor Laboratory, NY, USA, 2018 [**Poster Presentation**]
5. **Rahman MA**, Lin KT, Abdel-Wahab O, Krainer AR. NMD as a potential mechanism of oncogenesis in spliceosomal-mutant MDS. **Eukaryotic mRNA Processing Meeting**, Cold Spring Harbor Laboratory, NY, USA, 2017 [**Oral Presentation**]
6. **Rahman MA**, Krainer AR. Understanding Oncogenic Splicing Factor Mutations in MDS. **Hematologic Malignancies Meeting**, Northwell Health, NY, USA, 2016 [**Invited Seminar**]
7. **Rahman MA**, Nasrin F, Masuda A, Ohe K, Takeda JI, Ohno K. Alternative splicing of human *MUSK* exon 10 is physiologically regulated by multiple splicing regulatory cis-elements and cognate trans-factors. **RNA Biology Meeting**, Cold Spring Harbor Asia Conference, Suzhou, China, 2014 [**Oral Presentation**]
8. **Rahman MA**, Ohno Kinji. A myasthenia causing mutation in *COLQ* causes aberrant exon skipping by losing binding affinity for a splicing-enhancing SRSF1 and gaining binding affinity for a splicing-suppressing hnRNP H1. **The 6<sup>th</sup> Nagoya GCOE Retreat Symposium**, Nagoya, Japan, 2014 [**Poster Presentation**]
9. **Rahman MA**, Mayeda A, Ohe K, Masuda A, Ito M, Engel AG, Ohno K. Switching of hnRNP L to hnRNP LL converts PTB-mediated exon exclusion to inclusion in a congenital myasthenic syndrome. **Eukaryotic mRNA Processing Meeting**, Cold Spring Harbor Laboratory, NY, USA, 2013 [**Poster Presentation**]
10. **Rahman MA\***, Nasrin F\*, Masuda A, Ohe K, Ohno K. Alternative RNA splicing regulating the molecular architecture of NMJ. **The 5<sup>th</sup> Nagoya GCOE Retreat Symp.**, Nagoya, Japan, 2013 [**Poster Presentation**]
11. **Rahman MA**, Ohe K, Masuda A, Ito M, Hutchinson DO, Mayeda A, Engel AG, Ohno K. Mutation in congenital myasthenic syndrome reveals opposite splicing regulatory effects of hnRNPs L and LL. **The 35<sup>th</sup> Annual Meeting of the Japan Neuroscience Society**, Nagoya, Japan, 2012. . [**Poster Presentation**]
12. **Rahman MA**, Masuda A, Ito M, Ohno K. A mutation on a nonfunctional exon P3A in *CHRNA1* identified in congenital myasthenic syndrome causes aberrant inclusion of exon P3A by losing binding affinity for a splicing-suppressing hnRNP L and gaining binding affinity for a splicing-enhancing hnRNP LL. **RNA Meeting**, Tokyo, Japan, 2010. [**Oral Presentation**]

# APPENDIX B

*Curricula vitae of  
oncology clinical faculty*



**Samer Ahmad Al Hadidi, M.D., M.S. (CRDSA), F.A.C.P**  
**Curriculum Vitae**

**I. Biographical Information**

**A. Personal Data**

**Date of Birth:** June 26, 1987; Al-Salt, Jordan

**Marital Status:** Married since 2010 to Zain Alamarat. 2 daughters: Rose and Hanan

**Citizenship:** Permanent resident/ Green card holder.

**Home address:** 2900 N Braeswood Blvd, Apt 1113, Houston, TX, 77025

**Email:** [hadidi@bcm.edu](mailto:hadidi@bcm.edu)

**Cell phone:** 810-406-0412

**B. Education**

School of Medicine,  
University of Jordan,  
Amman, Jordan

M.D. in 2011; conferred with Highest Honors

Michigan State University,  
Flint, Michigan

Residency in Internal Medicine 2013-2016

University of Michigan,  
Ann Arbor, Michigan

Master in Clinical Research and Statistical Analysis M.S. CRDSA 2015-2017; conferred with Highest Honors

Baylor College of Medicine,  
Houston, Texas

Fellowship in Hematology/Oncology 2018-2021. Support: NIH 2020 T32 Cell and Gene Therapy. Training Grant Carlos Ramos MD, Advisor

**C. Academic Appointments**

7/16- 7/18	Assistant Professor, Department of Medicine, Division of Internal Medicine, Michigan State University, Flint, Michigan
7/16-7/18	Assistant Program Director, Internal Medicine Residency Program, Michigan State University, Flint, Michigan
7/16-7/18	Assistant Program Director, Transitional Year Residency Program, Michigan State University, Flint, Michigan

**D. Other Information**

**1. Awards**

**Undergraduate & Graduate School:**

Board of Governor's Scholar 2002-05

**Medical School:**

Highest Honors in Basic Sciences (2007)

King Hussein Cancer Center Smoking Cessation program Award (2008)

MD conferred with Highest Honor (2011)

Residency:

Resident of the year. Michigan State University, Flint, Michigan. (2013)  
Best Ambulatory Medicine Resident Award (2016)  
Research Scholar Award (2016)  
Honor degree, Master of Clinical Research and Statistical Analysis (MS CRDSA).  
School of Public Health, University of Michigan, Ann Arbor, Michigan. (2017)

Fellowship:

Best Fellow presentation, Cell and Gene Therapy, Department of Medicine,  
Hematology Oncology Section. Baylor College of Medicine, Houston, Texas  
(2019)  
Outstanding Fellow, Texas Society of Clinical Oncology (2019)  
Best clinical research presentation award, Baylor College of Medicine House staff  
Research Symposium 2020, Houston, Texas  
NIH 2020 T32 Cell and Gene Therapy Training Grant (5T32HL092332-18)  
(2020)  
Conquer Cancer Merit Award, 2020 ASCO Quality Care Symposium (2020)  
Center of Excellence in Health Equity, Training and Research grant, Baylor  
College of Medicine (2020)

Faculty:

Virtuous Physician Outstanding Teaching Award. School of Medicine. Michigan  
State University (2016-2018).  
Willys F. Mueller M.D award for outstanding teaching, Transitional year  
residency program. Michigan State University, Flint, Michigan (2017)  
Faculty teaching award, Michigan State University, Flint, Michigan (2018)

2. Board Eligibility/Certification

Diplomat, American Board of Internal Medicine 2016  
Licensure State of Michigan 01/25/2016– present  
Licensure State of Texas 02/02/2018 – present  
Board Eligible in Hematology- By June 2021  
Board Eligible in Medical Oncology- By June 2021

3. Other Positions

Rotating Resident, Leukemia Department. The University of Texas MD Anderson  
Cancer Center (2014)  
Rotating fellow, Lymphoma/Myeloma-Research, The University of Texas MD  
Anderson Cancer Center (2019-2021)  
Member, Trainee & Early Career (TEC) Council, American Society of Clinical  
Oncology. (2020-2021)  
Mentee, Reviewer Mentoring Program. Journal of Global Oncology (2019-2020)  
Mentee, Reviewer Mentoring Program. Journal of Clinical Oncology (2020-2021)  
Fellow, AACR-FDA Oncology educational fellowship (2020-2021)

## **II. Research Information**

### **A. Research Support**

**Funding Source:** T32 NIH Training Grant (5T32HL092332-18)

**Title:** ANCHOR (Allogeneic Natural Killer T cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies.

**Principal Investigator:** Carlos Ramos M.D.

**Funding Source:** Conquer Cancer Foundation

**Title:** Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies.

**Principal Investigator:** Samer Al Hadidi M.D.

**Funding Source:** Center of Excellence in Health Equity, Training and Research, Baylor College of Medicine

**Title:** Racial and socioeconomic disparities in lymphoma patients assessed for stem cell transplantation.

**Principal Investigator:** Samer Al Hadidi M.D.

### **B. National Scientific Participation**

1. Editorial Board:  
Cancer Treatment and Research Communications
2. Journal Ad Hoc Reviewer:  
Journal of Clinical Oncology  
Journal of Global Oncology  
JAMA Oncology
3. Professional Societies Membership  
2013-present American Medical Association  
2018-present American Society of Clinical Oncology  
2018-present American Society of Hematology  
2018-present Texas Society of Clinical Oncology  
2019-present American Association for Cancer Research

### **C. Publications:**

#### 1. Full Papers

1. **Al Hadidi S**, Towfiq B, Bachuwa G. Dystextia as a presentation of stroke. BMJ Case Rep. 2014;2014:bcr2014206987. Published 2014 Nov 20.

2. **Al Hadidi S**, Shaik Mohammed T, Bachuwa G. Unusual presentation of uterine leiomyoma. *BMJ Case Rep.* 2015;2015:bcr2014208995. Published 2015 Apr 9.
3. **Al Hadidi S**, Haddad RA, Abed F, Bachuwa G. Penile gangrene as a sign of uncontrolled diabetes mellitus. *BMJ Case Rep.* 2016;2016:bcr2015214303. Published 2016 Feb 5.
4. **Al Hadidi S**. Aspirin and Cancer Risk. *JAMA Oncol.* 2016;2(10):1371-1372.
5. Kyi HH, Aljariri Alhesan N, Upadhaya S, **Al Hadidi S**. Seizure Associated Takotsubo Syndrome: A Rare Combination. *Case Rep Cardiol.* 2017;2017:8458054.
6. **Al Hadidi S**, Katato K, Bachuwa G. Immunoglobulin D Multiple Myeloma Presenting as Spontaneous Fracture. *Case Rep Oncol.* 2017;10(1):272-275. Published 2017 Mar 29.
7. **Al Hadidi S**, Tareen K. Air in the portal vein: where computed tomography saved a patient's life. *Oxf Med Case Reports.* 2017;2017(4):omx015. Published 2017 Apr 4.
8. Osman M, Al Salihi M, Abu Sitta E, **Al Hadidi S**. A rare case of Epstein-Barr virus mucocutaneous ulcer of the colon. *BMJ Case Rep.* 2017;2017:bcr2017220717. Published 2017 Jul 6.
9. Abdalla A, Bachuwa G, **Al Hadidi S**. A case of hypercalcemia with double pathology. *J Community Hosp Intern Med Perspect.* 2017;7(3):178-181. Published 2017 Jul 13.
10. Upadhaya S, Baig M, Towfiq B, **Al Hadidi S**. Nodular pulmonary amyloidosis with primary pulmonary MALT lymphoma masquerading as metastatic lung disease. *J Community Hosp Intern Med Perspect.* 2017;7(3):185-189. Published 2017 Jul 13.
11. **Hadidi SA**, Shastri R. Vanishing Lung Syndrome. *J Am Osteopath Assoc.* 2017;117(8):541.
12. Alamarat Z, Onwuzurike N, Azher Q, **Al Hadidi S**. Huge teratoma in a teenager. *Oxf Med Case Reports.* 2017;2017(8):omx040. Published 2017 Aug 2.
13. Chughtai K, Gupta R, Upadhaya S, **Al Hadidi S**. Topical 5-Fluorouracil associated skin reaction. *Oxf Med Case Reports.* 2017;2017(8):omx043. Published 2017 Aug 10.

14. **Al Hadidi S**, Wu K, Aburahma A, Alamarat Z. Family with clots: antithrombin deficiency. *BMJ Case Rep.* 2017;2017:bcr2017221556. Published 2017 Aug 11.
15. Badami S, Kyi HH, Upadhaya S, **Al Hadidi S**. Pancreatic Adenocarcinoma Masquerading as Idiopathic Chronic Pancreatitis with Delayed Diagnosis. *Case Rep Oncol.* 2017;10(3):819-823. Published 2017 Sep 14.
16. Elounais F, Aburahma A, Alkotob ML, **Al Hadidi S**. Ventricular tachycardia after initiation of fingolimod. *BMJ Case Rep.* 2017;2017:bcr2017221819. Published 2017 Sep 27.
17. **Al Hadidi S**, Upadhaya S, Shastri R, Alamarat Z. Use of dictation as a tool to decrease documentation errors in electronic health records. *J Community Hosp Intern Med Perspect.* 2017;7(5):282-286. Published 2017 Oct 18.
18. Daher H, **Al Hadidi S**. Dysphagia lusoria presenting as epigastric pain. *BMJ Case Rep.* 2017;2017:bcr2017223687. Published 2017 Dec 5.
19. **Al Hadidi S**. Timing of Pregnancy and Survival in Women With Breast Cancer. *JAMA Oncol.* 2018;4(1):131.
20. **Al Hadidi S**, Aburahma A, Badami S, Upadhaya S. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. *Oncol Res Treat.* 2018;41(4):226-235.
21. **Al Hadidi S**. Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery [published correction appears in *JAMA Oncol.* 2018 Feb 1;4(2):265]. *JAMA Oncol.* 2018;4(2):262.
22. Jarrah J, Samji V, Meshesha M, Kothuru C, **Al Hadidi S**. Methicillin-resistant *Staphylococcus aureus* prostatic abscess after traumatic rectal injury. *Oxf Med Case Reports.* 2018;2018(3):omx111. Published 2018 Mar 23.
23. Daher H, Towfiq B, **Al Hadidi S**. Gradually Worsening Pruritic Plaques. *JAMA Oncol.* 2018;4(4):573-574.
24. Badami S, Upadhaya S, Velagapudi RK, **Al Hadidi S**. Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. *J Oncol.* 2018;2018:6279871. Published 2018 Jul 17.

25. Kheiri B, Osman M, **Al Hadidi S**. From a burn scar to malignancy! Marjolin's ulcer, a disease of wound neglect. *Oxf Med Case Reports*. 2018;2018(8):omy044. Published 2018 Aug 11.
26. Kyi HH, Zayed Y, **Al Hadidi S**. Ibrutinib-induced cardiomyopathy. *J Community Hosp Intern Med Perspect*. 2019;9(1):50-52. Published 2019 Feb 11.
27. **Al Hadidi S**, Udden M. Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia. *Clin Case Rep*. 2020;8(6):1112-1113. Published 2020 Mar 27.
28. **Al Hadidi S**, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma [published online ahead of print, 2020 Apr 20]. *Clin Lymphoma Myeloma Leuk*. 2020;S2152-2650(20)30182-8.
29. **Al Hadidi S**, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. *Ann Intern Med*. 2020;173(4):320-322.
30. **Al-Hadidi SA**, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. *Expert Opin Biol Ther*. 2020 Oct 2. doi: 10.1080/14712598.2020.1830056.

## 2. Other papers

1. Baniya R; Upadhaya S; Madala S; Saginala K; Oli S; Mohammed T; Bachuwa G; **Al Hadidi S**. Potassium-Competitive Acid Blockers versus Proton Pump Inhibitors in Endoscopic Submucosal Dissection-Induced Gastric Ulcers: A Systematic Review and Meta-Analysis, *American Journal of Gastroenterology*: October 2017 - Volume 112 - Issue - p S483,S485
2. Maegawa F, **Al Hadidi S**, Limsrivilai J, Chum M, Kettelle J, Riall T. Cost-Effectiveness Analysis of Curative Therapies for Early Stage Hepatocellular Carcinoma (HCC) within Milan Criteria *Journal of the American College of Surgeons*. ISSUE 4, SUPPLEMENT 2, E28, OCTOBER 01, 2017
3. Baniya R; Upadhaya S; **Al Hadidi S**. Sa1408 - Prior Use of Statin is Associated with Decreased Mortality and Severe Pancreatitis: A Meta-Analysis. *Gastroenterology AGA*. | VOLUME 154, ISSUE 6, SUPPLEMENT 1, S-295, MAY 01, 2018

4. **Al Hadidi S**, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Two Randomized Controlled Studies of Venetoclax in Patients with Chronic Lymphocytic Leukemia. *Blood* 2019; 134 (Supplement\_1): 5472.

3. Journal Articles submitted or in preparation:

1. **Al Hadidi S**; Chuang H; Miranda R; Lee HJ. Checkpoint Inhibition Therapy in Classic Hodgkin Lymphoma (Accepted. *Clinical Lymphoma Myeloma Leukemia*)
2. **Al Hadidi S**; Lee HJ. Checkpoint Inhibition Therapy in Relapsed/Refractory Transplant Ineligible Patients with Classic Hodgkin Lymphoma (Invited article. Submitted to *Journal of Oncology Practice*)
3. **Al Hadidi S**. Hematology & Oncology: Is it time for divorce? (In preparation for submission)
4. **Al Hadidi S**; et.al. Comparison of allogeneic stem cell transplantation versus non-transplant therapy for myelofibrosis in the JAK inhibitor era (In preparation for submission)

4. Abstracts accepted in last 5 years

1. **Al Hadidi, Samer** & Alamarat,Zain. (May, 2015). Family With Clots: Antithrombin Deficiency Presenting As Recurrent Extensive Thrombotic Episodes Poster presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
2. **Al Hadidi, Samer** & Katato,Khalil & Bachuwa, Ghassan. (April, 2015). Immunoglobulin D Multiple Myeloma Presenting As Spontaneous Fracture Poster presented at: American College of Medicine/Michigan chapter (spring); Sterling Heights, MI, USA.
3. **Al Hadidi, Samer** & Maegawa, Felipe. (October, 2017). Cost-effectiveness Analysis of Curative Therapies for Early Stage Hepatocellular Carcinoma within Milan criteria. Poster presented at: The American College of Surgeons Meeting (ACS Clinical Congress 2017); San Diego, CA, USA.
4. **Al Hadidi, Samer** & Ramkaji, Baniya. (May, 2015). Paraneoplastic cerebellar degeneration as a presentation of head and neck cancer with unknown primary. Poster presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.

5. **Al Hadidi, Samer** & Shaik Mohammad, Tabrez & Bachuwa, Ghassan. (October, 2014). Unusual presentation of uterine leiomyoma Poster presented at: American College of Physicians/ Michigan Meeting (Fall); Gaylord, MI, USA.
6. **Al Hadidi, Samer** & Shastri,Rupal. (May, 2015). Vanishing Lung Syndrome: A Hidden Bomb Poster presented at: American College of Physicians; Detroit, MI, USA.
7. **Al Hadidi, Samer** & Shastri,Rupal. (May, 2015). Vanishing Lung Syndrome: A Hidden Bomb Poster presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
8. **Al Hadidi, Samer**& Towfiq, Basim & Bachuwa, Ghassan. (October, 2014). Dystextia as a presentation of stroke Pos ter presented at: American College of Medicine/Michigan chapter (Fall); Gaylord, MI, USA.
9. Kyi, Htay Htay &**Al Hadidi, Samer**& Bachuwa,Ghassan. (May, 2017). Pregabalin- Induced Myoclonus Poster presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
10. Osman, Mohammad & Abu Sitta, Emad & Al-Salihi, Mohammad & **Al Hadidi, Samer**. (May, 2017). Ebstein Barr Mucocutaneous Ulcer of the Colon, a Diagnostic Dilemma Poster presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
11. Radaideh, Qais & **Al Hadidi, Samer**. (May, 2016). Kounis syndrome: Anaphylaxis or epinephrine effect? Poster presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
12. **Al Hadidi, Samer** & Katato,Khalil & Bachuwa, Ghassan. (May, 2015). Immunoglobulin D Multiple Myeloma Presenting As Spontaneous Fracture Oral Presentation presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
13. **Al Hadidi, Samer**& Towfiq, Basim & Bachuwa, Ghassan. (May, 2015). Dystextia as a presentation of stroke Oral Presentation presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.
14. Kheiri, Babikir & Osman, Mohammad& **Al Hadidi, Samer**. (May, 2017). Gastric Mixed Adenoneuroendocrine Carcinoma With Extranodal Marginal Zone B Cell Lymphoma of Mucosa Associated Lymphoid Tissue Oral Presentation presented at: Michigan State University/ Flint Area Medical Education (FAME); Flint, MI, USA.



15. **Samer Al Hadidi** et. al. Use of dictation as a tool to decrease documentation errors in electronic health records. Early Career faculty poster presentation. ACP national meeting, New Orleans, USA
16. **Samer Al Hadidi** et. al. (March,2019) Predictive ability of the change in the red cell distribution width for acute heart failure hospitalization and beyond .Hospital Medicine 2019, National Harbor, Md.
17. **Samer Al Hadidi** et. al. (June,2019) Participation of African Americans in clinical trials supporting FDA approval of cancer drugs. The American Society of Clinical Oncology Annual meeting.
18. **Samer Al Hadidi** et. al. (September ,2019) Participation of African Americans in Clinical Trials Supporting FDA Approval of Hematological Malignancies Drugs. The Society of Hematologic Oncology.
19. **Samer Al Hadidi** et. al. (September ,2019) Participation of African Americans in clinical trials supporting FDA approval of cancer drugs. The Texas Society of Clinical Oncology
20. **Samer Al Hadidi** et. al. ( December,2019)Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients with Multiple Myeloma. The American Society of Hematology.
21. **Samer Al Hadidi** et. al. (December,2019)Safety Analysis of Two Randomized Controlled Studies of Venetoclax in Patients with Chronic Lymphocytic Leukemia. The American Society of Hematology.
22. **Samer Al Hadidi** et. al. ( December,2019) Participation of African Americans in Clinical Trials Supporting FDA Approval of Breast Cancer Medications. 2019 San Antonio Breast Cancer Symposium.
23. **Samer Al Hadidi** et. al. (May ,2020) Participation of African Americans in clinical trials supporting FDA approval of cancer drugs. Baylor College House staff Research Symposium
24. **Samer Al Hadidi** et. al. (September ,2020) Assessment and Reporting of Quality of Life measures in Pivotal Clinical Trials of Lymphoma. The Society of Hematologic Oncology.
25. **Samer Al Hadidi et.al.** (October, 2020) Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies.

#### 4. Book Chapters

- Disorders of Hemostasis and Coagulation. Handbook of Benign Hematology.  
Co-author

### III. Teaching Information

#### A. Didactic course work

##### 1. Course taught at Michigan State University within Department of Medicine

- a. **Virtuous Physician preceptor:** Virtuous Physician preceptor responsible for teaching third year medical students professional conduct including recognizing the ways in which professional virtue is encouraged and the ways in which it is threatened during medical training, addressing threats to professionalism with mentors and with peers, recognizing how professional behavior impacts appropriate patient care and developing a framework for incorporating appropriate self care into life long practice. (2016-2018).
- b. **Internal Medicine Core rotation (Inpatient and Outpatient) for Internal Medicine residents, transitional year residents and medical students** (2016-2018)

##### 2. Lectures/Presentations in the last 3 years

1. Myeloid Sarcoma in a patient with Neurofibromatosis type I. Citywide Hematology conference. (2018)
2. Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation. Cell and Gene Therapy Yearly Conference Presentation. (2018)
3. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. Journal Club. Department of Hematology and Oncology. Baylor College of Medicine (2018)
4. Hematology and Oncology Emergencies. Lecture given as a part of Hematology/Oncology Lectures for Internal Medicine residents. Baylor College of Medicine. (2019)
5. Extranodal NK/T cell lymphoma, nasal type. Citywide Hematology conference. (2019)
6. Primary Amyloidoma of the chest wall. Citywide Hematology conference.(2019)
7. Lymphoma: when to consider IT chemotherapy?. VA High risk Hematology conference (2019)
8. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicenter, double-blind, placebo-controlled, randomized, phase 3 trial. Journal Club. Department of Hematology and Oncology. Baylor College of Medicine (2019)
9. ASH Annual Meeting, Lymphoma Updates. VA High risk Hematology conference (2020)

### 3. Miscellaneous Teaching/Research

Judge and Abstract Reviewer, Michigan State University/ Flint Area Medical Education (FAME) 2016

Judge and Abstract Reviewer, American College of Physicians Michigan Chapter Meeting 2016

Judge and Abstract Reviewer, Michigan State University/ Flint Area Medical Education (FAME) 2017

Judge and Abstract Reviewer, American College of Physicians Michigan Chapter Meeting 2017

Judge and Abstract Reviewer, American College of Physicians Texas Chapter Meeting 2019

Judge and Abstract Reviewer, American College of Physicians Texas Chapter Meeting 2020

### **IV. References**

- 1. Martha Mims M.D. , PHD (Department Chief):** Professor and Chair, Department of Hematology and Oncology. Baylor College of Medicine. (Email: [mmims@bcm.edu](mailto:mmims@bcm.edu), Cell phone: 713-444-7505)
- 2. Carlos Ramos M.D. (Research Mentor):** Professor, Cell and Gene Therapy, Department of Hematology and Oncology. Baylor College of Medicine. (Email: [caramos@bcm.edu](mailto:caramos@bcm.edu), Cell phone: 832-528-9954)
- 3. Courtney Miller-Chism M.D. (Fellowship Program Director):** Assistant Professor, Department of Hematology and Oncology. Baylor College of Medicine. (Email: [cnmiller@bcm.edu](mailto:cnmiller@bcm.edu), Cell phone: 713-628-7607)

**Erin Eyberg M.D.**  
**3913 27th Avenue South**  
**Minneapolis, MN, 55406**  
**(612) 716-7117**  
**e-mail: eybe0001@umn.edu**

**Skill Summary:**

Excellent broad based general surgical skills including basic and advanced laparoscopy, breast surgery (including seed localized lumpectomy), and endoscopy and trauma.

Considerable experience with multiple electronic medical records.

Exceptional skill in communicating with patients and referring physicians.

Performs well in high pressure situations.

Flexible regarding clinic, inpatient and operating room schedules

**Education:**

University of Minnesota, Minneapolis MN

Surgical resident

July 2005-June 2008

Hennepin County Medical Center, Minneapolis MN

Surgical resident

Jun. 2002- July 2004

Research resident

July -Sept. 2004

University of Minnesota Medical School, Minneapolis, MN

Doctor of Medicine

May 2002

University of Puget Sound, Tacoma, WA

Bachelor of Science, Biology, minor chemistry

May 1997

**Board Certification:**

Board Certified by the American Board of Surgery

April 2012-present

**Honors and Awards:**

Residency:

Award, best clinical research presentation by a resident,  
Minnesota Surgical Society

May 2005

Medical School

Scholarship to study at Karolinska Inst., Sweden

2002

Various scholarships

2000, 2001

**Professional Society Memberships:**

American College of Surgeons, associate member

2008-2014

American Medical Women's Association

1998-present

Officer

1999-2000

Delegate to national conference

1998-2000

**Licensure:**

Minnesota

2005-present

Wisconsin

2015-present

**Employment:**

Weatherby Healthcare Locum Tenens General and trauma surgery, and endoscopy	3/2012-11/2012 3/2015-present
Fairview Medical Group General surgery and endoscopy	4/2013-4/2015
Central Maine Medical Center General and trauma surgery (through Weatherby locum tenens)	6/2012-11/2012
Specialists in General Surgery, Ltd General and trauma surgery	9/2009-10/2011
University of Minnesota/University of Minnesota Physicians General and trauma surgery, Instructor of Surgery	8/2008-7/2009

**Research:**

Retrospective review case series of Heller myotomy with Dor fundoplication. Presented at Minnesota Surgical Society	Dec 2004-May 2005
Effects of Apomorphine on neglect secondary to TBI in rats	1997-1998

**Language/International Experiences:**

Surgical mission trip to Chimaltenango, Guatemala Behrhorst Clinic	3/2010
Karolinska Institute, Stockholm, Sweden, surgical rotation	April 2002
Institute of European Studies, Madrid, Spain	June-July 1996
Spanish: proficient at speaking, reading, and writing	

# Munawwar Hussain MD

102 Nice Ave Johnstown PA 15905 (814)270-0313 dr.munawwar@yahoo.com

---

(PAGE 1 OF 3)

## Education

Bachelors of Medicine and Bachelors of Surgery (M.B.B.S.): **Punjab Medical College, Pakistan.**

Date of degree M.B.B.S April, 2009

ECFMG certification: June, 2010

**Internal Medicine residency:** Conemaugh Health System/Temple University 07/2013-06/2016

**Medical Licensure:** PA MD 458539

**Board certification:** Internal Medicine 2016

## Work experience

- April 2007 – June 2007 worked as house officer in Coronary Care Unit, Allied Hospital, Pakistan
- July 2007 – July 2008 worked as house officer in Clinical Oncology and Radiotherapy Unit, Allied Hospital, Faisalabad Pakistan.
- August 2008 – December 2008 worked as house officer in Urology Department, Allied Hospital, and Faisalabad.
- January 2009 – July 2009 worked as Medical Officer in Mian Mohammad Trust Hospital, Faisalabad.
- August 2009 to December 2009 Rotation at emergency medicine at Loretto Hospital Chicago /Endocrinology rotation at Wayne state University Detroit MI
- 01/01/2010 to 06/26/2013 as Medical officer at Basic Health unit Rajoya, Tehsil & District Chiniot, Pakistan

- 07/01/2013 to June 2016. Internal Medicine Residency at Conemaugh Memorial Medical center, Johnstown PA
- July 2016 to August 2018 Hospitalist with APOGEE Physician at Conemaugh Health System Johnstown, PA 15905
- September 2018 to present Attending physician/Internal medicine faculty at Conemaugh Health System in internal medicine residency program

## **Research experience**

- **Late Metastatic Presentation of Ocular Melanoma**  
Nazish Malik, Munawwar Hussain and Syed Mussadiq Ali Akbar Naqvi  
*American Journal of Medical Case Reports*. **2017**, 5(10), 262-263. DOI: 10.12691/ajmcr-5-10-3
- **An unusual Presentation of Dieulafoy's Lesion as a Cause of Recurrent Lower Gastrointestinal/Rectal Bleeding: A Case Report**  
  
Nazish Malik, Munawwar Hussain and Syed Mussadiq Ali Akbar Naqvi *American Journal of Medical Case Reports*. **2017**, 5(10), 259-261. DOI: 10.12691/ajmcr-5-10-2
- **Stress Cardiomyopathy Associated with Anesthesia**  
  
Munawwar Hussain and Nazish Malik *American Journal of Medical Case Reports*. **2017**, 5(9), 237-238. DOI: 10.12691/ajmcr-5-9-2
- **A Rare Presentation of Primary Small-cell Carcinoma of Urinary Bladder**  
Munawwar Hussain, Ahmed Khalil and Nazish Malik  
  
*American Journal of Medical Case Reports*. **2019**, 7(8), 160-161. DOI: 10.12691/ajmcr-7-8-2
- **Rare Presentation of Salmonella Causing Infective Endocarditis and Mycotic Aortic Aneurysm** Munawwar Hussain and Ahmed Khalil  
*American Journal of Medical Case Reports*. **2019**, 7(2), 24-26. DOI: 10.12691/ajmcr-7-2-3
- **Spontaneous Tumor Lysis Syndrome in Myeloproliferative Disorder: A Rarely Reported Clinical Entity**  
by Sadaquat Liaqat, Asghar Marwat and Munawwar Hussain  
  
*American Journal of Medical Case Reports*. **2020**, 8(10), 361-362. DOI: 10.12691/ajmcr-8-10-10
- **Normothermic Thyroid Storm with Circulatory Collapse: An Unusual Presentation**

by Nazish Malik and Munawwar Hussain

*American Journal of Medical Case Reports*. 2020, 8(10), 363-364. DOI: 10.12691/ajmcr-8-10-11

- Khorana score as a predictive tool of venous thromboembolism in cancer patients in rural practice.

Ahmed Khalil, Daniel Ortolano, Thomas Simunich, Mohamed Saad Eldin, Munawwar Hussain, Sheetal L. Higbee

DOI: 10.1200/JCO.2020.38.15\_suppl.e24049 *Journal of Clinical Oncology* 38, no. 15\_suppl

## **Poster Presentation**

- An accident that led to an incident: An unusual presentation of Brown tumor  
Poster presentation at Western PA ACP annual meeting 2015
- Rare Presentation of Salmonella Causing Infective Endocarditis and Mycotic Aortic Aneurysm poster presentation at western PA ACP annual meeting 2019

## **Quality improvements projects**

- 2013 Quality improvement project of medicine reconciliation in our internal medicine clinic
- 2014 Quality improvement project of E-hand off sign out at internal medicine clinic at Conemaugh Memorial medical center

## **MEMBERSHIP IN HONORARY/PROFESSIONAL SOCIETIES**

- Member Pakistan Medical and Dental Council
- Member Pakistan Medical Association
- Member of American College of physician
- Member Chanabian Society, Punjab Medical College, Faisalabad
- Editor of College Magazine at Punjab Medical College Faisalabad Pakistan

## **Professional Achievements**

- Served as Judge for poster presentation in western PA annual meeting 2018
- Serves as Judge for poster presentation in western PA annual meeting 2019
- 2<sup>nd</sup> position in Jeopardy competition at annual ACP western PA meeting 2015



- Best internal medicine faculty 2019 at Conemaugh memorial medical center
- Best Internal medicine Faculty 2020 at Conemaugh Health Systems
- Member of Peer review committee at Conemaugh Health System
- Resident wellness curriculum for internal medicine residency program
- Wrote chapter on acute pain management in intern survival guide for new interns

## **HOBBIES & INTERESTS**

I spend my leisure time reading books, playing cricket, browsing internet, looking for new interesting websites. Reading History (world and Islamic), poetry and serving people are my special interests. Like to watch movies.

## Curriculum Vitae

**NAME:**

Fatima Khan MD

**ADDRESS:**

5410 Andover Dr,  
Tyler, TX 75707  
(646)591-9465 (cell)  
E-mail: fatimakhansherwani@gmail.com

**EDUCATION:**

12/1998 – 04/2004	King Edward Medical University Pakistan MBBS
04/2002	University of the Punjab Lahore, Pakistan BS
09/1996 – 10/1998	Nishat Science College Multan, Pakistan FSc
09/1992 – 06/1996	The Public School Multan, Pakistan, Matriculation

**POSTDOCTORAL TRAINING:**

07/2014 – 07/2015	Fellowship, Geriatric Medicine George Washington University Hospital Washington, DC
07/2011 – 07/2014	Residency, Internal Medicine Mount Sinai Medical Center Miami, FL

**SPECIALTY CERTIFICATION:**

2017	ACLS/BLS Recertification WakeForest Baptist Hospital
2016	ABIM Board Certification Internal Medicine
2013	ACLS Recertification, Mount Sinai Medical Center
2011	ACLS/BLS Course, Mount Sinai Medical Center
2010	ACLS Course, Shaukat Khanum Memorial Cancer Hospital & Research Centre
2011	USMLE Step 3: Score 90
2008	USMLE Step 2 CS (Clinical Skills)
2007	USMLE Step 2 CK: Score: 240/97
2006	USMLE Step 1: Score: 226/92
2005	FCPS Part 1: Medicine Board Certification: Pakistan Medical and Dental Council

**PROFESSIONAL LICENSURE:**

North Carolina Medical License  
 District of Columbia Medical License #MD042399  
 Texas Medical License

**EMPLOYMENT:**Academic Appointments:

*Wake Forest School of Medicine:*  
 Department of Internal Medicine

Section on Hospital Medicine  
 Wake Forest School of Medicine  
 Medical Center Boulevard  
 Winston-Salem, NC 27157-1010  
 (336) 713-5215 (office)

1/2016 – 12/2016  
 1/2017- 03/2019

Instructor  
 Assistant Professor  
 Section on Hospital Medicine

Professional Experience:

08/2019-Current

Hospitalist Internal Medicine  
 Christus Trinity Mother Frances Hospital  
 Tyler, TX

2015 - 2016

Hospitalist with NICHHS  
 Novant Health Thomasville Medical Center  
 Thomasville, NC

05/2011-06/2011

Medical Officer Department of Hematology Oncology  
 Shaukat Khanum Memorial Cancer Hospital and  
 Research Center

09/2010 – 03/2011

Voluntary Research Scholar, Department of Cardiology  
 And Cardiothoracic Surgery  
 Columbia University Medical Center  
 New York Presbyterian Hospital  
 New York, NY

05/2007 – 08/2010

Resident Doctor, Fellowship of College of Physicians  
 and Surgeons Trainee in Internal Medicine  
 Shaukat Khanum Memorial Cancer Hospital and  
 Research Center.

12/2004 – 06/2005

House Job  
 General Medicine, Mayo Hospital Lahore  
 South Medical Ward

06/2004 – 12/2004

House Job  
General Surgery, Mayo Hospital Lahore  
South Medical Ward

**RESEARCH ACTIVITY:****Peer Reviewed Journal Articles/Abstracts**

1. Khan F, Zubair H, Munir MB. Extracorporeal membrane oxygenation as temporary mechanical circulatory support: what needs further clarification with respect to prognostic factors. *Artificial Organs*. 2013 Mar; 37(3): 23. Cited in PubMed; PMID: 23330718. Publication Status: Published.
2. Successful Treatment Of Early Stage Monophasic Pulmonary Synovial Sarcoma With Minimally Invasive Robotic Video-Assisted Lobectomy D. Saha , A. Maiti , F. Khan , E. Rodriguez 1 2 3 4 University of Pittsburgh Medical Centre, Pittsburgh, PA, University of Texas Health Science Center at Houston, Houston, TX, Novant 1 2 3 Health Thomasville Medical Center, Thomasville, NC, Mount Sinai Medical Center, Miami Beach, FL [www.atsjournals.org/doi/abs/.../ajrccm-conference.2016.193.1\\_MeetingAbstracts.A6027](http://www.atsjournals.org/doi/abs/.../ajrccm-conference.2016.193.1_MeetingAbstracts.A6027)
3. Unilateral Pulmonary Hypoplasia Mimicking Pneumothorax: An Unusual Case A. Malik , , L. Chandra , F. Khan , N. Singh , A. N. Thomas 1 2 1 3 1 1 Howard University Hospital, Washington, DC, , George Washington University Hospital, Washington, DC
4. [www.atsjournals.org/doi/abs/.../ajrccm-conference.2015.191.1\\_MeetingAbstracts.A3049](http://www.atsjournals.org/doi/abs/.../ajrccm-conference.2015.191.1_MeetingAbstracts.A3049)
5. Invasive Pulmonary Aspergillosis And Diffuse Alveolar Hemorrhage Complicating Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Case Report A. Malik , I. Biney , V. Kodadhala , N. Singh , F. Khan , C. Coles , M. N. Fidelia-Lambert , V. A. Poddar , A. N. Thomas , 1 1 1 1 2 3 3 1 1 4 Howard University Hospital, Washington, DC, George Washington University Hospital, Washington, DC, Howard University Hospital, 1 2 3 Washington, DC, 4 [www.atsjournals.org/doi/abs/.../ajrccm-conference.2015.191.1\\_MeetingAbstracts.A1873](http://www.atsjournals.org/doi/abs/.../ajrccm-conference.2015.191.1_MeetingAbstracts.A1873)
6. ATS Abstracts. [http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1\\_MeetingAbstracts.A5709](http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A5709)
7. ATS Abstracts. [http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1\\_MeetingAbstracts.A3440](http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A3440)
8. ATS Abstracts. [http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1\\_MeetingAbstracts.A3979](http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A3979)

**Oral Presentation**

1. D Chen, F Khan, M Koroma-Nelson, A Mohammed, J Pandey, R Jayes, EL Cobbs The George Washington University School of Medicine and Veterans Affairs Medical Center, Washington DC (2015). There's No Place Like Home: An Examination of Senior Villages in Washington DC. Poster Presentation at AGS 2015 Annual Meeting; National Harbor, MD.
2. Fatima Khan, M.D., Bilal Munir, M.D., Faisal H. Cheema, M.D., Edward Y. Chan, M.D., Jeffrey Jiang, B.S., Zarrish S. Khan, M.D., Fahad Younas, M.D., Mansoor Mehmood, M.D., P. C. Schulze, M.D., Ph.D., Mathew R. Williams, M.D., Craig R. Smith, M.D.. (2010).
3. Management of Moderate Ischemic Mitral Regurgitation During Coronary Artery Bypass Grafting. Oral Presentation presented at: Annual Dallas Leipzig International Valve 2010; Dallas, TX.

**COMMUNITY ACTIVITIES AND SERVICE:**

05/2008 – 05/2008

Observership in the Medicine Department  
Sheikh Zayed Hospital  
Lahore, Pakistan

03-2005 – 04/2005	KEMC Trauma Course Participated in organization of 5 <sup>th</sup> Biennial International Conference of Pakistan Society of Cardiovascular and Thoracic Surgeons and 1 <sup>st</sup> Heart Summit of Emergent Countries
07/2003-07/2003	Electives in Cardiothoracic Surgery Aga Khan University Hospital
04/2003	Diabetes Association of Pakistan Participated in organization and proceedings of 15 <sup>th</sup> Annual course on Diabetes Mellitus King Edward Medical College
01/ 2003 – 01/2003	Department of Medicine Mayo Hospital, Pakistan Attended and participated in a conference on Bone Mineral Density Fatima Jinnah Medical College, Lahore

# JOHN “CHARLIE” KINCAID, MD

(501) 940-6260 | [JKincaid@UAMS.edu](mailto:JKincaid@UAMS.edu)

---



## Education, Training, and Licensure

Arkansas State Medical License

- Temporary through 12/4/20, Full licensure pending

University of Arkansas for Medical Sciences

- Fellowship, Hospice and Palliative Care Medicine
- Residency, Internal Medicine
  - Board Certified, August 2020
- Medical Doctorate

July 2020 - Present

July 2017 - June 2020

August 2011 - May 2016

University of Colorado at Boulder

- Bachelor of Arts: Molecular, Cellular, Developmental Biology and Biochemistry

August 2006 - May 2010

## Work Experience and Professional Development

Arkansas Children's Hospital, Little Rock, AR

May 2016 - June 2017

*Clinical Research Aide*, Department of Allergy and Immunology

- Recruited patients who presented to ACH Emergency Department for respiratory distress to investigate the effects of Rhinovirus on the severity of asthma exacerbations.
- Responsible for maintenance of records and protocol compliance with institutional and national regulations.

Arkansas Scribes Incorporated, Little Rock, AR

August 2010 - August 2017

*Scribe*

- Transcribed detailed histories and physical exam findings into the electronic medical record at Baptist Health Medical Center Emergency Department, Level II Trauma Center.

Cardiology Preceptorship

September 2012 - April 2013

Heart Clinic Arkansas, Dr. Randy Jordan, Interventional Cardiology

Pediatric Subspecialties Preceptorship

May 2012 - August 2012

Arkansas Children's Hospital: General Surgery, Emergency Medicine, Hematology/Oncology

- Designed and orchestrated outside of existing institutional availabilities

Goodrich-Kugel Research Group

April 2008 - May 2009

*Undergraduate Research Assistant*, University of Colorado at Boulder

- Investigated transcription activation of IL-2 gene.
- Funding awarded by Howard Hughes Medical Institute and National Institutes of Health

## Posters, Presentations, and Publications

Kincaid, JC, Hyde, CR. "Terminal Ventilatory Wean for Patients With COVID-19" Annual Assembly of Hospice and Palliative Care, 2021. Abstract, pending.

UAMS Division of Palliative Care, Journal Club. "The Role of Palliative Care in the Current HIV Treatment Era in Developed Countries." Merlin, JS, et al (2013). Presented 4 Nov 2020

UAMS Department of Internal Medicine

- Journal Club
  - "Early Palliative Care for Patients with Non-Small-Cell Lung Cancer." Temel, JS, et al (2010). Presented 22 Nov 2019.
  - "Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers." Huang, SS, et al (2019). Presented 19 Apr 2019.
- Afternoon Case Discussion
  - Disseminated Gonococcal Infection. Presented 15 May 2020.
  - Left Ventricular Free Wall Rupture after Acute Myocardial Infarction. Presented 29 Oct 2019.
  - Legionnaire's Disease. Presented 8 Feb 2019.
  - DRESS Syndrome. Presented 9 Mar 2018.

Denson JL, Kennedy JL, Dehority WN, Eickman MM, Schwalm KS, Stoner AN, **Kincaid JC**, Abramo TJ, Thompson TM, Ulloa EM, Burchiel SW, Young SA, Dinwiddie DL. Complete Genome Sequences of Two Novel Isolates of Human Parainfluenza Virus 1 Associated with Acute Respiratory Infection. Genome Announcements. 2016, Oct; 4(5): e01154-16. Pub Status: Published.

Dinwiddie DL, Hardin O, Denson JL, **Kincaid JC**, Schwalm KC, Stoner AN, Abramo TJ, Thompson TM, Putt CM, Young SA, Dehority WN, Kennedy JL. Complete Genome Sequences of Four Novel Human Coronavirus OC43 Isolates Associated with Severe Acute Respiratory Infection. Genome Announcements. 2018, May; 6(21): e00452-18. Pub Status: Published.

Kennedy JL, Denson JL, Schwalm KS, Stoner AN, **Kincaid JC**, Abramo TJ, Thompson TM, Ulloa EM, Burchiel SW, Dinwiddie DL. Complete Genome Sequence of a Novel WU Polyomavirus Isolate from Arkansas, USA, Associated with Acute Respiratory Infection. Genome Announcements. 2017, Jan; 5(2): e01452-16. Pub Status: Published.

Kennedy JL, **Kincaid JC**, Schwalm KC, Stoner AN, Abramo TJ, Thompson TM, Hardin O, Putt C, Dinwiddie DL. Genome Sequences of Three Novel Isolates of Human Parainfluenza Virus 2 Associated with Acute Respiratory Infection. Genome Announcements. 2017, Aug; 5(33): e00784-17. Pub Status: Published.

Kothari A, Burgess MJ, Crescencio JCR, Kennedy JL, Denson JL, Schwalm KC, Stoner AN, **Kincaid JC**, Davies FE, Dinwiddie DL. The role of next generation sequencing in infection prevention in human parainfluenza virus 3 infections in immunocompromised patients. Journal of Clinical Virology. 2017, Jul; 92(Epub 2017 May 12): 53-55. Pub Status: Published.

# Curriculum Vitae

## Timothy Dean Langford, M.D.

### Personal History:

Date of Birth: October 1, 1960  
Place of Birth: Searcy, Arkansas  
Home Address: 26 Chenal Circle  
Little Rock, Arkansas 72223

Spouse: Terri Joseph Langford

Children: Aaron Chandler Langford  
Brian Timothy Langford  
Caitlynn Shannon Langford

### Post Graduate:

University of Arkansas School of Medicine  
Doctor of Medicine: May 16, 1988  
Position in class: 25/122  
GPA: 3.0  
Scholarships: Dorothy Snider foundation Scholarship

### Undergraduate Education:

Arkansas State University: 1979-1983  
Bachelor of Science Zoology: 1983

### Extracurricular Activities:

- Medical Arts Club
- Beta Beta Beta
- Tau Kappa Epsilon Fraternity
- ASU Varsity Football team, 1980-1983
- Intramural Athletics
- Fellowship of Christian Athletes
- Phi Beta Sigma Freshman Honor Society

### Undergraduate Honors:

- Honor Roll (each semester)
- Phi Kappa Phi
- Outstanding Biology Student, 1982
- Who's Who Among American College and Universities
- Graduated Magna Cum Laude
- Southland Conference All-American Football team, four years
- Southland Conference McDonald Scholarship, 1983
- ASU Terry Gwinn Award, 1983
- National Football Foundation Hall of Fame Scholarship, 1983



## Post Graduate Training:

- General Surgery Internship: July 1988-June 1989
- University of Arkansas for Medical Sciences
- General Surgery Residency: July 1989-June 1990
- University of Arkansas for Medical Sciences
- Urology Residency: July 1990- June 1992
- University of Arkansas for Medical Sciences
- Chief Urology Resident: July 1992-June 1993
- University of Arkansas for Medical Sciences

## Practice History

Arkansas Urology, P.A.  
1300 Centerview Drive  
Little Rock, Arkansas 72211  
July 1, 1993- Present  
Present Memberships:

- American Association of Clinical Urologists
- American Board of Urology: Certified March 1995
- American Medical Society
- American Urologic Association
- Arkansas Medical Society
- Arkansas Urological Society
- Pulaski County Medical Society

## Leadership Positions:

- Secretary-Treasurer, Arkansas Urological Society 1996-2001
- President Arkansas Urological Society, 2002
- Arkansas Representative, South Central Section (SCS) of the American Urological Association (AUA)
- Treasurer, SCS/AUA, 2013-2016
- Program Chairman, SCA/AUA, 2017
- President, SCS/AUA , 2018
- Chief of Staff, Baptist Health-Little Rock, Arkansas 2014-2015
- President Arkansas Urology, P.A., 2011- present

## RESEARCH:

2021

ESCALATE: A PHASE III RANDOMIZED STUDY COMPARING ENZALUTAMIDE OR DAROLUTAMIDE WITH RADIUM-223 VS ENZALUTAMIDE OR DAROLUTAMIDE WITH PLACEBO AND THE EFFECT UPON SYMPTOMATIC SKELETAL EVENT-FREE SURVIVAL FOR MCRPC PATIENTS: PRINCIPAL INVESTIGATOR

TALAPRO 3: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

2020

APA RP: A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE 2 STUDY OF THE ADJUVANT TREATMENT OF APALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) IN TREATMENT-NAÏVE PARTICIPANTS WHO HAVE UNDERGONE RADICAL PROSTATECTOMY (RP) FOR NON-METASTATIC PROSTATE CANCER AND WHO ARE AT HIGH RISK FOR METASTASES: PRINCIPAL INVESTIGATOR

CAPitello 281: A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF CAPIVASERTIB + ABIRATERONE VERSUS PLACEBO + ABIRATERONE AS TREATMENT FOR PATIENTS WITH DE NOVO METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) CHARACTERISED BY PTEN DEFICIENCY (CAPITELLO-281): SUB-INVESTIGATOR

PREVALENCE: BIOMARKER STUDY TO DETERMINE FREQUENCY OF DNA-REPAIR DEFECTS IN MEN WITH METASTATIC PROSTATE CANCER: PRINCIPAL INVESTIGATOR

MAGNITUDE: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF NIRAPARIB IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE VERSUS ABIRATERONE ACETATE AND PREDNISONE FOR TREATMENT OF SUBJECTS WITH METASTATIC PROSTATE CANCER: PRINCIPAL INVESTIGATOR

2018

ProVent: A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER: SUB-INVESTIGATOR

2016

MDx: A PROSPECTIVE STUDY TO EVALUATE THE CLINICAL UTILITY OF THE CONFIRM MDX FOR PROSTATE CANCER ASSAY FOR MEN WITH PREVIOUS HISTOLOGICALLY NEGATIVE PROSTATE BIOPSIES: PRINCIPAL INVESTIGATOR

Oncotype: REAL-WORLD IMPACT OF THE ONCOTYPE DX GENOMIC PROSTATE SCORE ON CLINICAL DECISION MAKING

2014

OPKO: THE OPKO DIAGNOSTICS 4KSCORE AS A PREDICTOR OF PROSTATE CANCER PRIOR TO BIOPSY: PRINCIPAL INVESTIGATOR

# Jacob Leffert

Present Mailing Address: 920 Pine Valley Road, Little Rock, AR, 72207  
Permanent Mailing Address: 920 Pine Valley Road, Little Rock, AR, 72207  
501-339-4375 – jleffert@uams.edu

## EDUCATION

---

**University of Arkansas for Medical Sciences – Little Rock, AR** 2014-Present

Doctor of Medicine: 2018

Internal Medicine Residency: Expected Graduation 2021

**Hendrix College – Conway, AR** 2010-2014

Bachelor of Arts, Biochemistry and Molecular Biology, with Honors

Minor in Philosophy

## RESEARCH EXPERIENCE

---

**UAMS – Little Rock, AR** 2017-2020

- “Fertility Preservation Discussion in Young Adults with Cancer: How Often are We Documenting?”
  - Pandey, Y MD, Roy, A MD, Konda, M MD, **Leffert, J MD**, Makhoul, I MD, Sasapu, A MD. QI project that involved data collection on whether oncologists had fertility conversations before starting chemotherapy in young patient. Published in Journal of the National Comprehensive Cancer Network, Volume 18: Issue 3.5. <https://doi.org/10.6004/jnccn.2019.7487>
- “HIV-Vacuolar Myelopathy: An Unusual Early Presentation in HIV”
  - **Leffert, J MD**, Purushothaman, R MD, Vilanilam, G MD, Stanley, M MD, Kothari, A MD. One of the primary authors on an interesting presentation of HIV patient presenting initially with lower extremity paralysis. Published in International Journal of STD & AIDS. <https://doi.org/10.1177/0956462420933786>
- *Lung Cancer Drug and Antigen Experiments*
  - Cultured and cultivated small cell and non-small cell lung cancer lines which were then used in subsequent experiments and analyzed for cell cycle arrest
  - Advisor: Behjatolah M. Karbassi, PhD

**Hendrix College – Conway, AR** 2012-2013

- *Approaches to the Synthesis of Glucuronide Derivatives of Enantiomerically-Enriched Warfarin (Coumadin)*
  - Attempted to synthesize pure enantiomers of warfarin metabolites in lab for use clinically in gaging levels and therapeutic ranges of warfarin. Presented findings at ACS national meeting.
  - Advisor: Thomas Goodwin, PhD

## PRESENTATIONS

---

- 245<sup>th</sup> American Chemical Society National Meeting – New Orleans, LA** 2013
- Presented research at the undergraduate session of the annual ACS research conference.

## SERVICE & LEADERSHIP

---

- Hospice Home Care, Little Rock, AR** 2017
- Volunteered at hospice home care center in Little Rock, this included spending time with patients playing games, talking, and providing general company.

- North Street Clinic, Fayetteville, AR** 2016
- Volunteered at this interdisciplinary, student led clinic aimed at treating the underserved and largely uninsured Marshallese population in Northwest Arkansas.

- Preceptorship in Neuroscience – Little Rock, AR** 2015
- Completed a 6 week preceptorship; 4 weeks with two neurosurgeons and 2 weeks with a neurologist in Little Rock, AR.

- President of the Social Committee – Hendrix College, Conway, AR** 2013-2014
- This committee received approximately \$90,000 in funding from the school for the purpose of hosting a variety of social gatherings for the college, from comedians and concerts to a winter formal.

- Orientation Leader – Hendrix College, Conway, AR** 2012-2013
- Selected as orientation leader at Hendrix College twice. Helped freshman with move in and led orientation week activities that culminated in a trip to locations across Arkansas.

- Martin Hall Senator – Hendrix College, Conway, AR** 2012-2013
- Served as the Martin Hall senator on student government for Hendrix College.

- Martin Hall Treasurer – Hendrix College, Conway, AR** 2011-2012
- Served as the Martin Hall treasurer on Martin Hall Council.

## PROFESSIONAL SOCIETIES

---

**American College of Physicians** 2018-Present

**American Medical Society** 2017-Present

**American Chemical Society** 2012-2014

## WORK EXPERIENCE

---

- Hendrix College – Conway, AR**
- **Teaching Assistant** 2013
    - Worked in the organic chemistry I lab as the teaching assistant, duties included helping students perform the required experiments and cleaning and storing the chemicals after use

**Conway Orthopedics and Sports Medicine – Conway, AR**

- *Summer Internship* 2011
  - Worked closely with Dr. Thomas Roberts in clinic and assisted with knee and shoulder surgeries in the operating room

**Hendrix College – Conway, AR**

- *Chemistry Department – Lab Grader* 2011
  - Assisted in the grading of laboratory reports for the general chemistry lab

**Green Tree – Conway, AR**

- *Mobile Home Cleaner* 2007-2011
  - Assisted in the clean-up of mobile homes that had been foreclosed

**Centennial Valley Country Club – Conway, AR**

- *Life Guard* 2008-2010

**Luxury Pools and Spas – Conway, AR**

- *Physical Laborer* 2007
  - Helped in the formation and maintenance of pools

**PERSONAL INTERESTS**

---

- *Soccer*
- *Disc Golf*
- *Taekwondo*
- *Reading/Audiobooks*
- *Hiking*
- *Videogames*
- *Snow Skiing*
- *Kayaking/Canoeing*

# Sindhu Malapati, M.D.

Van Elslander Cancer Center- Ascension St. John Hospital  
19229 Mack Ave, Grosse Pointe Woods, MI 48236  
[SindhuMalapati@gmail.com](mailto:SindhuMalapati@gmail.com)  
312-934-3925

## Training

- Chief Fellow, Hematology and Oncology (7/1/2020-6/30/2021): Ascension St. John Hospital and Medical Center, Grosse Pointe, MI
- Fellowship, Hematology and Oncology (7/1/2018-6/30/2021): Ascension St. John Hospital and Medical Center, Grosse Pointe, MI
- Residency, Internal Medicine (7/1/2015- 6/30/2018): John H. Stroger Jr. Hospital of Cook County, Chicago. IL

## Medical Education

- Goa Medical College, Goa, India – MBBS, 2007- 2013

## Awards

- Merit Award- Conquer Cancer/ ASCO Foundation for ASCO 2020
- Merit Award- Conquer Cancer/ ASCO Foundation for Supportive Care in Oncology 2019
- Goa University Award for Excellence in Physiology 2008

## Professional Service

- Member, ASCO Trainee and Early Career Council, 2020-2021
- Drafted health system wide guidelines (Ascension, MI) for CNS prophylaxis in DLBCL, Dec 2019
- Drafted institutional guidelines (St. John Hospital) Blood transfusion practices, Nov 2018
- Secretary, House staff Association, John H Stroger Jr Hospital, 2017-2018
- Reviewer for BMJ Case reports and Cureus

## Clinical Trial Experience

- Local Principal Investigator for “Expanded access to Convalescent Plasma for the treatment of patients with COVID-19” (NCT04338360)

## Publications

### Review Article/ Publications

- 1) Yadi, L., **Malapati, S.**, Yu, T., Patnaik, A. An Integrative Approach for Sequencing Therapies in Metastatic Prostate Cancer. The American Journal Of Hematology/Oncology. Volume 13 Number 12 12.17
- 2) Kumar R, Bhandari S, Singh SRK, **Malapati S**, Cisak K. Incidence and Outcomes of Heparin-Induced Thrombocytopenia in Solid Malignancy: An Analysis of The National Inpatient Sample Database. British J Hematol. Br J Haematol. 2020 Jan 28. doi: 10.1111/bjh.16400.
- 3) Zayed Y, Kheiri B, Barbarawi M, Banifadel M, Abdalla A, Chahine A, Obeid M, Haykal T, Yelangi A, **Malapati S**, Bachuwa G, Seedahmed E. Extended Duration of Thromboprophylaxis for Medically Ill Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Intern Med J. 2019 Jul 5. doi: 10.1111/imj.14417.
- 4) **Malapati S**, Singh SRK, Kumar R, Hadid T. Outcomes of in-hospital cardiopulmonary resuscitation (ICPR) for cardiac arrest in adult patients with metastatic solid cancers: A nationwide inpatient sample (NIS) database analysis from 2012 to 2014. Accepted for publication in Cancers

### Abstracts/ Posters

- 1) **Malapati S**, Singh SRK, Kumar R, Hadid T. (May 2020) Neoadjuvant treatment with chemotherapy or chemoradiation in stage III non-small cell lung cancer: Analysis of the National Cancer Database. J Clin Oncol 38: 2020 (suppl; abstr 7046)
- 2) **Malapati S**, Singh SRK, Kumar R, Abdalla A, Hadid T. (May 2020) Perioperative chemotherapy versus adjuvant chemoradiation in resectable gastric cancer: A National Cancer Database Analysis. J Clin Oncol 38: 2020 (suppl; abstr 7066)
- 3) Singh SRK, **Malapati S**, Neme K, Michael A, Mikulandric N, Vulaj V, Emole J. Etanercept with extracorporeal photopheresis (ECP) for steroid-refractory acute graft versus host

disease following allogeneic hematopoietic stem cell transplantation. *J Clin Oncol* 38: 2020 (suppl; abstr 7543)

- 4) Abdalla A, **Malapati S**, Singh SRK, Szpunar S, Hadid T, Kafri Z, Aref A. Total mesorectal excision compared to local excision in locally advanced rectal cancer achieving pathological response with neoadjuvant therapy: A National Cancer Database Analysis. *J Clin Oncol* 38: 2020 (suppl; abstr 4107)
  
- 5) Kumar R, Bhandari S, Ngo P, Singh SRK, **Malapati S**, Rojan A. Clinical outcomes of patient migration in locally advanced rectal cancer from community cancer centers: An analysis of the National Cancer Database. *J Clin Oncol* 38, 2020 (suppl 4; abstr 81).
  
- 6) **Malapati S**, Singh SRK, Kumar R, Mouabbi J, Hadid T. Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive? *Blood* (2019) 134 (Supplement\_1): 2353.
  
- 7) **Malapati S**, Singh S, Kumar R, Ahmed J, Vohra I, Katiyar V. In-Hospital Outcomes in Elderly Acute Myeloid Leukemia (AML) Receiving Aggressive Inpatient Care: An Analysis of National Inpatient Sample (NIS) Database between Years 2005 and 2014. *Blood* (2019) 134 (Supplement\_1): 2149.
  
- 8) Singh S, **Malapati S**, Kumar R, Lingamaneni P, Khaddour L, Donthireddy V. Elective Splenectomy in Immune Thrombocytopenic Purpura: An Analysis of National Inpatient Sample (NIS) Database between Years 2006 and 2014. *Blood* (2019) 134 (Supplement\_1): 4672.
  
- 9) Singh S, **Malapati S**, Kumar R, Lupak O, Kuriakose P. Predictors of Transfer to Different Facility at Discharge in Patients Admitted with Hematologic Malignancy: A Nationwide Inpatient Sample (NIS) Database Analysis. *Blood* (2019) 134 (Supplement\_1): 2132.
  
- 10) Putta A, Shaka H, Banskota S, Singh SRK, **Malapati S**, Farooq M, Batra K. Therapeutic Plasma Exchange (PLEX) in Thrombotic Microangiopathy (TMA): Experiences of an Inner-City Hospital over a Decade. *Blood* (2019) 134 (Supplement\_1): 3691.
  
- 11) Kumar R, Bhandari S, Singh SRK, **Malapati S**, Khurana S, Cisak K. Incidence and Outcomes of Cardiovascular Disease in Hemophilia Patients: An Analysis of National Inpatient Sample Database. *Blood* (2019) 134 (Supplement\_1): 2176.



- 12) **Malapati S**, Singh SRK, Kumar R, Mouabbi J, Abdalla A, Dul C, Hadid T. Bilateral mastectomy in ductal carcinoma in situ: 10-year analysis of national inpatient sample database. AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-04.
- 13) **Malapati S**, Singh SRK, Kumar R, Ahmed J, Vohra I, Katiyar V, Kafri Z. Outcomes of in-hospital cardiopulmonary resuscitation (ICPR) for cardiac arrest in adult patients with metastatic solid cancers: A nationwide inpatient sample (NIS) database analysis from 2012 to 2014. J Clin Oncol 37, 2019 (suppl 31; abstr 44)
- 14) Katiyar V, Vohra I, **Malapati S**, Singh SRK, Lingamaneni P, Mackie O, Shariff R. Cultural disparities in end-of-life choices and advanced care planning in cancer patients. J Clin Oncol 37, 2019 (suppl 31; abstr 3)
- 15) Singh SRK, **Malapati S**, Kumar R, Thanikachalam K, Al Khatib Y. Predictors of transfer to different facility at discharge in patients admitted with metastatic solid malignancy: Five-year National Inpatient Sample (NIS) database analysis. J Clin Oncol 37, 2019 (suppl 31; abstr 38)
- 16) **Malapati S**, Singh SRK, Kumar R, Ahmed J, Katiyar V, Vohra I. Geographic distribution of clinical trials for breast cancer across the United States, 2011-2015. J Clin Oncol 37, 2019 (suppl 27; abstr 140)
- 17) Rayli P, Putta A, Katiyar V, Singh SRK, Batra K, **Malapati S**. Retrospective Audit of Malignant Epidural Spinal Cord Compression (MESCC) in an Inner-City Safety Net Hospital. International Journal of Radiation Oncology Biology Physics, Volume 105, Issue 1, E124 - E125.
- 18) Ahmed TA, **Malapati S**, Yim B, Singh SRK, and Gupta S. (January 2018). Regorafenib tolerance and outcomes in inner-city minority colorectal cancer population. J Clin Oncol 36, 2018 (suppl 4S; abstr 722)
- 19) Singh SRK, **Malapati S**, Lu P & Rosen F. (October 2017). Factors affecting adherence to standard cisplatin-based chemotherapy regimen for locally advanced squamous cell head and neck cancer in an inner-city safety net hospital. J Clin Oncol 35, 2017 (suppl 31S; abstract 252)
- 20) **Malapati S**, Saul D, Singh SRK, Sahni A, Fakhran S. (November 2016). A rare cause of Chylothorax. Poster presented at: American College of Physicians Illinois Regionals; Chicago, IL, USA.

**Online abstract**

- 1) Singh SRK, Lu P, **Malapati S**, Ahmed TA & Mullane M. Outcomes in left versus right metastatic colorectal cancer (mCRC) in patients presenting to an inner-city safety net hospital. *Journal of Clinical Oncology*. 2018, May; 36(15\_suppl): e15542.
- 2) **Malapati S**, Khan U, Mouabbi J, Kafri Z, Hadid T, Berri R, Sakhi R, Mazzara P, Szpunar S. (2019). Single center experience: Management of metastatic appendiceal cancer with peritoneal carcinomatosis. *Journal of Clinical Oncology*. 37. e15103-e15103. 10.1200/JCO.2019.37.15\_suppl.e15103.
- 3) Lupak O, Han X, Patil N, Thanikachalam K, Xie P, Jabbour H, Al Saheli Z, **Malapati S**, Farhan S, Emole J. Disparities in utilization of autologous stem cell transplantation as consolidative therapy for multiple myeloma: A single-institution retrospective review. *J Clin Oncol* 38: 2020 (suppl; abstr e20504)
- 4) Mouabbi J, **Malapati S**, Abdalla A, Biedny A, Hayward D, Szpunar S, Hadid T, Berri R, Kafri Z. A new prognostic model for high-grade appendiceal mucinous neoplasms with peritoneal carcinomatosis. *J Clin Oncol* 38: 2020 (suppl; abstr e16718)
- 5) Kumar R, Bhandari S, Singh SRK, **Malapati S**, Rojan A. Survival outcomes of neoadjuvant versus adjuvant chemotherapy in early-stage pancreatic adenocarcinoma: A subgroup analysis of the National Cancer Database. *J Clin Oncol* 38: 2020 (suppl; abstr e16777)
- 6) Singh SRK, **Malapati S**, Kumar R, Wang D. Overall survival in metastatic melanoma since the introduction of immunotherapy: A National Cancer Database Analysis. *J Clin Oncol* 38: 2020 (suppl; abstr e19333)

## Quality Improvement Projects

- 1) **Malapati S**, Dul C. Time to receiving chemotherapy in triple negative breast cancer and identification of causes of delay- Quality Assessment. Presented at institutional cancer committee
- 2) **Malapati S**, Bobba A, Nauman A, Angl A, Rodriguez J, Desta R, Ayoub A, Bedrose S, Wang Y. Improving patient satisfaction and patient experience in Primary Care Medical Home by improving communication to patients regarding delays while waiting to be seen by their provider- PDSA cycles 2 and 3.

## Ongoing Projects

- 1) FLEX sub-study: PIK3CA and ARID1A expression as predictors of outcomes in young breast cancer patients
- 2) Effect of radiation therapy on outcomes in early stage TNBC, stratified by TILs
- 3) Disparities in cancer care among minorities with breast cancer at Van Elslander Cancer Center
- 4) HeartMath device for management of stress at diagnosis of early stage breast cancer
- 5) Nanoparticle radiosensitization of CD34+ sub-clone in B-cell lymphoma
- 6) Geriatric Assessment in the Oncology Clinic: Development of a Scoring System to Risk-Stratify Elderly Patients Receiving Chemotherapy

### **Board Certification and Professional Society membership**

- American Board of Internal Medicine certified
- ASCO, ASH, MSHO, ESMO

### **Language Fluency**

- English, Telugu and Hindi

# HASAN RANA

(734) 530-8729

Hasanrana07@gmail.com

[hasan.rana@ascension.org](mailto:hasan.rana@ascension.org)

## Medical licensure:

State of Indiana 2020 – Present, Board certified

DEA License (May 2020) – Active

## Certifications:

- ECFMG
- ACLS
- BLS
- Arterial catheter insertion
- Central venous catheter insertion
- Thoracentesis
- Abdominal paracentesis

## Experience:

August 2020 – June 2021

**Ascension St Vincent Hospital**, Indianapolis, IN – *Hospitalist*

With academic appointment at Indiana University (Adjunct Clinical Professor)

June 2017 – June 2020

**Ascension St John Hospital**, Detroit, MI — *Resident, Internal Medicine*

Awards: Wayne State School of Medicine Resident Teaching Award 2018 – 2019, 3<sup>rd</sup> place in research award for Internal Medicine

February 2017 - May 2017

**Services Institute of Medical Sciences**, Lahore, Pakistan — *House Officer in Medicine (2 months) and Otolaryngology and Neck surgery (2 months)*

August 2016 - January 2017

**Pondview Personal Physicians**, Madison Heights, MI — *Medical Scribe and assistant*

Medical scribe for primary care practice with other duties including preparing patients for facet and intra-articular injections, maintaining sterilization and data entry for Zahid Sheikh, MD

August 2016 - November 2016

**Busch's Fresh Food Market**, West Bloomfield, MI — *Cashier*

August 2016 - September 2016

**John D Dingell VA Medical Center**, Detroit, MI — *Externship*

Externship in Internal Medicine with Amir Iqbal, MD

August 2016 - January 2017

**HUDA Clinic**, Detroit, MI — *Volunteer*

Obtaining history and physical examination of patients under the care of various visiting physicians including Danial Rashid, MD and Saqib R. Nakadar, DO for an underserved, urban population

June 2016 - July 2016

**Sunoco Gas Station**, Brownstown, MI — *Cashier/Clerk*

March 2016 - June 2016

**Oakwood Specialty Center**, Dearborn, MI — *Observership*

Observership under Kashif Chaudhry, MD (Nephrology) and assisting in clerical duties

December 2015 - March 2016

**Doctor's Hospital & Medical Centre**, Lahore, Pakistan — *House Officer*

Junior physician in Neurology under the supervision of Amer Ikram, MD (Neurology)

June 2012 - July 2012

**Heart & Vascular Institute**, Detroit, MI — *Intern*

Assisting with dictations, history and physical examination of patients and clerical duties under the supervision of Tamam Mohamad, MD and Hamid Sattar, MD in Interventional Cardiology clinic

May 2012 - June 2012

**Hope Cancer Care**, Las Vegas, NV — *Intern*

Observership with Raja Mehdi, MD (Hematology & Oncology) in an outpatient oncology and hematology clinic

## **Education:**

March 2014 - June 2016

- USMLE Step 1: Passed in first attempt
- USMLE Step 2 Clinical Skills: Passed in first attempt
- USMLE Step 2 Clinical Knowledge: Passed in first attempt
- USMLE Step 3: Passed in first attempt

November 2008 - April 2014

**Lahore Medical & Dental College**, Lahore, Pakistan — *M.B:B.S*

Bachelor's in Medicine and Surgery

August 2005 - June 2007

**Lahore American School**, Lahore, Pakistan — *High School Diploma*

GPA **3.46**, AP English Literature, AP American History, AP Biology and AP Chemistry cleared

August 2004 - June 2005

**Woodhaven High School**, Woodhaven, MI — *High School*

GPA **3.5**

## **Citizenship:**

United States of America

## **Language fluency:**

English, Urdu, Punjabi, and Hindi

# Curriculum Vitae



## **Nishanth Thalambedu, MD**

3505 West Moreland Road, Willow Grove, Pennsylvania, 19090

Phone: 917-497-2131 | Nishanth.medc@gmail.com

## **EDUCATION**

MD (Doctor of Medicine)

Abington Jefferson Health

**2018-Present**

Residency in Internal Medicine

M.B.B.S (Bachelor of Medicine and Bachelor of Surgery)

**2006-2011**

Kurnool Medical College, India.

## **TESTS AND BOARDS**

USMLE step 3 – 243

USMLE step 2 CS – Pass

USMLE step 2 CK – 246

USMLE step 1 – 246

MRCP Part 1 & 2 – Pass

## PUBLICATIONS

1. **Nishanth Thalambedu**, El-Habr AH. Gemcitabine induced pneumonitis: a case report and review of literature. *Journal of Community Hospital Internal Medicine Perspectives*. 2020 Nov 1;10(6):579-82. **PMID: 33194133**
2. **Nishanth Thalambedu**, Atiq MU, Patel S. A Case of Docetaxel-Induced Rhabdomyolysis. *Cureus*. 2020 Jul;12(7). **PMID: 32855894**
3. **Nishanth Thalambedu**, Khan Yasir. Fluorouracil (5-FU)-induced Cardiomyopathy. *Cureus*. 2019, Jul; 11(7): 5162. Cited in PubMed; **PMID: 31528514**
4. **Nishanth Thalambedu**, Yasir Khan, Qian Zhang, Shristi Khanal and Ammar Ashfaq. Immune-mediated Colitis from Dual Checkpoint Inhibitors. *Cureus*. 2019, Nov; 11(11): e6233. Cited in PubMed; **PMID: 31890432**
5. **Nishanth Thalambedu**, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Ammar Ashfaq, Qian Zhang and Mishal Shaukat. Comparative Efficacy of Elotuzumab With Panobinostat and Ixazomib in Multiple Myeloma; A Meta-Analysis. *Journal of the National Comprehensive Cancer Network*. 2020, Mar; 18(3.5): CLO20-062.
6. **Nishanth Thalambedu**, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat and Qian Zhang. A Meta-Analysis on the Safety of Panobinostat Compared to Eltozumab and Ixazomib for the Treatment of Multiple Myeloma. *Journal of the National Comprehensive Cancer Network*. 2020, Mar; 18(3.5): CLO20-061.
7. **Nishanth Thalambedu**, Ullah W, Khanal S, Basyal B, Fidler C, Cohen S. S0015 Oral Anticoagulants for Venous Thromboembolism (VTE) in Pancreatic Cancer: Friend or Foe. *Official journal of the American College of Gastroenterology| ACG*. 2020 Oct 1;115:S7.

8. **Nishanth Thalambedu**, Roomi S. PHENIBUT POISONING. Chest. 2020 Oct 1;158(4):A803.
  
9. **Nishanth Thalambedu**, Ashfaq AA, Manda N. THINK OUTSIDE THE BOX. Chest. 2020 Oct 1;158(4):A1490.
  
10. **Nishanth Thalambedu**, Iqra Iqbal, Shristi Khanal and Muhammad Atique Alam Khan. Graves Disease and T3 Thyrotoxicosis: A Case Report. Journal of The Endocrine Society. 2020, Apr; 4(supplement\_1): SUN-520.
  
11. **Nishanth Thalambedu**, Shafaq Tariq and Daniel Rosenberg. PANCREATIC DIABETES: IT'S NEITHER TYPE 1 NOR TYPE 2. 2020 AACE ANNUAL SCIENTIFIC & CLINICAL CONGRESS ABSTRACTS. Endocrine Practice. 2020, May; 26(Supplement 2): 123.
  
12. **Nishanth Thalambedu**, Shujaul Haq and Abdallah El-Habr.. EVALI: on the rise. JOURNAL OF INVESTIGATIVE MEDICINE. 2020, Apr; 68(4): 919-920.
  
13. **Nishanth Thalambedu** and Yasir Khan. A Traveler's tale: dengue fever in a traveler. JOURNAL OF INVESTIGATIVE MEDICINE. 2020, Apr; 68(4): 938-939.
  
14. Ullah W, **Nishanth Thalambedu**, Haq S, Saeed R, Khanal S, Tariq S, Roomi S, Madara J, Boigon M, Haas DC, Fischman DL. Predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19. Journal of community hospital internal medicine perspectives. 2020 Sep 2;10(5):402-8. **PMID: 33235672**



15. Jafar MS, **Nishanth Thalambedu**, Kolandra L, Roomi S. False, Reversed but Not True: A Curious Case of Hyperkalemia. *Cureus*. 2020 Aug;12(8). **PMID: 33005500**
  
16. Sohaib Roomi, Mahnoor Fatima Sherazi, Waqas Ullah, Omair Ali Khan, Artem Minalyan, Muhammad Atiq and **Nishanth Thalambedu**. Rhabdomyosarcoma from uterus to heart. *Journal of Community Hospital Internal Medicine Perspectives*. 2020, May; 10(3): 245-249. **PMID: 32850073**
  
17. Yasir Khan and **Nishanth Thalambedu**. Combined Immunotherapy in Metastatic Melanoma with Unknown Primary. *Cureus*. 2019, Aug; 11(8): e5324. Cited in PubMed; **PMID: 31598431**.
  
18. Yasir Khan, Waqas Khan, **Nishanth Thalambedu**, Ammar A Ashfaq and Waqas Ullah. Optic Neuritis: A Rare Paraneoplastic Phenomenon of Hodgkin's Lymphoma. *Cureus*. 2019, Jul; 11(7): e5181. Cited in PubMed; **PMID: 31565590**
  
19. Ammar Ashfaq, Waqas Ullah, Shristi Khanal, Muhammad Abdullah Zain, **Nishanth Thalambedu**, Faisal Inayat and Muhammad Umair Atiq. Takotsubo cardiomyopathy: a rare complication of acute viral gastroenteritis. *Journal of Community Hospital Internal Medicine Perspectives*. 2020, May; 10(3): 258-261. **PMID: 32850074**
  
20. Iqra Iqbal, Muhammad Atique Alam Khan, Yasir Khan, **Nishanth Thalambedu** and Samavia Munir. Hypercalcemia Due to Paraneoplastic Production of 1,25-Dihydroxyvitamin D in a Young Female with Dysgerminoma. *Cureus*. 2019, Nov; 11(11): e6097. Cited in PubMed; **PMID: 31886038**
  
21. Ullah W, **Nishanth Thalambedu**, Zahid S, Zia Khan M, Mir T, Roomi S, Fischman DL, Virani SS, Alam M. Percutaneous coronary intervention in patients with cardiac allograft vasculopathy: a Nationwide Inpatient Sample (NIS) database

analysis. Expert Rev Cardiovasc Ther. 2021 Feb 4:1-7. doi:  
10.1080/14779072.2021.1882851. Epub ahead of print. **PMID: 33507114**

22. Shahrzad Abdollahi, **Nishanth Thalambedu**, Steven J Cohen, Amy Mackenzie and Ida Micaily.. IMPACT OF GERIATRIC ASSESSMENT ON CHEMOTHERAPY REGIMEN OUTCOMES AND ADVERSE EVENTS ON THE OLDER PATIENT WITH CANCER IN THE COMMUNITY HOSPITAL SETTING. Journal of Geriatric Oncology. 2019, Nov; 10(6): S100.
  
23. Shujaul Haq, **Nishanth Thalambedu**, Shristi Khanal and Rajeshkumar Patel. Massive pulmonary embolism, size does not matter. JOURNAL OF INVESTIGATIVE MEDICINE. 2020, Apr; 68(4): 942-942.
  
24. Harshwant Grover, Puneet Dhillon, **Nishanth Thalambedu**, Umer Shoukat and Rehan Saeed. BLACK MEDIASTINUM: PRIMARY MEDIASTINAL MELANOMA. Chest. 2019, Oct; 156(4): A100-A101.
  
25. Muhammad Arslan Cheema, **Nishanth Thalambedu**, Hasan Abbas, Jason Zhou. Intraperitoneal Fat Infarction - A Rare Cause of Epigastric Pain. Drexel Med Journal. 2019, Apr; 13(1): 111.
  
26. Yasir Khan and **Nishanth Thalambedu**. Hospice utilization and management of patients with advanced gastrointestinal cancer. JOURNAL OF INVESTIGATIVE MEDICINE. 2020, Apr; 68(4): 939-939.

## **SUBMITTED PAPERS:**

1. Tzarnas Stephanie, Thelmo Franklin and **Thalambedu Nishanth**. A Red Herring: Evans Syndrome Presenting Initially as Diarrheal Illness in an Adult Male. BMJ Case Reports. 2020, Mar; Pub Status: **Submitted**.
2. Botros Shenoda, Chetan Jeurkar, and **Nishanth Thalambedu**. A Spotlight on Sex-difference in Bone Marrow Transplant. Review article. Hematology, Transfusion and Cell Therapy. 2020, Apr; Pub Status: **Submitted**
3. Shujaul Haq, **Nishanth Thalambedu** and Bilal H Lashari. Alcoholic cardiomyopathy, Stroke and DOACs: An Intricate Tale. Journal of Community Hospital Internal Medicine Perspectives. 2020, May; Pub Status: **Submitted**.
4. Waqas Ullah, **Nishanth Thalambedu**, Salman Zahid, Sammer Saleem, Donald C. Haas, Salim Virani and Mahboob Alam. Septal myectomy or Alcohol Ablation for Hypertrophic Cardiomyopathy: A Nationwide Inpatient Sample (NIS) Database Analysis. The American Journal of Cardiology. 2020 December; Pub Status: **Submitted**
5. Waqas Ullah, Salman Zahid, **Nishanth Thalambedu**, Maria Khan, H. Todd Massey, Donald Haas, Vakhtang Tchantchaleishvili, Eduardo Rame. The impact of peripheral arterial disease on left ventricular assist device implantation – A Propensity matched Analysis of the Nationwide Inpatient Sample Database. Artificial Organs. 2020, Oct; Pub Status: **Accepted**.

## **CONFERENCE PRESENTATIONS**

**Nishanth Thalambedu** and Andrew Chalhoub. (November, 2018). An Internist dilemma in managing a patient on Intrathecal pain pump: A case Report Poster presented at: The Pennsylvania Pain Society Annual Meeting and Scientific Sessions; Bedford, PA, USA.

**Nishanth Thalambedu**, Seema Sethi, Herbert Auerbach. (January, 2020). Angioimmunoblastic T cell Lymphoma: A diagnostic dilemma Poster presented at: 12th Annual T-Cell Lymphoma Forum 2020; San Diego, CA, USA.

## **TEACHING EXPERIENCE**

**Clinical Fellow, St Georges University School of Medicine, True blue, Grenada.**

- Anatomy, Physiology and Biochemistry

## WORK EXPERIENCE

07/2018 - Present	<b>Residency in Internal Medicine</b> Abington Jefferson Health, Abington, Pennsylvania, USA
2/2018 – 06/2018	<b>Medical Officer</b> Gayathri Hospital, Kurnool, India.
08/2017 – 12/2017	<b>Clinical Fellow</b> St Georges University School of Medicine, True blue, Grenada.
05/2017 –05/2017	<b>Observer</b> University Of Nebraska Medical Center, Cardiology, Omaha, Nebraska
04/2017 – 04/2017	<b>Observer</b> University Of Nebraska Medical Center, Nephrology, Omaha, Nebraska
02/2017 – 03/2017	<b>Externship</b> New York Methodist Hospital, Internal Medicine, Brooklyn, New York city, New York.
07/2016 – 12/2016	<b>House Officer</b> Barrackpore Medical Center and Private Hospital Limited, Trinidad and Tobago.
02/2014 – 06/2016	<b>House Officer</b> North Central Regional Health Authority, Trinidad and Tobago.
09/2013 – 01/2014	<b>Observer</b> Barrackpore Medical Center and Private Hospital Limited, Trinidad and Tobago.

07/2012 – 08/2013	<b>Medical Officer</b> Kurnool Heart and Multispecialty Hospital, Kurnool, India.
06/2012	<b>Graduated medical school</b>

## **VOLUNTEER WORK**

### **09/2014 Forum of Indian Nationals in Trinidad & Tobago, Couva, Trinidad and Tobago**

My job included welcoming and triaging people and guiding them to the appropriate services. I was also involved in the effective functioning of the camp by organizing the essential supplies and collecting and distributing donations.

### **2011-2012 National Pulse Polio program**

My job included triaging people and guiding them to the appropriate services. I was also involved in actively educating public in rural India regarding the importance of getting vaccination.

### **2011-2012 National Rural Health Mission (NRHM), School Health program, India**

My Job included visiting the primary schools in rural areas and screening children below age 10 for common diseases like infections, vision problems, malnutrition and referring them to appropriate services.

### **01/2007 MEDIFAIR, Kurnool Medical College, India.**

I worked under the guidance of the Department of Biochemistry and educated visitors about Diabetes and its complications.

## **Membership Professional Societies**

- American College of Physicians (ACP)
- Medical Council of India (MCI)
- Andhra Pradesh Medical Council (APMC)

## **Certifications**

- ACLS Certified
- BLS Certified
- State License (Pennsylvania), Exp. Date: 06/2021

## **Hobbies**

- Cricket, Soccer, Travelling, Cooking.

## **Language Fluency**

- English (Full professional efficiency).
- Telugu (Native)
- Hindi and Tamil (Good)

## Min Chong Yoo, MD, FACS

333 W Depot Ave #609, Knoxville, TN 37917

(720) 237-4813

[myoo@utmck.edu](mailto:myoo@utmck.edu)

---

### Professional

**Assistant Professor**, Department of Surgery, Division of Transplant Surgery. University of Tennessee Medical Center, Knoxville, TN, July 2020 – present

**Transplant Surgeon**, Solutions by Sanford. Sanford Hospitals, Fargo and Bismarck, ND and Sioux Falls, SD, May 2019 – June 2020

**Transplant Surgeon**, Porter Adventist Hospital, Denver, CO, Sept 2015 – Feb 2019

**Assistant Professor**, Department of Surgery, Division of Transplant, Surgery. University of Tennessee Health Science Center, Memphis, TN, July 2013 – Sept 2015

**Clinical Instructor**, Department of Surgery, University of Texas Southwestern Medical Center, July 2010 – June 2011

### *Certifications*

**American Board of Surgery** – Certificate #059055, March 2014 – December 2024

---

### Licensing

**North Dakota Medical License**, PT15700, active May 10, 2019 to Present

**Colorado Medical License**, Number DR.0055751, active, August 27, 2015 – Present

**South Dakota Medical License**, Number 9809, active, February 23, 2016 – Present

**Tennessee Medical License**, Number 4677, active, July 1, 2011 – Present

**Texas Medical License**, Number N7512, active, August 16, 2010 – Present

---

### Education

**Abdominal Transplant Surgery Fellowship**, University of Tennessee Health Science Center, Methodist Transplant Institute, Memphis, TN, July 2011 – June 2013

**Renal Transplant/Access Fellowship**, University of Texas Southwestern Medical Center, Dallas, TX, July 2010 – June 2011

**General Surgery Residency**, University of Texas Southwestern Medical Center, Dallas, TX Parkland Health and Hospital System, July 2005 – June 2010

**Doctor of Medicine**, University of Texas Southwestern Medical School at Dallas, TX August 2001 – May 2005

**Bachelor of Science**, Chemical Engineering, with High Honors, University of Texas at Austin August 1997 – May 2001

---

**Min Chong Yoo, MD, FACS**

[myoo@utmck.edu](mailto:myoo@utmck.edu)

---

## **Publications**

Lake-Bakaar G, **M Yoo**, D Cronin. *Mirizzi Syndrome: four case reports and a review of the literature*. Journal of Surgery and Anesthesia, 2018 June; 2 (1): 115.

**Yoo MC**, JM Vanatta, KA Modanlou, L Campos, N Nezakatgoo, S Nair, JD Eason. *Steroid-free liver transplantation using rabbit antithymocyte globulin induction in 500 consecutive patients*. Transplantation, 2015 June; 99(6): 1231-1235.

**Yoo MC**, JM West, JD Eason, JM Vanatta. *The advantages and disadvantages of perioperative transesophageal echocardiography during liver transplantation*. Journal of Anesthesia and Clinical Research 2012; S4:003.

**Yoo MC**, R Saxena, IJA Davidson. *Peritoneal dialysis access in ACS Surgery: Principles and Practice*, SW Ashley, WG Cance, RJ Valentine, GJ Jurkovitch, SJ Swanson, LM Napolitano, JH Pemberton, H Chen, TS Riall, eds. Ontario: Decker Publishing, 2012.

Davidson IJA, **MC Yoo**, DG Biasucci, P Browne, C Dees, B Dolmatch, M Gallieni, A LaGreca, JR Korndorffer, B Nolen, S O'Rear, E Peden, M Pittiruti, G Reed, D Scott, D Slakey. *Simulation training for vascular access interventions*. Journal of Vascular Access 2010; 11(3): 181-190

**Yoo, MC**. *A case of bleeding access*. Journal of Vascular Access 2010; 11(3): 191.

Davidson I, B Dolmatch, **MC Yoo**. *The art of controversy*. Journal of Vascular Access 2010; 11 (3): 197-198.

**Yoo MC**, L Villegas, DB Jones. *Basic ultrasound curriculum for medical students: validation of content and phantom*. Journal of Laparoendoscopic and Advanced Surgical Technique. Part A. 14(6):374-9, 2004 Dec.

---

## **Presentations**

**Yoo, M**. Solid organ transplantation. University of Tennessee Medical Center, Medical Student Surgery Rotation Lecture. September 2020, November 2020.

**Yoo M**. Long-term Kidney Transplant Outcomes and Chronic Graft Loss. American Society of Transplant Surgeons Academic Universe, National Transplant Curriculum. December 2019.

**Yoo M**. Surgical management of hepatocellular carcinoma: orthotopic liver transplant. Presentation. A Multidisciplinary Approach to the Management of Hepatocellular Carcinoma, February 4, 2017.

**Yoo M**. Surgical Aspects of Transplant. Presentation, Transplant Core Curriculum, Porter Adventist Hospital, December 15, 2016.



**Min Chong Yoo, MD, FACS**

[myoo@utmck.edu](mailto:myoo@utmck.edu)

---

**Presentations (continued)**

**Yoo M.** Liver Transplant. Presentation, Transplant Core Curriculum, Porter Adventist Hospital, October 18, 2016.

**Yoo M.** Porter Transplant Update. Presentation, Nursing Mega-Grand Rounds, Porter Adventist Hospital. May 9, 2016.

Caicedo JC, **M Yoo.** Minorities and Transplantation: reducing disparities in donation and access. Luncheon Workshop, American Transplant Congress, May 5, 2015.

**Yoo M,** E Wong, J Eason, J Vanatta. Outcomes of pediatric en-bloc kidneys after circulatory death. Poster presentation at the American Society of Transplant Surgeons 15<sup>th</sup> Annual State of the Art Winter Symposium, January 15-18, 2015. Junior Investigator Award for Top Abstracts in the Junior Faculty Category.

Caicedo JC, S Varma, L Nino, **M Yoo,** J Ortiz, C Jones, J Locke, C Modlin, R Sharma, T Thambi- Pillai, J Hong, A Hernandez, O Grandas, R Higgins, L Ratner. Are the Kidney Transplant Centers Doing Enough To Outreach and Educate Minorities in US? National Study of Culturally and Linguistically Competent Efforts Reported in Kidney Transplant Center Websites. Poster presentation at the American Society of Transplant Surgeons 15<sup>th</sup> Annual State of the Art Winter Symposium, January 15-18, 2015.

Hall D, K Modanlou, E Wong, J Eason, **M Yoo,** S Satapathy, L Campos, N Nezakatgoo, V Puri, S Nair, J Vanatta. Older liver recipients with renal dysfunction benefit from combined liver-kidney transplant vs. liver transplant alone. Poster presentation at the American Society of Transplant Surgeons 15<sup>th</sup> Annual State of the Art Winter Symposium, January 15-18, 2015.

Vanatta J, K Das, J Eason, K Modanlou, **M Yoo,** S Nair, L Campos, N Nezakatgoo, V Puri, N Dbouk, S Satapathy. Outcome of sorafenib therapy in recipients of orthotopic liver transplant with explants revealing HCC beyond Milan criteria. Poster presentation at the American Society of Transplant Surgeons 15<sup>th</sup> Annual State of the Art Winter Symposium, January 15-18, 2015.

**Yoo MC,** JM Vanatta, KA Modanlou, L Campos, N Nezakatgoo, S Satapathy, S Nair, JD Eason. Single center experience using hepatitis B core-positive and hepatitis C positive donor allografts. Poster presentation at American Society of Transplant Surgeons 13<sup>th</sup> Annual State of the Art Winter Symposium Jan 31-Feb 3, 2013. Poster of Distinction Winner

Vanatta JM, **MC Yoo,** KA Modanlou, L Campos, S Nair, S Satapathy, JD Eason. Outcomes of orthotopic liver transplantation for HCV: analysis of hepatitis B core antibody positive

**Min Chong Yoo, MD, FACS**

[myoo@utmck.edu](mailto:myoo@utmck.edu)

---

**Presentations (continued)**

donors and hepatitis C antibody positive donors. Poster presentation at American Society of Transplant Surgeons 13<sup>th</sup> Annual State of the Art Winter Symposium Jan 31-Feb 3, 2013.

**Yoo MC**, DP Bolanowski, MS Riegel, Z Sun, DS Douglass, R Rodriguez, MG Powell, R Brown, JD Arenas. Use of ECMO support to improve DCD liver graft viability in a porcine model. Presentation, Annual Fellows Conference: Advances in Organ Transplantation, 2011.

**Yoo MC**, MA Debroy, DM Desai, C Lu, MR Mulloy, R Rojas, M Vazquez, JD Arenas. *Early, aggressive treatment of renal failure improves outcomes in liver transplant patients.* Presentation, North Texas Chapter of the American College of Surgeons, Annual Meeting, February, 2011.

**Yoo, MC.** *Transplant tourism.* University of Texas Southwestern Department of General Surgery Grand Rounds Presentation, January 19, 2011.

**Yoo, MC.** *A case of bleeding access.* Case Presentation, Controversies in Dialysis Access Meeting, October 2010.

**Yoo MC**, FR Arko, RE Schwarz, JC Mansour. *IVC leiomyosarcoma in a Jehovah's Witness.* Interesting Case Presentation, North Texas Chapter of the American College of Surgeons Annual Meeting, February 2010.

**Yoo MC.** *Disruptive physician behavior.* University of Texas Southwestern Department of General Surgery Grand Rounds Presentation, October 7, 2009.

**Yoo MC**, CL Roland, RA Iyengar, CC Barnett. *Simple cystectomy for side-branch IPMN.* Case Report Presentation Southwestern Surgical Congress, April 2008

**Yoo MC**, CL Roland, RA Iyengar, CC Barnett. *Simple cystectomy for side-branch IPMN.* Interesting Case Presentation, North Texas Chapter of the American College of Surgeons Meeting, February 2008

**Yoo, MC.** *Aortoenteric fistula: A case presentation.* St Paul Hospital, Department of Surgery Grand Rounds Presentation, June 2007

**Yoo MC**, L Villegas, DB Jones. *Basic ultrasound curriculum for medical students: validation of content and phantom.* Poster presentation at 2003 Society of American Gastrointestinal Endoscopic Surgeons Meeting. Oral presentation at 2003 North Texas Chapter of the American College of Surgeons Meeting.

---

**Min Chong Yoo, MD, FACS**

[myoo@utmck.edu](mailto:myoo@utmck.edu)

---

## Research

**Ultrasound training curriculum for Medical Students.** Design and validation of an ultrasound curriculum for medical students. Dr. Daniel Jones, M.D., Dept of Surgery, University of Texas Southwestern Medical School, Summer 2002

**Genetically enhanced vascular stents.** Implantation of bioresorbable materials in an animal model to evaluate in-vivo inflammatory response. Dr. Robert Eberhart, Ph.D., Dept of Surgery, University of Texas Southwestern Medical School, Summer 2001

**Evaluation of signal bleed-through in the thrombophilia micro-array.** Optimization of a DNA chip-based screening test for thrombophilia. Dr. Ron McGlennen, M.D., Dept of Laboratory Medicine and Pathology, University of Minnesota Twin Cities Summer 2000

---

## Honors and Awards

Junior Investigator Award – Junior Faculty Category, Top Abstracts, American Society of Transplant Surgeons 15<sup>th</sup> Annual State of the Art Winter Symposium, January 15-18, 2015.

Alpha Omega Alpha Honor Medical Society, The University of Texas Southwestern Medical Center at Dallas, Gamma Chapter of Texas, March 2008

University of Texas Southwestern Competitive Dean’s Scholarship, 2004 – 2002  
Bryan Williams Alumni Scholarship (Southwestern Medical Foundation), 2001

Ernest Cockrell, Jr. Scholar (Academic Scholarship), 1997 – 2001  
Robert C. Byrd Scholarship (Academic Scholarship), 1997 – 2001  
University Honors, 1997 – 2000

Jerry Junkins Memorial Scholarship (Corporate National Merit Scholar), 1997

---

## Professional Organizations and Activities

Subcommittee chair, Patient Review Committee, TNUK. August 2020 – present  
Primary Surgeon, Living Donor Kidney Program, COPM. February 2018 – February 2019  
Primary Surgeon, Kidney Transplant Program, COPM. February 2018 – February 2019  
COPM Regional Review Board Representative for Region 8, September 2016 – February 2019  
Abstract reviewer, American Society of Transplant Surgeons Winter meeting, 2018, 2019  
American Liver Foundation, Nashville Chapter, Board member, 2014 – 2015  
Tennessee Kidney Foundation, Board member, 2014- 2015  
American Society of Transplant Surgeons, Member, 2010 – present  
American College of Surgeons, Fellow, 2017 - present, Associate member 2013 – 2017  
Parkland Surgical Society, 2001-present  
Wilson Student Surgical Society, 2001-2005; President 2004 – 2005; VP 2003 – 2004  
Omega Chi Epsilon Chemical Engineering Honor Society, 1999 – 2001; President 2000  
College of Engineering Student Mentor, 1998 – 2001  
Society of Women Engineers, 1997-2000; Encounter with Engineering Chair 1998

# APPENDIX C

*Act 181*

1 State of Arkansas  
2 92nd General Assembly  
3 Regular Session, 2019  
4

As Engrossed: S2/4/19

# A Bill

SENATE BILL 151

5 By: Senators Irvin, Bledsoe, B. Davis, J. English  
6 By: Representatives M. Gray, Barker, Bentley, Brown, Capp, Cavanaugh, Crawford, Dalby, C. Fite,  
7 Lundstrum, J. Mayberry, Petty, Rushing, Speaks, Vaught, Gazaway  
8

## For An Act To Be Entitled

9  
10 AN ACT CONCERNING THE PURSUIT OF A NATIONAL CANCER  
11 INSTITUTE-DESIGNATED CANCER CENTER AT THE WINTHROP P.  
12 ROCKEFELLER CANCER INSTITUTE AT THE UNIVERSITY OF  
13 ARKANSAS FOR MEDICAL SCIENCES; TO CREATE THE  
14 UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES NATIONAL  
15 CANCER INSTITUTE DESIGNATION *TRUST FUND*; AND FOR  
16 OTHER PURPOSES.  
17  
18

## Subtitle

19  
20 CONCERNING THE PURSUIT OF A NATIONAL  
21 CANCER INSTITUTE-DESIGNATED CANCER CENTER  
22 AT THE WINTHROP P. ROCKEFELLER CANCER  
23 INSTITUTE AT THE UNIVERSITY OF ARKANSAS  
24 FOR MEDICAL SCIENCES.  
25  
26

27 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:  
28

29 SECTION 1. DO NOT CODIFY. Legislative findings.

30 The General Assembly finds that:

31 (1) In 2018, approximately sixteen thousand (16,000) Arkansans  
32 were diagnosed with cancer in 2018, which means that forty-four (44)  
33 Arkansans were diagnosed with cancer per day;

34 (2) Of those sixteen thousand (16,000) Arkansans diagnosed with  
35 cancer, six thousand nine hundred ten (6,910) will die of the disease;

36 (3) The four (4) types of cancer with significantly high annual



1 diagnosis rates in Arkansas are:

2 (A) Lung and bronchus cancer, with two thousand seven  
3 hundred twenty (2,720) diagnoses;

4 (B) Breast cancer, with two thousand one hundred sixty  
5 (2,160) diagnoses;

6 (C) Prostate cancer, with one thousand two hundred sixty  
7 (1,260) diagnoses; and

8 (D) Colon and rectal cancer, with one thousand three  
9 hundred seventy diagnoses (1,370);

10 (4) Over the past twenty-eight (28) years, nationwide cancer-  
11 related deaths have decreased by five percent (5%), but in Arkansas the rate  
12 of cancer-related deaths has increased by nine percent (9%);

13 (5) Only Kentucky, Mississippi, and Oklahoma had higher cancer-  
14 related death rates in the past twenty-eight (28) years than Arkansas;

15 (6) Cancer is the second-leading cause of death in Arkansas and  
16 may become the leading cause of death within the next decade, surpassing the  
17 current leading cause, cardiovascular disease, based on the diagnosis trends  
18 in the state;

19 (7) There are currently seventy (70) National Cancer Institute-  
20 Designated Cancer Centers, located in thirty-six (36) states and the District  
21 of Columbia, including National Cancer Institute-Designated Cancer Centers in  
22 Texas, Missouri, Oklahoma, and Tennessee;

23 (8) There are no National Cancer Institute-Designated Cancer  
24 Centers in Arkansas, Mississippi, or Louisiana;

25 (9) In 2018, the State of Oklahoma received the seventieth  
26 National Cancer Institute-Designated Cancer Center;

27 (10) Having a National Cancer Institute-Designated Cancer Center  
28 in Arkansas will improve and expand access to clinical trials, cancer  
29 treatment, cancer prevention, cancer screening, and education in Arkansas;

30 (11) A National Cancer Institute-Designated Cancer Center in  
31 Arkansas would act as a hub of groundbreaking treatments and care for the  
32 communities around the state;

33 (12) Arkansas cancer patients often times are required to leave  
34 the state to receive treatment at a National Cancer Institute-Designated  
35 Cancer Center;

36 (13) National Cancer Institute-Designated Cancer Centers have

1 expanded treatment options due to research grant funds and experimental  
2 trials, and hundreds of research studies are underway at these centers,  
3 ranging from basic laboratory research to clinical assessments of new  
4 treatments not currently available in Arkansas;

5 (14) Having a National Cancer Institute-Designated Cancer Center  
6 in the state would save the lives of thousands of Arkansans through expanded  
7 treatment opportunities, including opportunities to participate in  
8 experimental cancer treatments;

9 (15) Being a National Cancer Institute-Designated Cancer Center  
10 would allow the Winthrop P. Rockefeller Cancer Institute at the University of  
11 Arkansas for Medical Sciences to be awarded more research funds, which will  
12 provide additional experimental cancer treatments in the state;

13 (16) A National Cancer Institute-Designated Cancer Center will  
14 provide support for cancer treatment providers, clinics, and hospitals in  
15 Arkansas;

16 (17) In addition to the human suffering caused by cancer, there  
17 are economic costs that result from the disease, including medical costs and  
18 the impact on the productivity of the cancer patient and his or her family;

19 (18) The Winthrop P. Rockefeller Cancer Institute at the  
20 University of Arkansas for Medical Sciences is pursuing designation as a  
21 National Cancer Institute-Designated Cancer Center for the benefit of the  
22 more than three million (3,000,000) citizens of Arkansas;

23 (19) The National Cancer Institute recommends that a cancer  
24 center have at least twenty million dollars (\$20,000,000) in National Cancer  
25 Institute-funded research;

26 (20) The Winthrop P. Rockefeller Cancer Institute at the  
27 University of Arkansas for Medical Sciences currently has approximately ten  
28 million dollars (\$10,000,000) in National Cancer Institute-funded research;

29 (21) The Winthrop P. Rockefeller Cancer Institute at the  
30 University of Arkansas for Medical Sciences can apply for only a limited  
31 number of National Cancer Institute grant funds because over sixty percent  
32 (60%) of the National Cancer Institute's grant applications require that the  
33 cancer center be a National Cancer Institute-Designated Cancer Center in  
34 order to apply for the grant funds;

35 (22) In order to achieve status as a National Cancer Institute-  
36 Designated Cancer Center, the Winthrop P. Rockefeller Cancer Institute at the

1 University of Arkansas for Medical Sciences will need to recruit:

2 (A) A renowned expert in cancer research to serve as the  
3 Director of the Winthrop P. Rockefeller Cancer Institute at the University of  
4 Arkansas for Medical Sciences; and

5 (B) Nationally recognized National Cancer Institute-funded  
6 medical professionals;

7 (23) To be successful in gaining status as a National Cancer  
8 Institute-Designated Cancer Center, ongoing, dedicated financial support from  
9 the State of Arkansas is critical;

10 (24) The Winthrop P. Rockefeller Cancer Institute at the  
11 University of Arkansas for Medical Sciences will need a stream of funding  
12 between ten million dollars (\$10,000,000) and twenty million dollars  
13 (\$20,000,000) per year to establish and maintain a National Cancer Institute-  
14 Designated Cancer Center;

15 (25) Like other states that have been successful in securing  
16 status as a National Cancer Institute-Designated Cancer Center for their  
17 cancer centers, it is incumbent that the State of Arkansas invest in this  
18 initiative;

19 (26) It is a strategic goal of the Winthrop P. Rockefeller  
20 Cancer Institute at the University of Arkansas for Medical Sciences to  
21 become a National Cancer Institute-Designated Cancer Center;

22 (27) State government funds will assist the Winthrop P.  
23 Rockefeller Cancer Institute at the University of Arkansas for Medical  
24 Sciences secure vital investments from other public and private sources;

25 (28) The Winthrop P. Rockefeller Cancer Institute at the  
26 University of Arkansas for Medical Sciences is committed to raising at least  
27 thirty million dollars (\$30,000,000) in private funds to support the pursuit  
28 of achieving status as a National Cancer Institute-Designated Cancer Center;

29 (29) The private resources pursued by the Winthrop P.  
30 Rockefeller Cancer Institute at the University of Arkansas for Medical  
31 Sciences are a part of a cohesive and focused plan that will forever change  
32 the state;

33 (30) It is estimated that having a National Cancer Institute-  
34 Designated Cancer Center will bring in an additional seventy million dollars  
35 (\$70,000,000) annually to Arkansas's economy and will create one thousand  
36 five hundred eighty-four (1,584) new jobs over five (5) years;



1           (31) The state should establish a fund solely for the purpose of  
2 pursuing and maintaining status as a National Cancer Institute-Designated  
3 Cancer Center for the Winthrop P. Rockefeller Cancer Institute at the  
4 University of Arkansas for Medical Sciences;

5           (32) If upon June 30, 2027, the Winthrop P. Rockefeller Cancer  
6 Institute at the University of Arkansas for Medical Sciences has not achieved  
7 status as a National Cancer Institute-Designated Cancer Center, then the fund  
8 created in this act should sunset; and

9           (33) Future General Assemblies will have the authority and  
10 responsibility to evaluate the progress of the Winthrop P. Rockefeller Cancer  
11 Institute at the University of Arkansas for Medical Sciences toward achieving  
12 status as a National Cancer Institute-Designed Cancer Center and adjust this  
13 act accordingly.

14  
15           SECTION 2. Arkansas Code Title 19, Chapter 5, *Subchapter 11*, is  
16 amended to add an additional section to read as follows:

17           19-5-1149. University of Arkansas for Medical Sciences National Cancer  
18 Institute Designation Trust Fund – Report.

19           (a) There is created on the books of the Treasurer of State, the  
20 Auditor of State, and the Chief Fiscal Officer of the State a trust fund to  
21 be known as the “University of Arkansas for Medical Sciences National Cancer  
22 Institute Designation Trust Fund”.

23           (b) The fund shall consist of:

24                   (1) Moneys obtained from private grants or other sources that  
25 are designated to be credited to the fund; and

26                   (2) Any other funds authorized or provided by law.

27           (c) The fund shall be used by the Winthrop P. Rockefeller Cancer  
28 Institute at the University of Arkansas for Medical Sciences solely to  
29 achieve and maintain status as a National Cancer Institute-Designated Cancer  
30 Center.

31           (d) The Treasurer of State shall invest the moneys available in the  
32 fund.

33           (e)(1) The investment of funds under this section is exempt from § 19-  
34 3-518(a)(2)(B)(i)(b) and (c).

35                   (2) Moneys in the fund may be invested in any instrument:

36                           (A) Listed in § 19-3-518(b)(1)(B); and

1 (B) Approved by the guidelines established by the State  
2 Treasury investment policy approved by the State Board of Finance.

3 (f) Moneys remaining in the fund at the end of each fiscal year shall  
4 carry forward and be made available for the purposes stated in this section  
5 in the next fiscal year.

6 (g)(1) The Winthrop P. Rockefeller Cancer Institute at the University  
7 of Arkansas for Medical Sciences shall submit a semiannual report containing  
8 the following information to the Governor; the Legislative Council or, if the  
9 General Assembly is in session, the Joint Budget Committee; the Senate  
10 Committee on Public Health, Welfare and Labor; and the House Committee on  
11 Public Health, Welfare, and Labor:

12 (A) The balance of the fund as of the reporting date;

13 (B) A list of the administrative costs paid for from the  
14 fund, including without limitation salaries, pensions, and packages;

15 (C) The total revenue received by the fund during the  
16 reporting period; and

17 (D) A detailed description of the steps taken and the  
18 progress made toward achieving status as a National Cancer Institute-  
19 Designated Cancer Center during the reporting period.

20 (2) The semiannual report required under this subsection shall  
21 be submitted by January 1 and July 1 of each year.

22  
23  
24 /s/Irvin

25  
26  
27 **APPROVED: 2/19/19**  
28  
29  
30  
31  
32  
33  
34  
35  
36